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ABSTRACT 
 
Vitamin D deficiency remains prevalent throughout the world, with severe deficiencies 
resulting in skeletal muscle myopathies. Within skeletal muscle, a dynamic network of 
mitochondria exists primarily functioning to produce ATP via oxidative phosphorylation. 
Recent investigations have proposed that vitamin D related metabolites are able to 
modulate mitochondrial function within skeletal muscle cell lines and human 
populations with severe vitamin D deficiencies. Therefore, the aims of this thesis were 
to further explore the role of vitamin D related signalling via the VDR and diet-induced 
vitamin D deficiency in modulating skeletal muscle mitochondrial function. It was 
demonstrated that a reduction in the VDR significantly reduced mitochondrial 
respiration in the C2C12 skeletal muscle cell line without altering mitochondrial protein 
content. Furthermore, in vivo investigations revealed a reduction in skeletal muscle 
mitochondrial respiration following 3-months of diet-induced vitamin D deficiency in 
mice. Finally, we also demonstrated an impairment in voluntary wheel running 
performance and the subsequent adaptive response following diet-induced vitamin D 
deficiency in mice. In summary, this thesis contributes novel data towards the 
understanding of the role of the vitamin D and the VDR in modulating skeletal muscle 
mitochondrial function.  
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CHAPTER 1 
 
REVIEW OF LITERATURE 
 
 
 
 
 
 
 
 
 
 
 
 
  
	 2 
1.1 General Introduction 
Skeletal muscle is composed of cells from multiple tissues. Therefore, in this context 
skeletal muscle may be considered an organ. Skeletal muscle comprises ~40% of 
total body mass making it the largest organ within the human body [1]. The primary 
functions of skeletal muscle are to produce movement, maintain posture, store and 
move substances within the body, and generate heat. Not only does skeletal muscle 
account for ~30% of the resting metabolic rate [1], it is also the predominant site of 
glycogen storage and insulin stimulated glucose disposal [2, 3], highlighting its critical 
role in the maintenance of metabolic homeostasis. One of the defining features of 
skeletal muscle is a remarkable adaptive response (i.e. plasticity) in response to both 
positive and negative stimuli. For example, significant increases in skeletal muscle 
mass are observed during postnatal development via the process of hypertrophy [4, 
5]. This process can also be induced in adult skeletal muscle via contractile activity 
and mechanical overload in the form of strength training [6]. Whilst skeletal muscle is 
able to undergo distinct periods of growth, it is also susceptible to periods of atrophy 
such as during the age related loss of muscle mass termed sarcopenia [7]. Given 
that physical inactivity is a major risk factor in the development of sarcopenia, 
exercise training is currently the most effective preventative treatment [8, 9]. Whilst 
regular physical activity plays an important role in maintaining skeletal muscle health, 
nutritional status is also known to play a key role. The manipulation of nutrient intake 
particularly surrounding acute bouts of physical activity has been studied extensively 
[10-13]. These interventions are designed to augment the post exercise signalling 
response and therefore increase the subsequent training stimulus. Whilst these 
interventions are designed to enhance skeletal muscle exercise adaptation, in 
	 3 
contrast, many individuals who suffer from poor nutritional status and dietary 
deficiencies may display impaired physical function and adaptation to exercise.  
 
A common nutritional deficiency is that of vitamin D [14]. Vitamin D belongs to a 
group of fat-soluble seco-steroids and is primarily obtained via the exposure of the 
skin to sunlight [15]. Given the increase in time spent indoors, excessive use of sun 
screen and the reports of an increased risk in skin cancer following excessive sun 
exposure, it is unsurprising that the prevalence of vitamin D deficiency is still 
widespread [16]. Deficiencies are not only reserved to specific high risks groups, but 
are also evident within athletic populations [17]. Given this, the characterisation of 
these deficiencies and the effect that they have upon skeletal muscle health is an 
important area of research. A greater understanding on the impact of these 
deficiencies is needed in order to best optimise skeletal muscle form and function 
throughout lifespan to promote a greater quality of life and prevent disease. 
 
1.2 Introduction to Skeletal Muscle 
1.2.1 Skeletal Muscle Biology and Metabolism 
Skeletal muscle accounts for 40% of total body mass in mammals and accounts for 
30% of the resting metabolic rate in humans [1]. Playing a critical role in metabolic 
homeostasis and glycaemic control, skeletal muscle is the predominant site of 
glucose disposal under insulin-stimulated conditions [3]. In addition, skeletal muscle 
is the primary site of glycogen storage within the body containing approximately 80% 
of the total stores [18].  
	 4 
Mammalian skeletal muscle fibres are comprised of multiple different fibre types 
which are delineated by their individual biochemical properties [5]. Based upon the 
contractile property of “time-to-peak tension”, skeletal muscle fibres may be defined 
as either slow- or fast-twitch fibres [5]. There are four different subgroups of fibres, 
which can be classified based upon the expression of myosin heavy chain (MyHC) I, 
IIa, IIb, and IIx although, MyHC IIb is not detectable in human skeletal muscle [19, 
20]. Type I fibres classically display slow-twitch characteristics and are red in 
appearance indicating a higher content of both myoglobin and mitochondria, whereas 
type IIx and IIb are white in colour and type IIa fibres have a more intermediate 
colour. Interestingly, a spectrum of fibre types with both pure or hybrid MyHC 
expression have been identified making the classification of skeletal muscle fibres a 
complex and debated issue [21-23]. The ability to classify fibres has progressed 
significantly via the correlation of histochemical and physiological studies of individual 
motor units, electron microscopy of fast and slow muscle fibres, novel procedures for 
myosin adenosine triphosphatase (ATPase) histochemistry, and biochemical studies 
on oxidative and glycolytic enzymes in different muscles [5]. Further approaches 
involving microarray analyses of single muscle fibres will likely shed more light on the 
complex issue of skeletal muscle fibre typing [24]. 
 
The primary role of skeletal muscle fibres is to generate tension via contraction. 
Contraction is facilitated by the binding of myosin heads to actin filaments which slide 
over one another according to the sliding filament theory [25]. This process begins 
with the myosin head binding to adenosine triphosphate (ATP). The enzyme myosin 
ATPase then hydrolyses ATP into adenosine diphosphate (ADP) and a phosphate 
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group. This results in the myosin head becoming energized which subsequently 
attaches to the binding site of the actin filament to form crossbridges. As a result of 
this binding, the phosphate group is then released. The myosin head is then able to 
tilt and rotate in a movement known as the power stroke. This rotation allows the 
myosin head to generate force and pull the actin filament towards the M-line. 
Following the power stroke, myosin then releases ADP and myosin remains bound to 
the actin filament until the next supply of ATP binds to myosin. Once ATP is bound, 
myosin is then released and the contraction cycle can be repeated when ATPase 
hydrolyses ATP. It is important to note that in order for these events to occur there 
needs to be a continual supply of ATP and calcium (Ca2+) [26].  
 
In response to exercise induced contraction, skeletal muscle is able to rapidly 
modulate energy production, blood flow and substrate utilisation. Indeed, during 
maximal exercise, whole-body metabolic rate can increase up to 20-fold and ATP 
turnover within skeletal muscle can increase 100-fold than that of at rest [27]. Given 
that intramuscular concentrations of ATP are low (20-25 nmol/kg/dry weight), 
alternative metabolic pathways need to be activated in order to maintain this rapid 
turnover of ATP [28]. The three mains sources of ATP regeneration are 
phosphocreatine (PCr), anaerobic glycolysis and oxidative metabolism [27]. In order 
to meet this increase in ATP demand, skeletal muscle contains a large pool of 
mitochondria and is reliant upon oxidative phosphorylation for energy production 
during prolonged exercise. During both submaximal and maximal exercise, it has 
been estimated that tricarboxylic acid (TCA) cycle flux increases up to 70- and 100-
fold respectively [29]. Therefore, skeletal muscle is the primary site for the 
	 6 
metabolism of both carbohydrates and lipids for energy production. Substrates for 
oxidation can be provided from extra-muscular sources such as plasma free fatty 
acids or plasma glucose or intra-muscular sources such as triglycerides or glycogen 
[30]. The relative contribution of these is dependent on exercise intensity and 
duration, as well as training status and preceding dietary intake [31, 32].  
 
1.2.2 Skeletal Muscle Plasticity in Response to Endurance Exercise 
Regular physical activity in the form of endurance training results in a number of 
profound physiological and metabolic adaptations in a multitude of populations [33-
35]. The adaptations serve to reduce the degree of perturbations to homeostasis for 
a given exercise intensity and therefore reduce the onset of fatigue. Functionally, 
these adaptations result in an increase in maximal oxygen uptake (V̇O2max) as well as 
rightward shift in lactate threshold [36, 37]. Whilst improvements in V̇O2max are largely 
governed by adaptations to the cardiovascular system [38, 39], exercise capacity at 
submaximal workloads is more closely related to adaptations within skeletal muscle 
[40]. Alterations in substrate metabolism including a reduction in glycogen utilisation 
[41], a shift towards greater lipid oxidation [42] as well a reduction in glycolysis [43] 
are all observed with endurance exercise training. These adaptations allow for a 
greater absolute exercise intensity to be supported predominantly by aerobic energy 
production and therefore a reduction in the accumulation of lactate in both the blood 
and muscle [28, 44, 45].  
 
Regular endurance training also results in a shift towards a more oxidative and 
fatigue-resistant phenotype in skeletal muscle [46, 47]. In humans, an increase in 
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both type I and IIa skeletal muscle fibres are observed in endurance-trained 
individuals, whereas type IIa and IIx are increased in sedentary individuals [46, 48, 
49]. Hypertrophy of both type I and IIa fibres is also apparent, as well as an altered 
expression of MyHC isoforms to a slower phenotype [47, 50]. Given the close 
relationship between muscle fibre composition and the oxygen cost of locomotion, 
this alteration in the phenotype of skeletal muscle is of physiological importance with 
improved metabolic health observed across multiple populations [51-53].  
 
Another hallmark of skeletal muscle remodelling following endurance exercise is the 
increase in capillary density [47, 54]. Otherwise known as angiogenesis, the 
formation of new blood vessels within skeletal muscle is stimulated by mechanical 
factors such as increased shear stress and the elevated tissue strain following 
repeated contractions. Increased capillarization within skeletal muscle been observed 
to range from 10 to 25% following 4-24 weeks of endurance training [55-58]. Both 
exercise duration and intensity seem to have minimal influence over exercise 
induced angiogenesis given that studies have observed similar increases in 
capillarization following both moderate and high-intensity endurance exercise [58-60]. 
Whilst blood flow to skeletal muscle is low at rest, during exercise, these rates can 
increase up to 100-fold in order to meet the increase in oxygen demand [61]. It is this 
large increase in blood flow that induces a significant amount of shear stress within 
the capillary bed and therefore promotes angiogenesis [62]. Several vasodilators are 
also known to induce angiogenesis [63], with the most characterised being nitric 
oxide (NO), which simultaneously induces vasodilation and enhances the expression 
of vascular endothelial growth factor (VEGF) [64]. VEGF is known to be a key 
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mediator or exercise induced angiogenesis with skeletal muscle and is essential for 
the development and maintenance of a normal muscle capillary bed [65].          
 
Finally, aerobic exercise also promotes a large increase in mitochondrial mass, 
enzyme activity and oxidation efficiency [66-68]. The mitochondria undergo a large 
remodelling process involving coordinated events of mitochondrial biogenesis, 
fission, fusion and mitophagy [66, 69-73]. All of which contribute to the development 
of trained skeletal muscle phenotype. These processes will be discussed in more 
detail below (Section 1.3.2).  
 
1.3 Introduction to Mitochondria 
1.3.1 Mitochondrial Biology and Metabolism 
Approximately two billion years ago, mitochondria arose from the engulfment of an a-
proteobacterium by a precursor of the modern eukaryotic cell [74]. Across this time 
frame, the mitochondria retained its double membrane structure along with its core 
function of ATP production [75, 76]. This double membrane structure results in four 
distinct compartments within the organelle. These compartments are known as the 
inner membrane, the outer membrane, the intermembrane space, and the matrix 
[77]. The classical ‘textbook’ view which displays the mitochondria as a bean like 
structure, with the outer membrane encasing the highly folded inner membrane, has 
recently been challenged. These images were largely based upon two-dimensional 
electron micrographs however, since the introduction of three-dimensional 
reconstitution technologies, a more detailed picture of mitochondrial morphology has 
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been developed [78]. It is now accepted that the mitochondria exist within a tubular 
reticulum that is able to respond to the dynamic energy demands of the cell [79].  
 
Despite the majority of the genetic material being lost to the nuclear genome 
following endosymbiosis, the mitochondria still possesses its own genetic material 
[80]. The human mitochondrial genome contains the genetic coding information for 
13 proteins [81]. These proteins are core constituents of the mitochondrial electron 
transport chain, which are embedded within the inner membrane. These proteins, 
also known as complexes I to IV function together with the Krebs cycle to create an 
electrochemical gradient through the coupled transfer of electrons across the 
respiratory chain to oxygen (O2) and the pumping of protons from the mitochondrial 
matrix across the inner membrane and into the intermembrane space [82]. This 
electrochemical gradient powers complex V, which is also known as ATP synthase. 
ATP synthase is an ancient rotary turbine that catalyses the synthesis of cellular ATP 
[82]. Commonly referred to as “the powerhouse of the cell”, the mitochondria are the 
engines that primarily function to produce both ATP and carbon dioxide (CO2) at the 
expense of substrates and molecular O2.  
 
Within skeletal muscle ATP is not stored in great quantities (20-25 nmol/kg/dry 
weight) and during skeletal muscle contraction or a heightened metabolic demand, 
ATP demand can increase up to 100-fold [27]. Therefore, this results in a rapid and 
sustained demand for the production of ATP. In order to meet this requirement, 
skeletal muscle is densely populated with mitochondria, which produce ATP via a 
process known as oxidative phosphorylation. This process takes place in the 
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mitochondrial inner membrane where the individual complexes that make up the 
electron transport chain reside [83]. The energy conserving complexes known as 
complexes I, III and IV are protein-lipid enzyme complexes that function to pump 
protons across the inner mitochondrial membrane [84, 85]. Whilst complex II is also 
an important member of the electron transport chain, it is mechanistically incapable 
of pumping protons [86]. Under steady state conditions the total extrusion and re-
entry of protons across the inner mitochondrial membrane is balanced. However, 
during active synthesis of ATP, the primary pathway for proton re-entry is that of ATP 
synthase. In brief, the TCA cycle intermediates nicotinamide adenine dinucleotide 
(NADH) and flavin adenine dinucleotide (FADH) donate electrons to the individual 
complexes [82, 87]. Hydrogen ions (H+) are then extruded into the intermembrane 
space by proton pumping complexes. This results in the intermembrane space 
becoming positively charged in comparison to the mitochondrial matrix. As a result of 
this difference, H+ ions diffuse through the ATP synthase enzyme, which drives the 
conversion of ADP to ATP [87].  
 
Whilst the primary function of the mitochondria is the bioenergetic production of ATP, 
mitochondria are also involved in a number of other processes within the cell 
including apoptosis, the generation of reactive oxygen species (ROS) and Ca2+ 
handling [88-90].  
 
1.3.2 Mitochondrial Plasticity in Response to Endurance Exercise 
Mitochondrial biogenesis is a well-characterised response to increased contractile 
activity in skeletal muscle [66, 69]. During this process, mitochondria not only 
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increase in number and volume, but also undergo coordinated events of fission and 
fusion, increases in respiratory capacity and alterations in substrate utilisation [66, 
69, 70]. The magnitude of these changes are dependent on both training volume and 
intensity [91], whilst they are also reversible following periods of de-training [92, 93]. 
These processes are highly dynamic in their nature with half-lives of approximately 
one week having been observed for mitochondrial proteins [94, 95].  
 
One of the key characteristics of mitochondrial biogenesis is an increase in 
mitochondrial mass, with regular contractile activity increasing skeletal muscle 
mitochondrial density by up to as much as 100% [96]. Transmission electron 
microscopy (TEM) is currently regarded as the gold standard technique to assess 
mitochondrial volume density [97], although cardiolipin content and citrate synthase 
(CS) activity are also viewed as valid biomarkers [98]. Studies utilising TEM have 
provided evidence of an increase in both the size and number of the mitochondria in 
response to exercise in both rats [99] and humans [100-105]. Similarly, studies 
employing CS activity as a surrogate marker of mitochondrial mass have reported 
similar findings [68, 106, 107]. Increases in the size and number of the mitochondria 
translate to increases in protein content of the mitochondrial fraction within skeletal 
muscle including key components of the electron transport chain such as cytochrome 
c (cyt c) [66, 70, 108]. In concordance with these changes, increases in the activity of 
TCA cycle enzymes CS, NAD-specific isocitrate dehydrogenase, succinate 
dehydrogenase (SDH) and malate dehydrogenase all increase in rat skeletal muscle 
following daily running exercise [70]. Enzymes within the electron transport chain 
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show similar responses with SDH, NADH dehydrogenase, NADH-cyt c-reductase 
and cyt c-oxidase all increasing up to two-fold [47].   
 
Within skeletal muscle, the mitochondria exist within a morphologically tubular 
reticulum that is dynamic in its nature [79]. Due to the large size of skeletal muscle 
fibres, the existence of a dynamic mitochondrial reticulum may be beneficial in 
instances where the demand for both energy and substrates is not homogeneously 
distributed across the fibre [79]. Alterations within the shape and size of this reticulum 
are likely regulated by metabolite transport, increases in energy demand and oxygen 
diffusion [109, 110]. Indeed, in response to endurance exercise training, it was noted 
that the commonly observed increases in mitochondrial protein content are due to the 
proliferation of the mitochondrial reticulum [71]. Not only does this reticulum fuse and 
proliferate, but it also undergoes events of fission where potentially damaged or 
dysfunctional regions of the mitochondria are segregated and subsequently broken 
down [110]. These events of both fusion and fission are simultaneously regulated in 
order to maintain mitochondrial homeostasis and emerging evidence suggests that 
they are key to the mitochondrial remodelling response to endurance exercise [72, 
73, 111, 112]. Several proteins are known to facilitate the processes of fusion and 
fission including; mitofusins 1 and 2 (MFN1 and MFN2), optic atrophy type 1 (OPA1), 
dynamin-related protein 1 (DRP1), fission 1 (FIS1) and mitochondrial fission factor 
(MFF). Whilst the precise roles of the aforementioned fusion/fission proteins across 
the time course of exercise adaptation are still to be elucidated, a number of studies 
have sought to characterise the mitochondrial remodelling process in response to 
chronic endurance exercise [112-116]. Current evidence points towards a shift 
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towards an increase in mitochondrial fusion in response to exercise or chronic 
contractile activity. For example, 12-weeks of aerobic exercise results in an increase 
in the protein expression of both MFN1 and 2, both of which are known to be 
involved in the fusion of outer mitochondrial membrane [113]. Additionally, increases 
in the expression of OPA1 have been observed when utilising electrical stimulation 
as a means to induce contractile activity in both rats and humans [112, 114]. OPA1 is 
known to modulate fusion of the inner mitochondrial membrane and regulate cristae 
morphology [117]. In concert with its increased expression in both rat and human 
skeletal muscle following chronic contractile activity, the mitochondria were observed 
to be larger and more reticular in their morphology [112, 114]. Whilst others have 
reported similar increases in pro-fusion proteins, they have also observed increases 
in mitochondrial fission related proteins in response to exercise training [115, 116]. 
Following 8-weeks of swimming exercise, an increase in Drp1 was observed as well 
as Mfn2 and Opa1 in mouse skeletal muscle [115]. Similar responses were observed 
following seven high-intensity interval training sessions with increases in the protein 
content of both FIS1 and DRP1, as well as MFN1 [116]. Although Drp1 is a known 
mediator of mitochondrial fission, an increase in protein content alone is unlikely to 
result in an increase in mitochondrial fission. Either mitochondrial translocation or 
post translational modifications such as phosphorylation are a more accurate readout 
of Drp1 activity [118]. For example, recent evidence suggests that the 
phosphorylation of Drp1 at serine 637 is increased in mouse skeletal muscle 
following chronic endurance exercise training [111]. A modification that has been 
proposed to reduce mitochondrial Drp1 translocation and mitochondrial fission [119]. 
Interestingly, the action of Drp1 has also been linked to mitochondrial fusion events. 
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Mitochondria have been reported to undergo events of both complete and transient 
fusion, with transient fusion events dependent on Drp1 action [111, 120]. Whilst 
these data indicate a pro-fusion phenotype in response to exercise, it was recently 
observed that the previously reported increases in pro-fusion proteins such as MFN1, 
MFN2 and OPA1 in response to exercise are reduced when normalised for 
mitochondrial protein content [72]. However, a reduction in FIS1 was independent of 
changes in mitochondrial protein content [72]. Although the data points towards a 
pro-fusion phenotype, it is difficult to interpret such studies given the dynamic nature 
of these mitochondrial remodelling process. Static measurements in response to 
exercise training only provide a snapshot of the whole story and clearly more 
evidence and better models to study these processes are needed for future 
investigations.  
 
As mentioned previously, sections of the mitochondrial reticulum may be segregated 
via fission related processes and subsequently broken down by the catabolic process 
of autophagy [110, 115]. The selective removal of dysfunctional mitochondria is 
commonly referred to as mitophagy, highlighting the specific and non-random nature 
of this process [121]. Events of mitophagy may be upregulated in response to 
increased mitochondrial fragmentation, loss of mitochondrial membrane potential and 
increased mitochondrial ROS emission [122-124]. Currently, the most established 
pathway for the process of mitophagy involves PTEN-induced putative kinase 1 
(PINK1) and the ubiquitin E3 ligase Parkin [125]. Under normal conditions, PINK1 is 
continuously degraded following translocation to the inner mitochondrial membrane 
[126]. However, following the depolarization of the mitochondrial membrane, PINK1 
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translocation is impaired, which results in its stabilization on the outer mitochondrial 
membrane [127]. Under these conditions, PINK1 undergoes autophosphorylation on 
serine residues 228 and 402, which serve to recruit and activate Parkin [128, 129]. 
Both Parkin and Ubiquitin are phosphorylated by PINK-1 allowing for the accretion of 
polyubiquitin chains on the outer mitochondrial membrane, tagging the organelle for 
degradation [130-132]. Polyubiquitination results in the binding of the autophagy 
related protein p62 which can associate with lipidated microtubule-associated 
protein-light chain 3 (LC3II) [133, 134]. LC3II is located on the phagophore 
membrane and its binding with p62 results in the autophagosomal engulfment of the 
mitochondria [133]. Finally, this autophagosome is completely degraded at the 
lysosome [133, 135]. It should be noted that whilst these pathways are well 
established in lower organisms, the precise mechanisms of mitophagy within skeletal 
muscle are still to be elucidated. The role of mitophagy in the exercise-induced 
mitochondrial remodelling process is an ongoing area of research with the roles of 
both PINK1 and Parkin becoming the focus of attention. For example, it has 
previously been reported that in response to a period of chronic swimming exercise, 
the protein content of both Pink1 and Parkin remained unchanged [115]. However, 
protein content alone is unlikely to be an accurate readout for mitophagy given the 
activity of said proteins is reliant on localisation to outer mitochondrial membrane and 
phosphorylation status. Interestingly, both phospho-PINK1Thr257 and ParkinSer65 were 
elevated in trained human skeletal muscle when compared with sedentary individuals 
[136]. Additionally, following 6-weeks of voluntary wheel running, an increase in the 
localisation of Parkin to the outer mitochondrial membrane was observed in mouse 
skeletal muscle [137]. Whilst these data potentially highlight an increase in basal 
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mitophagy in trained skeletal muscle, it should be noted that further downstream 
markers of increased autophagy such as p62 or LC3II mitochondrial localisation were 
not apparent in trained mouse skeletal muscle [137]. In addition to the established 
mechanisms of PINK1 and Parkin, the beta-cell lymphoma 2 (BCL-2) related protein 
BCL-2 interacting protein 3 (BNIP3) has been reported to increase in both mouse 
and rat skeletal muscle following chronic endurance exercise [138, 139]. Due to its 
localisation within the mitochondria and its ability to interact with LC3, BNIP3 can be 
defined as a mitophagy receptor [140]. Primarily involved in hypoxia induced 
mitophagy, BNIP3 is transcriptionally regulated by hypoxia-inducible factor 1-alpha 
(HIF1a) [141] and phosphorylation promotes binding with LC3 therefore facilitating 
mitophagy [142]. Again, the precise mechanisms of BNIP3 mediated mitophagy 
within skeletal muscle are unknown and it remains to be seen whether the reported 
increases in BNIP3 result in an increase mitophagic activity. Clearly more research is 
needed to fully understand how mitophagy contributes to the exercise induced 
mitochondrial remodelling process. More sophisticated models to assess mitophagy 
such as the mito-Quality Control and MitoTimer mouse will aid in the development of 
our understanding of said processes [143, 144]. These models both utilise 
fluorescent probes that are sensitive to either changes in pH or oxidation allowing for 
the assessment of mitophagy and mitochondrial morphology in a tissue-specific 
manner [143, 144].  
 
As discussed previously, the core function of the mitochondria is to generate ATP at 
the expense of substrates and molecular O2. The respiratory function of the 
mitochondria can be assessed by measuring the oxygen consumption rate within 
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isolated mitochondria [145]. In response to exercise training, it is well established that 
the capacity to generate ATP is increased within human skeletal muscle 
mitochondria [93, 146]. Whilst O2 consumption is commonly assessed in isolated 
mitochondria, its measurement in permeabilised muscle fibres is currently considered 
the gold standard [147]. Cross-sectional studies have shown that training status is 
associated with an increase in mass-specific mitochondrial respiration [148-151] and 
it was Holloszy that first demonstrated an increase in O2 consumption in response to 
exercise training in isolated mitochondria from rat skeletal muscle [66]. Mitochondria 
from the trained cohort exhibited a high level of respiratory control and tightly coupled 
oxidative phosphorylation, indicating that the increase in the capacity of the electron 
transport chain was associated with an increase in the capacity to generate ATP [66]. 
Findings which were later confirmed in mitochondria isolated from guinea pig [152] 
and human skeletal muscle [153]. More recently, utilising protocols to assess 
mitochondrial respiration in permeabilised muscle fibres, it has been reported that 
exercise training increases human skeletal muscle mitochondrial respiratory capacity 
in an exercise intensity dependent manner [154-156]. Training volume on the other 
hand, is not a primary determinant of training-induced changes in mitochondrial 
respiration within human skeletal muscle [91, 157]. Differences in the ensuing 
adaptations following exercise training may result from differences in fibre type 
recruitment. Exercise undertaken at higher relative exercise intensities may result in 
an increase in the recruitment of type II fibres [158, 159]. Additionally, key signalling 
cascades that are known to be key drivers of training-induced adaptations are also 
known to be differentially regulated by exercise intensity with higher exercise 
intensities resulting in an increased signalling response [160].    
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Alongside gross changes in mitochondrial respiration, the sensitivity of oxidative 
metabolism to ADP is also altered in response to endurance exercise training. Initially 
postulated by Holloszy [69], this model suggests that less ADP would be required to 
stimulate a given rate of aerobic ATP production [69]. Typically, during exercise, free 
ADP concentrations rise, however, following exercise training this increase is 
attenuated highlighting tighter metabolic control [161, 162]. More recently, the 
development of a protocol utilising high-resolution respirometry to determine 
biologically relevant ADP Michaelis-Menten constant (Km) values [163] and thereby 
assess ADP sensitivity across multiple ADP concentrations within permeabilised 
muscle fibres has yielded ambiguous results [150, 164, 165]. Indeed, cross sectional 
analyses of healthy humans across differing physical activity levels indicates a 
decrease in ADP sensitivity in athletic individuals [150]. Furthermore, the sensitivity 
of the mitochondria to ADP as measured by the apparent Km  for ADP was three-fold 
higher when comparing athletic to sedentary subjects [150]. Whilst similar findings 
have been reported in rat skeletal muscle following exercise training [165] and 
indirectly suggested by others [166, 167], a decrease in the sensitivity of skeletal 
muscle mitochondria to ADP following exercise training seems surprising. A possible 
means to explain this paradox involves the control of cellular respiration within 
different skeletal muscle fibre types. For example, the apparent Km for ADP has been 
reported to be up to 30-fold higher in rat and mouse skinned fibres from the soleus 
when compared to the gastrocnemius [168, 169].  Additionally, whilst the sensitivity 
of ADP is decreased in athletic individuals and following exercise training, absolute 
rates of respiration are higher following training likely due to an increased 
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mitochondrial volume which may be more relevant to whole-body physiology [170]. 
Finally, given that the rates of absolute respiration are increased, an increased 
sensitivity to ADP and therefore lower apparent Km in trained individuals would result 
in resting mitochondrial respiration of between 25-65% that of maximal [171]. 
Therefore, the observed increase in apparent Km in this instance may contribute to 
the fine tuning of mitochondrial respiration in order to better meet the local energy 
demands of skeletal muscle [150]. The attenuation of mitochondrial ADP sensitivity 
following training is depicted below (Figure 1.1) [172].  
 
Figure 1.1. ADP respiratory kinetics in permeabilised skeletal muscle fibres in the presence of 
saturating concentrations of pyruvate plus malate pre and post exercise training. A) 
Mitochondrial respiration normalised to dry weight both pre and post training intervention. B) 
Mitochondrial respiration normalised to dry weight with rescaled axis highlighting that less ADP is 
required to elicit a given rate of oxygen consumption post training. C) The same data now expressed 
as percentage of maximum. D) The same data expressed as a percentage of maximum highlighting 
that a higher concentration of ADP is required to achieve 50% of maximal respiration. These data 
suggest that the intrinsic sensitivity of the mitochondria is actually decreased with training. Holloway 
(2017).  
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1.3.3 Mitochondrial Plasticity in Response to Nutritional Interventions 
Primarily utilised in an additive fashion to exercise training, a number or nutritional 
strategies and nutrient compounds have been proposed to enhance mitochondrial 
function and remodelling within skeletal muscle [173]. Whilst many compounds have 
shown promise in vitro [173], this section will focus on nutritional compounds that 
elicit mitochondrial alterations within skeletal muscle in vivo.  
 
Compounds that could potentially mimic the benefits of exercise in the absence of a 
training stimulus (i.e. exercise mimetics) were proposed and gained widespread 
attention in the media [174]. The most heralded of these approaches was the 
administration of the peroxisome proliferator-activated receptor delta (PPAR-d) 
agonist GW501516 in combination with 4-weeks of endurance exercise resulted in a 
robust increase in running time (68%) and distance (70%) in mice [174]. Following 
this observation, the authors then substituted exercise for the administration of the 5’ 
adenosine monophosphate-activated protein kinase (AMPK) agonist 5-
aminoimidazole-4-carboxamide ribonucleotide (AICAR) [174]. The combined 
compound administration resulted in increase in running time (23%) and distance 
(44%) and the proposal that the compound combination was able to act as an 
exercise mimetic and enhance skeletal muscle metabolism [174]. Unfortunately, the 
authors did not compare the combined treatment of GW501516 and AICAR to 
exercise alone or in combination with exercise. Additionally, the treatment of 
GW501516 alone was unable to increase exercise capacity, suggesting it is not an 
exercise mimetic and more likely an exercise enhancer [174]. Garnering widespread 
attention, the feasibility of exercise mimetics has since been brought into question 
	 21 
[175-177]. Since the early promise, the work has failed to translate into human 
studies primarily due to the poor bioavailability of AICAR [178, 179]. Furthermore, the 
chronic activation of PPAR-d has been linked to cancer progression, raising 
questions in regards to its efficacy as a proposed long-term treatment [180]. Given 
the widespread, multi-organ health benefits of exercise [181], an exercise mimetic 
targeting a single protein is unlikely to be feasible [175, 176]. More recently however, 
the use of bioactive compounds (vitamins or polyphenols) seems to hold promise 
[172, 173, 182]. 
 
One of the most well-known polyphenols is resveratrol which is found in grapes and 
was first isolated from red wine [183]. Resveratrol has been shown to aid in 
mitochondrial remodelling in mice fed a high-fat diet [184]. Indeed, mice fed a high-fat 
diet for 15-weeks with the addition of resveratrol show signs of increased 
mitochondrial volume, evidenced by increased mitochondrial size, mitochondrial DNA 
(mtDNA) content, SDH and CS activity [184]. Further to this, resveratrol was also 
shown to increase endurance capacity in mice and promote fat oxidation [185]. In 
contrast however, these promising reports in rodents have failed to translate to 
human studies and resveratrol supplementation has led to maladaptive responses to 
exercise training [186, 187]. 
 
Another polyphenol with a similar structure to that of resveratrol is quercetin which 
has been reported to promote numerous health benefits [188]. The supplementation 
of quercetin in mice across a 7-day period resulted in a doubling of mtDNA content in 
skeletal muscle as well increases in cyt c [189]. The adaptations were likely mediated 
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by an upregulation of the transcriptional coactivator peroxisome proliferator-activated 
receptor gamma co-activator 1-alpha (PGC-1a) [189]. In concert with the observed 
increases in mitochondrial content, mice fed quercetin exhibited increases in exercise 
capacity [188]. Whilst some of these findings have been replicated in human 
populations, including increased exercise performance and mtDNA content [190], 
others have shown no effect [191-193].  
 
The flavanol (-)-epicatechin a derivative of cocao has shown early promise, primarily 
via the consumption of small amounts of dark chocolate which has been linked to 
multiple health benefits including reductions in the development of cardiovascular 
disease [194]. In terms of its effects on the mitochondria, Nogueira and colleagues 
were the first to demonstrate that 15-days of (-)-epicatechin supplementation in mice 
increased mitochondrial volume in concert with increases in treadmill running 
performance, fatigue resistance and skeletal muscle capillarity [195]. Interestingly, 
the supplementation of (-)-epicatechin alone was able to increase skeletal muscle 
mitochondrial protein content as well skeletal muscle capillarity to a similar extent as 
the exercise alone group suggesting beneficial effects can be achieved without a 
training stimulus. Although the combined treatment of exercise and (-)-epicatechin 
resulted in further additive increases suggesting the combination treatment may be 
optimal [195]. Further studies examined the role of (-)-epicatechin following 5-weeks 
of endurance training followed by 2-weeks de-training [196]. The supplementation of 
(-)-epicatechin across the de-training period was able to maintain the prior training 
induced increases in cyt c oxidase activity and capillary to fibre ratio [196]. Whilst 
these data have yet to be repeated in human trials, the supplementation of flavanols 
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including (-)-epicatechin appears to hold promise for enhancing mitochondrial 
adaptations to endurance exercise training.  
 
Dietary nitrate is primarily obtained via the consumption of green leafy vegetables or 
from the consumption of beetroot juice [197]. The supplementation of dietary sodium 
nitrate over a three-day period resulted in a reduction in the oxygen demand during 
submaximal workloads in healthy trained individuals [198]. Furthering this work, 
multiple parameters of mitochondrial respiration were altered following the same 
supplementation protocol [199]. Nitrate supplementation increased the mitochondrial 
respiratory control ratio, suggesting an improved coupling between oxidative 
phosphorylation and ATP production [199]. Furthermore, supplementation also 
resulted in an increased phosphate/oxygen (P/O) ratio at submaximal concentrations 
of ADP indicative of altered stoichiometry [199]. Interestingly, beetroot juice, a source 
of dietary nitrate, also reduces the oxygen cost of exercise at submaximal workloads 
[200, 201], although this does not seem to be mediated by adaptations to the 
mitochondria [202].  
 
Omega-3 fatty acids, particularly those enriched with eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) are known to alter mitochondrial membrane 
phospholipid composition following supplementation [203, 204]. An increased 
incorporation of polyunsaturated fatty acids into the mitochondrial membrane resulted 
in an increase in mitochondrial ADP sensitivity in human skeletal muscle [203]. 
Maximal ADP stimulated respiration remained unchanged, a finding also observed in 
rodents [205], suggesting the function of the electron transport chain was not altered 
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[203]. No changes were also observed in the protein content of adenine nucleotide 
translocase 1 (ANT1) and 2 (ANT2) or ATP synthase although post-translational 
modifications of these proteins may mediate the observed increase in ADP sensitivity 
[203, 206]. More recently, the effects of EPA and DHA supplementation both 
preceding and across a period of immobilisation have been studied. Whilst 14-days 
of immobilisation reduced ADP stimulated respiration (-20%), the supplementation of 
omega-3 fatty acids during the 4-weeks preceding and during the immobilisation 
period attenuated these reductions [207]. Whilst similar observations were noted for 
respiration stimulated by submaximal ADP concentrations, the pre control group had 
increased respiration when compared to the pre supplementation group [207]. 
Therefore, the fact that omega-3 supplementation attenuated to reductions in 
respiration may be a product of reduced respiration in the pre-supplementation 
controls. Whilst interesting, the effects of omega-3 supplementation on mitochondrial 
adaptation to training are yet to be studied.  
 
Given the wide variety of vitamins and bioactive compounds isolated from various 
fruits and vegetables there are still many questions to be answered in terms of how 
these compounds may enhance mitochondrial function either alone or in combination 
with training. Studies utilising bioactive compounds are often limited by the 
bioavailability of said compounds and future research should examine the extent to 
which the compound in question is absorbed and bioavailable to skeletal muscle 
[182].  
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1.4 Introduction to Vitamin D 
1.4.1 History of Vitamin D 
The idea that the adequacy of the diet could be described by the content of 
carbohydrate, fat, protein and minerals remained largely unchallenged until the 
beginning of the twentieth century when reports began to emerge suggesting that 
additional micro-organic nutrients may be required [208, 209].  
 
Towards the end of the nineteenth century the industrial revolution had taken place 
which resulted in the urbanisation of the population. The resulting smoke from 
industrial plants polluted the atmosphere, and in low-sunlight countries such as 
England, rickets appeared in epidemic proportions [210]. Rickets is a condition by 
which the skeleton becomes poorly mineralised and deformed often resulting in pain 
and growth abnormalities [211]. The previous discovery of vitamins led to the 
reasoning that rickets may also be caused by some form of dietary deficiency [212]. 
Early investigations utilised cod liver oil to cure rickets with the vitamin A contained 
within cod liver oil viewed as the therapeutic. However, despite the removal of 
vitamin A from cod liver oil via aeration and heating, cod liver oil still retained the 
ability to cure rickets [213] suggesting that cod liver oil contained another active 
vitamin. Once characterised, this vitamin later became known as vitamin D [212, 214, 
215], now viewed as an essential nutrient [215].  
 
During the same period, it was discovered that rickets could be both prevented and 
cured in children by exposing them to either sunlight or artificially induced ultraviolet 
B (UVB) light [216]. Studies in goats also revealed that sunlight exposure was 
	 26 
important for the maintenance of calcium balance due to the fact that those animals 
that were maintained indoors lost much their calcium to lactation [217]. This work 
resulted in the discovery that irradiation of the animals’ diets could induce vitamin D 
activity and thus cure rickets [218]. The discovery that UVB light could be utilised to 
induce vitamin D activity and fortify foods resulted in the elimination of rickets as 
major medical problem [218, 219]. This work also revealed that vitamin D was not a 
vitamin and was in fact a steroid hormone [219].  
 
1.4.2 Forms of Vitamin D 
Multiple biological forms of vitamin D are known to exist. Vitamin D2, also known as 
ergocalciferol was first isolated from the irradiation of plant sterols [214]. Vitamin D3, 
which is also known as cholecalciferol was first identified following the isolation of 7-
dehydrocholesterol which is the precursor for vitamin D3 within the skin. The fact that 
vitamin D3 is the form that is produced in the skin was later confirmed via the 
chemical identification of both pre-vitamin D3 and vitamin D3 in the skin [220, 221]. 
Both vitamin D2 and D3 are the major sources of vitamin D that contribute to vitamin 
D status. Both forms are found within dietary sources however, only D3 is produced 
endogenously within the skin following the exposure to UVB irradiation [221]. The 
chemical structure of both vitamin D forms is depicted below with the side chain of D2 
containing a double bond and the addition of a methyl group at carbon 24 (Figure 
1.2).  
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Figure 1.2. Nutritional forms of vitamin D. Vitamin D3 also known as cholecalciferol and vitamin D2 
also known as ergocalciferol [222]. 
 
 
 
1.4.3 Synthesis of Vitamin D 
Upon exposure to sunlight and more specifically UVB irradiation at a wavelength of 
290-315 nm [223], human skin is able to synthesise vitamin D [224]. The 
photochemical process that takes place in the plasma membrane of skin cells, results 
in the conversion of 7-dehydrocholesterol (precursor to cholesterol and vitamin D3) to 
the thermodynamically unstable pre-vitamin D3 (pre-cholecalciferol) [224]. It is the 
thermal isomerisation of pre-vitamin D3 that results in the formation of vitamin D3, 
which is a seco-steroid hormone [225]. Within 8 h of exposure to UVB irradiation, 
~80% of pre-vitamin D3 is converted to vitamin D3 [226]. When a sufficient quantity of 
D3 is produced, pre-vitamin D3 is converted to the biologically inactive photoproducts 
of tachysterol and lumisterol [227].  
 
Multiple factors can influence the synthesis of vitamin D. For example, the 
pigmentation of the skin plays an important role in regulating the dermal synthesis of 
vitamin D3 [228]. An increased melanin pigmentation will reduce the efficiency of the 
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sunlight mediated photosynthesis of pre-vitamin D3 [228]. The amount of radiation 
that actually enters the atmosphere and is therefore available for the cutaneous 
production of vitamin D is also an important factor [229, 230]. This is dependent on 
the time of the day, latitude, and season which alter the zenith angle of the sun [231]. 
As well as melanin, any substance that absorbs UVB radiation such as sunblock or 
clothing will also reduce the cutaneous production of vitamin D3 [232-234]. The use of 
sunscreen is widely used and effective method of reducing the damaging effects of 
chronic exposure to sunlight such as sunburn, skin cancer and skin damage. A 
sunscreen with a sun protection factor (SPF) of 30 will absorb up to 97.5% of UVB 
radiation and therefore reduce the production of vitamin D3 [232]. 
 
1.4.4 Dietary Sources of Vitamin D 
Nutrients that are not naturally synthesized will need to be obtained via an alternative 
source and an obvious solution to this is through dietary intake. Although there are 
few, some dietary sources of vitamin D do exist [235]. Dietary sources of vitamin D 
include oily fish, powdered milk, eggs and shitake mushrooms, as well as fortified 
foods such as bread, milks, cheese and breakfast cereals [235]. The current 
Recommended Daily Allowance (RDA) for vitamin D is 15 µg/day (600 IU) up to the 
age of 70 years and 20 µg/day (800 IU) thereafter [236]. Investigations into the 
current dietary intake of vitamin D reveal that the median intake for adults within the 
USA was 5.8 µg/day when both fortified foods and supplements were included [237]. 
Adding further difficulty to obtaining a sufficient amount of vitamin D from the diet, it 
has been reported that some foods stating fortification with vitamin D may contain 
less than 80% of the vitamin D claimed [231, 238]. Therefore, intake of vitamin D 
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containing foods is limited and it is unlikely that humans obtain enough vitamin D 
from dietary sources to compensate for a lack of sunlight exposure [237]. 
 
1.4.5 Metabolism of Vitamin D 
Whether vitamin D is obtained via the exposure to sunlight or from dietary sources, 
both forms will enter the circulation bound to the vitamin D binding protein (DBP) 
[239]. The DBP is present within serum in the micromolar concentrations and is 
responsible for the transport of all vitamin D metabolites with the highest affinity for 
25(OH)D [240, 241].  
 
Once in circulation, vitamin D undergoes a series of hydroxylation steps including; 
25-hydroxylation, 1a-hydroxylation, and 24-hydroxylation, which are all performed by 
cytochrome P450 mixed-function oxidases (CYPs) [242-244]. The first hydroxylation 
step (25-hydroxylation) occurs within the liver and converts vitamin D to 25(OH)D 
[245]. A number of CYPs have been established to have 25-hydroxylase activity 
including both CYP27A1 and CYP2R1 [242]. CYP2R1 is considered the main 25-
hydroxylase as this enzyme is able to 25-hydroxylate both vitamin D2 and D3 with 
comparable kinetics where as CYP27A1 does not 25-hydroxylate vitamin D2 [242, 
246].  
 
The second hydroxylation step, 1a-hydroxylation is performed primarily in the kidney 
and unlike 25-hydroxylation, only one enzyme is recognised to have 1a-hydroxylation 
activity [243, 244]. This enzyme, known as CYP27B1, is able to convert the 25(OH)D 
produced within the liver to its more biologically active metabolite 1a,25-
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dihydroxyvitamin D (1a,25(OH)2D3) [243, 244, 247, 248]. Despite the kidney being 
known as the main site of 1a,25(OH)2D3 production, a number of other tissues or cell 
types have been shown to express CYP27B1 including keratinocytes, epithelial cells, 
pancreatic islets, cerebellum, and skeletal muscle [249-251]. The ability of the cell to 
bypass the kidney and perform the 1a-hydroxylation step internally will be dependent 
on the ability of the cell to internalize the 25(OH)D bound to the DBP [252, 253]. 
Within skeletal muscle, this is likely achieved via the recently identified membrane 
bound protein Megalin [252] (Figure 1.4).  
 
Lastly, 24-hydroxylation is the final hydroxylation step with CYP24A1 the only 
established enzyme with 24-hydroxylase activity. This pathway is known to result in 
the conversion of the biologically active form of vitamin D (1a,25(OH)2D3) to the 
inactive calcitroic acid. Similar to CYP27B1, CYP24A1 is predominantly expressed 
within the kidney however a number of studies have also revealed its expression in 
other cell types and tissues including skeletal muscle [250, 251]. 
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Figure 1.3. Vitamin D Metabolism. Schematic illustrating the metabolism of vitamin D obtained via 
the exposure of the skin to sunlight or dietary ingestion of vitamin D containing foods. Once in 
circulation, vitamin D is bound to the vitamin D binding protein. Vitamin D then undergoes two 
hydroxylation steps, the first in the liver (25-hydroxylation) and the second in the kidney (1a-
hydroxylation). Note that some target tissues including skeletal muscle also express CYP27B1 
allowing for the local production of 1a,25(OH)2D3. The final hydroxylation step, 24-hydroxylation, 
results in the conversion of   1a,25(OH)2D3 to inactive by products.   Vitamin D has known actions in a 
number of tissues including bone, intestine, kidney, immune cells, tumour micro-environment, adipose 
tissue and skeletal muscle. Adapted from [254].   
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1.4.6 Measurement of Vitamin D Status 
Over 40 metabolites of vitamin D have been identified [255] making the analysis of 
vitamin D metabolism challenging. These metabolites are all in circulation in a variety 
of concentrations and some have an extremely short half-life making them of minimal 
physiological relevance [256]. Currently, it is the measurement of 25(OH)D which 
regarded as the best representation of vitamin D exposure [257]. In comparison to its 
parent sterol which has a half-life of 24 h, 25(OH)D has a half-life of 21-30 days [249, 
258]. Whilst 1a,25(OH)2D3 is the most biologically active form of vitamin D, it 
circulates in the picomolar (pmol.L-1) concentrations where as 25(OH)D circulates in  
nanomolar (nmol.L-1) concentrations [259, 260].  
 
Whilst the majority of vitamin D is obtained by UVB exposure, the potential for 
supplementation and the fortification of foods with both vitamin D2 and D3 can 
increase the amount derived from endogenous sources [261, 262]. Therefore, it is an 
important consideration to make sure that the assay in question is able to determine 
the amount of both the D2 and D3 metabolites. Various methods have been utilised 
for the measurement of vitamin D metabolites including radioimmunoassay (RIA), 
vitamin D-binding protein assays, high performance liquid chromatography coupled 
with ultra-violet spectrophotometry, and liquid chromatography coupled with mass 
spectrometry (LC-MS/MS) methods [263]. Given that all RIAs evaluated have 
displayed a problem with the detection of 25(OH)D2 and under-recover this 
metabolite [264], isotope dilution LC-MS/MS is considered the gold standard for 
measuring serum total 25(OH)D [265]. Isotope dilution LC-MS/MS is able to quantify 
both 25(OH)D2 and 25(OH)D3 simultaneously with the sum of the two values 
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representing a precise and accurate measure of total 25(OH)D and therefore vitamin 
D status [265, 266].  
 
1.4.7 Categorization of Vitamin D Status 
The current US Institute of Medicine guidelines for vitamin D status are generally 
accepted worldwide (Table 1.1) with the Endocrine Society providing similar 
categorization guidelines [236, 267]. Despite these guidelines, there still remains 
conflicting views on defining vitamin D deficiencies and the concentration of vitamin 
D that could be deemed optimal [268-270]. It has been suggested that in the optimal 
serum concentrations of 25(OH)D for optimal bone mineral density, bone turnover 
and muscle strength should be >75 nmol.L-1 [268, 271]. Others have even suggested 
that concentrations of >100 nmol.L-1 should be considered optimal based upon the 
fact that those in such rich environments close to the equator present with 25(OH)D 
concentrations within this range [272]. The debate on what constitutes vitamin D 
deficiency will likely continue, particularly with the development of more sensitive 
methods to measure an increasing amount of vitamin D metabolites.  
 
Serum 25(OH)D Classification 
<12 nmol.L-1 Severely Deficient 
12 – <30 nmol.L-1 Deficient 
30 – 50 nmol.L-1 Inadequate 
>50 nmol.L-1 Adequate 
Table 1.1. US Institute of Medicine (2011) vitamin D concentrations for classifications of vitamin D 
status [236].  
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1.4.8 Prevalence of Vitamin D Deficiency 
Even in areas with ample sunlight exposure, it has been estimated that around 1 
billion people worldwide currently have insufficient serum 25(OH)D levels according 
to the US Institute of Medicine guidelines [273]. In support of this there are a 
multitude of large population based trials from across Europe that report a high 
frequency of individuals with serum concentrations of <50 nmol.L-1 [274-276]. Further 
to this, it has been reported that 13% of individuals in Europe have vitamin D 
concentrations of <30 nmol.L-1, with that figure rising to 40% including those with 
concentrations <50 nmol.L-1 [14]. With similar prevalence reported within the US 
[277], Australia [278] and even the Middle East [279] it is clear that vitamin D 
deficiency is a common occurrence globally.  
 
Whilst vitamin D deficiency is common across the general population, certain 
subgroups are at an increased risk [14, 16, 280]. For example, children with low birth 
weight, pregnant women and the institutionalised elderly often present with 
inadequate 25(OH)D concentrations [16, 280]. Given that dermal synthesis of vitamin 
D decreases with age and the fact that those who are institutionalised will spend less 
time outdoors due to poor health status, it unsurprising that poor vitamin D status is 
commonly observed within this subgroup [281]. Whilst vitamin D insufficiency is 
common place within the general public, it has also been reported that insufficiency is 
also common within professional athletes [17]. Out of the 61 athletes tested from 
across four differing sports, 61% had serum 25(OH)D concentrations <50 nmol.L-1 
with only one from the 61 tested having concentrations >100 nmol.L-1 [17].  
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1.5 Physiological Role of Vitamin D 
1.5.1 Physiological Effects of Vitamin D Deficiency 
Clearly the reports of a high prevalence of vitamin D insufficiency across multiple 
populations and subgroups are striking however, they do not report on the 
physiological implications of such deficiencies. The classical role of vitamin D 
involves the maintenance of bone health, with severe deficiencies known to cause 
rickets [211], osteomalacia [282] and osteoporosis [283], as well as an increased risk 
of fractures [284].        
 
Rickets is a clinical syndrome in children which results from a delay or failure in 
mineralisation of the growth plate within growing bones [285, 286]. Rickets caused 
due to nutritional deficiencies is currently the most common form of the syndrome 
across the globe [285, 287]. Vitamin D deficiency is a prerequisite for the 
development of nutritional rickets in children, associated with a lack of sunlight 
exposure and an inadequate intake of vitamin D from the diet [288]. Therefore, 
adequate skin exposure to sunlight is essential for the prevention of rickets [223]. 
The prevalence of vitamin D deficiency rickets is most common in children between 
three months and two years of age [289]. Due to the fact that 25(OH)D readily 
crosses the placenta, new-born infants may be provided with some protection from 
vitamin D deficiency providing the mother had adequate serum concentration of 
25(OH)D [290]. In addition to the more classical roles of vitamin D, vitamin D 
deficiency has also been associated with an increased incidence of cardiovascular 
disease [291], diabetes [292], Alzheimer’s disease [293] and chronic kidney disease 
[294].   
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1.5.2 Musculoskeletal Effects of Vitamin D Deficiency 
Alongside the classical actions of vitamin D, several lines of evidence now support a 
role for vitamin D in the maintenance of skeletal muscle function. A prominent feature 
of vitamin D deficiency is proximal muscle weakness [295], whilst deficiency has also 
been linked to impaired physical performance, diffuse muscle pain, gait impairments 
and an increased risk of falls [296-299].  
 
Multiple animal models have been utilised to study vitamin D deficiency and its role in 
musculoskeletal health. Vitamin D deficiency can be achieved via dietary means 
[300-303], a reduction in sunlight exposure [300] or by the administration of ethane 1-
hydroxy-1, 1-diphosphonate which blocks the production of 1a,25(OH)2D3 [303]. 
Early research into the musculoskeletal effects of vitamin D deficiency revealed 
symptoms of skeletal muscle myopathy including impaired contraction kinetics and 
weakness in the skeletal muscle of chicks and rats [300, 301]. Despite the observed 
impairments in contraction kinetics, no abnormalities were reported in any 
histochemical measures of skeletal muscle morphology or within ATP concentrations 
in the skeletal muscle of vitamin D deficient chicks [300]. Similar observations have 
been made in rat skeletal muscle whereby diet-induced deficiency resulted in a 
significant decrease in muscle force [304]. Interestingly, prolonged deficiency 
resulted in dysregulation of both calcium and phosphate homeostasis and when 
phosphate levels were corrected muscle strength returned to normal [304]. In support 
of this, the administration of vitamin D3 to vitamin D deficient chicks resulted in an 
increase in the incorporation of phosphate into skeletal muscle, suggesting that 
vitamin D stimulates phosphate fluxes across muscle membranes [305]. Whilst these 
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data suggest the effects of vitamin D deficiency on skeletal muscle may be indirect, a 
reduced expression of components of the sarcomere, including actin and the myosin-
troponin complex were also observed in the same animals which may explain the 
reductions in muscle force [303, 305]. More recently, diets containing increased 
calcium and phosphate have been utilised in order to try to minimise the observed 
hypocalcemia and hypophosphatemia that are associated with the induction of 
vitamin D deficiency [302]. Interestingly, when fed this diet, mice have a reduced grip 
strength as well an increased gene expression of Myostatin and muscle RING-finger 
protein-1 (Murf1) [302], two known regulators of skeletal muscle mass [306, 307]. 
Similar impairments in physical function were observed when mice were fed a 
vitamin D deficient diet for longer periods (8-12 months) [308]. Whilst mice fed a 
vitamin D deficient diet displayed reductions in grip endurance, sprint speed and 
stride length, no changes were observed in absolute grip strength, lean mass or 
markers of muscle morphology [308].  
 
Observational studies suggest a positive association between serum 25(OH)D levels 
with muscle strength and lower extremity function in older individuals [296, 309, 310]. 
Within a cohort of 1234 men and women aged over 65, subjects with serum 
concentrations of <25 nmol.L-1 displayed a reduction in physical capacity (timed walk 
and chair stands) than those with serum concentrations >75 nmol.L-1 [296]. In 
addition, individuals with a baseline serum concentration of <25 nmol.L-1 are reported 
to have a two-fold greater risk of developing sarcopenia [311]. Studies of this design 
however, are unable establish a causal link between vitamin D deficiency and the 
associated impairments in physical performance. Vitamin D deficiency also results in 
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a dysregulation of calcium and phosphate homeostasis which may result in indirect 
effects on skeletal muscle function. Furthermore, these data are often reserved to 
elderly populations making generalisations difficult, particularly given that these 
cohorts may already suffer from pre-existing conditions that involve high levels of 
systemic inflammation which can substantially degrade vitamin D status [312].  
 
1.5.3 Musculoskeletal Effects of Vitamin D Supplementation 
The effects of vitamin D deficiency upon the musculoskeletal system have been well 
studied to date [296, 300-302, 309]. Given the potential for impairments in 
musculoskeletal health with deficiency, many have also aimed to determine the 
potential health benefits of supplementation across multiple populations. 
Supplementation of vitamin D is commonly administered in combination with calcium 
due to the well-established role of vitamin D in maintaining calcium homeostasis 
[254].  
 
Firstly, multiple observational studies have reported associations between serum 
25(OH)D levels and markers of muscle function including, hand grip strength, lower 
limb strength and gait speed in elderly populations [313-315], although not all have 
reported such associations [316]. Similar observations have been made in athletic 
populations with serum 25(OH)D levels positively associating with increased muscle 
strength, sprint time, hand grip strength [317-320], although again others have failed 
to show such associations [321, 322]. Whilst the majority of such studies report a 
benefit of increasing serum 25(OH)D, particularly for those in the lower echelons of 
serum 25(OH)D, studies of this design are unable to determine causality.  
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Multiple randomised control trials (RCTs) have sought to establish the effect of 
vitamin D supplementation on skeletal muscle performance however, the results 
have been indifferent. The daily combination of vitamin D (800 IU) and calcium (1200 
mg) over a 12-week period resulted in improvements in timed up and go (TUG) test, 
knee flexor strength, knee extensor strength and grip strength in cohort of elderly 
women [323]. Similar observations were made when daily vitamin D (800 IU) and 
calcium (1000 mg) supplementation was carried out over a 12-month period with 
improvements in TUG test and quadriceps strength reported [324]. Improvements in 
skeletal muscle function in both studies resulted in a reduction in the amount of falls 
over the study period when compared to calcium supplementation alone [323, 324]. 
Some improvements in muscle function have also been observed in athletic 
populations. Footballers randomised to receive daily vitamin D (5000 IU) for a period 
of 8-weeks recorded improvements in vertical jump height and 10 metre sprint time 
[17]. Further to this, a single dose of vitamin D (150,000 IU) resulted in improvements 
in quadriceps and hamstring strength in a cohort of Judoka athletes [325]. On the 
other hand, multiple RCTs have reported conflicting results. For example, 6-months 
of vitamin D (400 IU/day) and calcium (500 mg/day) resulted in no improvements in 
grip or knee strength in a cohort of elderly female patients [326]. Similarly, 
supplementation of vitamin D every 3-months (150,000 IU) for 9-months resulted in 
no change in grip strength and did not reduce the number of falls in a cohort of 
community-dwelling women [327]. Further negative results have also been reported 
in athletic populations with multiple studies showing no differences in muscle 
strength, muscle power, sprint time and hand grip strength with daily vitamin D 
supplementation [328-331].  
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Meta-analyses combining many of these RCTs have also reported indifferent results 
on the proposed benefits on vitamin D supplementation [332-336]. A meta-analysis 
combining six RCTs reported an increase in both lower and upper limb strength 
following vitamin D supplementation in young healthy individuals [332]. Whilst similar 
increases in lower limb strength were reported in athletic individuals, vitamin D 
supplementation did not increase upper limb strength or muscle power when eight 
RCTs were combined [333]. One meta-analysis containing 30 RCTs with a combined 
5615 individuals reported a favourable effect of vitamin D when compared with 
placebo on skeletal muscle strength [334]. Supplementation was deemed more 
effective in adults with 25(OH)D concentration of <30 nmol.L-1 and in individuals older 
individuals (>65 years). Whilst another meta-analysis reported similar findings in 
relation to supplementation being more effective in those with serum concentrations 
of <30 nmol.L-1, they overall reported no effective of vitamin D supplementation 
muscle strength [335]. Interestingly, vitamin D supplementation was reported to have 
a positive additive effect when combined with resistance training in increasing lower 
limb muscle strength in older adults [336], suggesting vitamin D status may influence 
exercise adaptation.  
 
Clearly, conflicting evidence exists when it comes to the proposed benefits of 
supplemental vitamin D on musculoskeletal health. Disparity in outcomes may in part 
be explained by the multitude of supplementation protocols and periods employed 
throughout previous studies. Whilst some studies have opted for a daily approach 
(400 to 800 IU) [323, 324], others have utilised large single dose bolus’ (300,000 IU) 
[337] which could result in different outcomes. Indeed, large single dose bolus’ have 
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been shown to have detrimental effects and actually increase the risk of falls and 
fractures [338-340]. A possible explanation for this involves an increase in the 
activation of CYP24A1, the hydroxylase responsible for the catabolism of 
1a,25(OH)2D3 [338]. Previously, rats given a large bolus of vitamin D (75,000 
IU/week) displayed a significant increase in renal CYP24A1 which resulted in a 
significant reduction (60%) in serum 1a,25(OH)2D3 [341]. Therefore, high bolus’ may 
be counterproductive and actually dysregulate vitamin status in the short-term [338]. 
On the whole, vitamin D seems to be most effective in elderly populations and even 
more so in those that in the lower ranges of serum 25(OH)D [334, 335].  
 
1.6 The Vitamin D Receptor 
1.6.1 Discovery of the Vitamin D Receptor 
The first study to propose that vitamin D acted through a specific binding protein or 
vitamin D receptor (VDR) was published by Haussler and Norman in 1969 [342]. In 
this study, the authors reported on the successful isolation of a receptor for the 
biologically active form of vitamin D from the chromatin fraction of the chicken 
intestine [342]. Subsequent work built upon the biochemical properties of the 
receptor with the discovery that the protein primarily resided within the cytoplasm 
before translocating to the nucleus upon ligand binding [343, 344]. The binding of the 
VDR with 1a,25(OH)2D3 takes place with a high affinity and high selectivity [345] 
although, the VDR is able to bind albeit less effectively to other vitamin D metabolites 
[346]. Finally, the cloning of the VDR in 1987 provided direct evidence that the VDR 
was indeed a member of the steroid class of nuclear receptors [347-349].  
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1.6.2 Function of the Vitamin D Receptor 
Upon ligand binding and nuclear translocation, the VDR serves to recruit 
coregulatory complexes that mediate gene regulation at the transcriptional level 
[350]. The discovery of a number of gene candidates that were activated by 
1a,25(OH)2D3 prompted investigations into how vitamin D related signalling could 
promote their respective regulation [351, 352]. Studies investigating the regulation of 
genes such as Osteocalcin [352] and Cyp24a1 [351] suggested that the VDR bound 
to vitamin D response elements (VDREs) within the promoter regions of the 
respective regulated genes. The binding of the VDR to these VDREs is dependent 
upon the VDR forming a heterodimer protein complex with the steroid receptor family 
known as the retinoid X receptor (RXRs) [353]. Upon binding of the VDR:RXR 
complex to the VDREs, the complex is able to recruit multiple coregulatory 
complexes of unique functions that serve to remodel chromatin and subsequently 
influence gene transcription. These complexes remodel chromatin via the 
repositioning of nucleosomes via ATPase enzyme activity [354], modify lysine or 
arginine residues of histones 3 and 4 at specific locations via the activity of histone 
acetyltransferases [355] or bind with complexes that allow for the entry of RNA 
polymerase II into the transcriptional apparatus and the subsequent activation of 
transcription [356].   
 
Alongside these classical actions of the VDR, binding of 1a,25(OH)2D3 to the VDR 
has also been proposed to result in rapid non-genomic signalling [357]. For example, 
a VDR distinct of the nuclear VDR has been proposed to exists on the cell membrane 
due to the fact that some vitamin D analogues are able to initiate rapid signalling 
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events without binding to the nuclear receptor [358]. A specific protein was identified 
that resided in the basal-lateral membranes of chick intestinal epithelium which was 
able to bind to 1a,25(OH)2D3 and regulate Ca2+ transport across such membranes 
[359]. This protein was initially termed the membrane-associated rapid response 
steroid (MARRS) binding protein however, it was later identified as a multifunctional 
thioredoxin-like protein known as glucose responsive protein 58 (GRP58) or 
endoplasmic reticulum protein 57 (ERp57) [360, 361]. Binding of 1a,25(OH)2D3 
stimulates intracellular calcium flux with osteoblasts as well as the activation of 
protein kinase C (PKC) [362]. Whilst VDR independent signalling events involving the 
MARRS protein have been identified, others have also shown that the traditional 
VDR may also possess the ability to mediate plasma membrane signalling. Indeed, 
the action of 1a,25(OH)2D3 are lost in osteoblasts from VDR knock-out (KO) mice 
[363] whilst a 1a,25(OH)2D3 mediated translocation of the VDR has been observed 
within skeletal muscle cell lines [364].  
 
1.6.3 Development of the Vitamin D Receptor Knock-Out Mouse 
Our understanding of the physiological roles of the VDR has been enhanced 
significantly by the development of mouse models with the targeted deletion of genes 
encoding for the VDR [365-368]. The first, often referred to as the Tokyo strain, was 
developed via the removal of exon 2 from the VDR gene that encodes the first zinc 
finger of the DNA-binding domain, essential for biological function of the VDR [367]. 
The second strain was developed in a similar fashion, albeit this time via the removal 
of the second zinc finger of the DNA-binding domain [365]. The Leuven strain was 
developed by utilised a Cre-lox system and the crossing of VDRlox mice with 
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phosphoglycerate kinase-Cre mice [366]. Finally, the München strain was developed 
via the targeted disruption of the first zinc finger of the DNA-binding domain which 
resulted in the expression of a VDR with intact hormone binding domain but lacking 
the first zinc-finger for DNA binding [368]. These mouse strains have been primarily 
utilised as a model to study hereditary vitamin D-resistant rickets (HVDDR). This 
autosomal recessive disorder caused by a defect in the VDR gene results in target 
tissue insensitivity to 1a,25(OH)2D3 [369].  
 
Interestingly, mice with the targeted ablation of the VDR are unaffected at birth and 
are indistinguishable from their respective littermates [365]. However, as of the third 
week of life abnormalities begin to emerge. Most notably, impaired mineral 
homeostasis in the form of hypocalcemia, as well as growth plate abnormalities are 
observed from 21-days [365]. Later experiments revealed a significant reduction in 
duodenal calcium absorption in VDR-KO mice at 10-weeks of age, highlighting the 
critical role for the VDR in maintaining mineral homeostasis [366, 368]. Across a 
similar timeframe, VDR-KO mice also develop secondary hyperparathyroidism with a 
progressive increase in serum parathyroid hormone (PTH) levels observed from 21-
days of age [365]. In correlation with increased serum PTH levels, an increase in 
renal phosphate losses are observed resulting in hypophosphatemia [365]. 
Disturbances in mineral homeostasis accompany growth plate abnormalities with an 
expansion, flaring and under mineralisation of the growth plate observed, 
characteristics that are consistent with the development of rickets [365]. As of 4-
weeks of age mice begin to develop alopecia [365, 367] which progresses to 
complete hair loss over a 3-month period, a trait that is also observed in humans with 
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VDR related mutations [369]. Later consequences include significant reductions in 
body weight at 6-weeks as well as a reduction in bone mineral density at 7-weeks of 
age [367]. The development of osteomalacia is followed by the severe under 
mineralisation of the bone at 10-weeks of age highlighted by a coverage of 85% of 
the bone with osteoid [370]. Finally, mutant mice progressively deteriorate until 
premature death occurs around 15-weeks of age [367].  
 
Interestingly, much of the observed phenotypes can be rescued by placing the VDR-
KO mice on a rescue diet with increased calcium and phosphorus content, thereby 
preventing the impaired mineral homeostasis that develops in VDR-KO mice [370]. 
Mice placed on this diet from 16-days of age show no signs of impaired mineral 
homeostasis or impaired bone development [370]. Similarly, the transgenic 
overexpression of the VDR within the intestine of VDR-KO mice also results in the 
prevention of the impaired mineral homeostasis previously observed [371]. Whilst 
neither osteomalacia or rickets are observed in mice fed the rescue diet, the 
development of alopecia still persists [372]. These data demonstrate that the actions 
of the VDR on skeletal development are predominantly indirect and the observed 
phenotype of VDR-KO mice is largely a result of impaired intestinal calcium 
absorption [370-372]. Interestingly, the rescuing of the impaired mineral homeostasis 
in VDR-KO mice provides a mouse model in which it is possible to identify which 
phenotypic traits are secondary effects of impaired mineral homeostasis or of a direct 
result of the loss of the VDR.  
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1.6.4 Detection of the Vitamin D Receptor in Skeletal Muscle 
The detection of the VDR within skeletal muscle is technically challenging due to low 
expression levels, the multicellular nature of skeletal muscle, differences in VDR 
expression across development and finally the non-specificity of antibodies [373]. 
 
One of the first reports suggesting a role for the VDR in skeletal muscle described 
the presence of a high affinity 1a,25(OH)2D3 binding protein in human derived 
myoblasts and myotubes [374]. However, since these early indications of positive 
VDR expression within skeletal muscle, following research has yielded ambiguous 
results [250, 375, 376]. Recently, real-time polymerase chain reaction (RT-PCR) was 
employed to detect VDR transcripts in a multitude of tissue extracts [250]. In 
comparison to the duodenum, a classical site of VDR action, skeletal muscle 
transcripts were detected at a substantially lower rate (4000x lower) [250]. Despite 
these extremely low levels, the VDR has been successfully detected in skeletal 
muscle cell lines [250, 375, 377] and rodent skeletal muscle [250] using the highly 
specific VDR-D6 antibody [373]. Whilst the VDR has also been detected in human 
skeletal muscle extracts, the antibody used has previously been called into question 
[378, 379]. In addition, the successful detection of the VDR within human skeletal 
muscle has been reported following a course of oral vitamin D supplementation in 
elderly subjects [380, 381], raising the possibility that supplementation aids in 
detection. On the other hand, a number of studies have failed to detect the VDR 
within skeletal muscle samples utilising both immunoblot and immunohistochemical 
approaches [375, 376]. Given the extremely low expression levels, current protein 
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detection methods may not be sensitive enough to reliably detect the VDR within 
skeletal muscle.  
 
One such method that has been described to aid in the detection of the VDR within 
skeletal muscle involves the use of a hyperosmolar lysis buffer (HLB). In comparison 
to more commonly used sucrose based lysis buffers, a urea based lysis buffer 
resulted in a much more robust detection of the VDR in mouse skeletal muscle 
extracts [250]. Given the tight binding of the VDR to DNA, it is hypothesised that the 
HLB may facilitate the release of DNA-bound proteins and be more effective in 
protein unfolding and denaturation [382, 383]. In support of this method, similar urea 
concentrations have aided in the detection of other transcription factors within 
skeletal muscle, including heat-shock proteins [384]. Despite the reported success 
using this method, others have reported conflicting results. Utilising the same 
method, it was reported that the VDR was undetectable in human skeletal muscle 
extracts despite loading up to 150 µg of protein [375]. Failure to detect the VDR, a 
predominantly nuclear protein, was also reported even when the nuclear fraction 
from whole skeletal muscle homogenates was probed [381]. Clearly issues still 
persist in the reliable detection of the VDR within skeletal muscle. Whilst the 
detection of the VDR in vitro does not seem to be an issue, its detection in adult 
skeletal muscle extracts remains problematic.  
   
1.6.5 The Vitamin D Receptor in Skeletal Muscle 
Despite the difficulties surrounding the detection of the VDR within skeletal muscle, 
our understanding on the role of the VDR within skeletal muscle has been enhanced 
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primarily via the use of in vitro models of myogenesis and the development of VDR-
KO mouse models [365-368, 370, 375, 377, 385]. Functionally, VDR-KO mice display 
reductions in grip strength, impaired swimming performance and increased fatigue 
indicating impaired skeletal muscle performance [302, 386]. Whole-body impairments 
in skeletal muscle function are supported by morphological changes within the 
skeletal muscle of VDR-KO mice. Animals at 3-weeks of age, prior to the onset of the 
secondary metabolic changes such as hypocalcemia, displayed a shift in muscle 
fibre diameters as well as a 20% decrease in size [387]. Morphological changes are 
still observed at both 8- and 12-weeks of age and persisted even with the 
administration of a rescue diet containing increased mineral content [302, 387]. 
Interestingly, these changes are observed across multiple muscles suggesting the 
actions of the VDR are not limited to skeletal muscle of specific fibre types [302, 387]. 
A number of myogenic regulatory factors including myogenic factor 5 (Myf5), 
transcription factor E2-aplha (E2A), myogenic differentiation 1 (MyoD) and myogenin 
were all increased [302, 387], whilst the expression of immature forms of MHC were 
also observed in the small muscle fibres of VDR-KO mice [387]. Myostatin mRNA, a 
negative regulator of muscle mass, was also increased within the skeletal muscle of 
VDR-KO mice, possibly explaining the observed reductions in muscle fibre size [302]. 
Given the ubiquitous expression of the VDR, including within the central nervous and 
vestibular system, the assessment of the direct effects of the loss of the VDR within 
skeletal muscle are difficult within this mouse model [388]. Recently, mice with the 
tissue-specific knockout of the VDR within skeletal muscle have been generated 
however, limited research has been performed to date utilising this model [385, 389]. 
Interestingly, these mice develop a number of metabolic defects including increased 
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serum insulin levels, insulin resistance and glucose intolerance [389]. Whilst the 
morphological characterisation of these mice was not the primary aim of the study, 
they did report a slight decrease in muscle fibre size concomitant with increases in 
forkhead box O1 (FOXO1) at both the gene and protein level [389]. The increased 
activation of FOXO1 could potentially explain the reductions in fibre size observed in 
both whole-body and skeletal muscle specific VDR-KO mice given its role in skeletal 
muscle atrophy [390, 391].  
 
The regeneration of skeletal muscle following an insult or injury is a complex process 
and recent evidence suggests that VDR activation may be increased during times of 
regeneration. Interestingly, a significant increase in the activation of both the VDR 
and CYP27B1 were observed following skeletal muscle injury induced via the 
injection of barium chloride (BaCL2) or freeze crush [251, 392, 393]. The increase in 
VDR expression was localised to the myonuclei of regenerating muscle fibres 
however, co-localisation was also observed with satellite cells suggesting an 
increase in activation specifically during the regenerative processes [251, 393]. 
Similar observations were reported following an acute bout of resistance exercise 
performed via electrical stimulation in rodent skeletal muscle [394]. Both VDR and 
CYP27B1 expression increased both immediately and 3 h post electrical stimulation, 
however endurance exercise failed to stimulate corresponding increases in 
expression [394]. Similarly, an acute bout of high-intensity treadmill based exercise in 
rats failed to increase VDR expression alone, although exercise in combination with 
vitamin D supplementation resulted in an increase in VDR expression [395]. Whilst 
these data highlight an increase in VDR expression during times of skeletal muscle 
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regeneration, it could be argued that the means to induce said processes are 
supraphysiological. Given endurance exercise failed to increase VDR expression 
alone, significant muscle damage may have to take place to induce VDR activation 
with skeletal muscle. 
 
Alongside its proposed roles in skeletal muscle regeneration, the VDR has also been 
studied in the context of skeletal muscle development [251, 377, 387, 396-399]. The 
VDR appears within 13-days of gestation in rats and resides within the mesoderm, a 
precursor to the musculoskeletal system [396]. Additionally, components of vitamin D 
related signalling including the VDR and CYP24A1 are expressed within 
mesenchymal stem cells [397], whilst the expression of the VDR within skeletal 
muscle decreases across development in mice [250]. Multiple studies have utilised 
the myogenic C2C12 skeletal muscle cell line to study the role of vitamin D and its 
related signalling on myogenesis [251, 377, 387, 398, 399]. The treatment of this cell 
line with 25(OH)D and 1a,25(OH)2D3 results in a reduction in proliferation [251, 377, 
398], an inhibition of myotube formation during serum starvation and an increase in 
individual myotube size [377]. Alterations in key markers of cell cycle progression 
including Rb, myc, ATM, and cyclin D1 as well the phosphorylation status of Rb 
contribute to the vitamin D induced anti-proliferative effects within the C2C12 cell line 
[377, 398]. Whilst vitamin D treatment resulted in a decrease in overall myotube 
number, individual myotube size was increased, in concordance with a 
downregulation of myostatin [377]. In contrast, others have reported that 
1a,25(OH)2D3 treatment in C2C12’s stimulates myotube formation when a high 
serum model of myogenesis is employed [398]. It is likely that the different models 
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employed to study myogenesis resulted in a different differentiation time course 
leading to conflicting effects of 1a,25(OH)2D3. Whilst the increased expression of the 
VDR is observed following treatments with 25(OH)D and 1a,25(OH)2D3 [377, 398] 
these models cannot confirm whether the effects on myogenesis observed are 
mediated by ligand dependent or independent roles of vitamin D. One study 
examining myogenesis following siRNA-mediated knock-down of the VDR observed 
similar effects on proliferation and differentiation [400] suggesting a direct role for the 
VDR in mediating myogenic signalling. However, given the transient nature and 
partial deletion often seen with siRNA approaches, improved in vitro models are 
needed to more clearly elucidate the role of the VDR in the development of skeletal 
muscle.  
 
As previously discussed, the VDR also possesses non-genomic roles involving 
transient signalling events [357]. In support of a non-genomic role for the VDR within 
skeletal muscle, the VDR rapidly translocates (1-10 minutes) from the nucleus to the 
cytoplasm upon exposure of cultured chick myoblasts to vitamin D [364]. Similar 
translocation to the plasma membrane was reported in C2C12s, with translocation 
dependent on intact microtubular transport and caveolae structure [401]. Binding of 
1a,25(OH)2D3 with the VDR at the plasma membrane in turn activates c-SRC, 
phosphoinositide-3-kinase (PI3K) and inositol triphosphate (IP3) which in turn leads 
to the release of Ca2+ from the sarcoplasmic reticulum [402, 403]. Furthermore, the 
actions of vitamin D signalling have been proposed to result in the translocation of 
PKCa from the cytosol to the cell membrane [404]. PKCa activates the L-type 
voltage dependent Ca2+ channel (VDCC) and Ca2+ store-operated entry (SOCE) 
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channel resulting in an increase in Ca2+ flux within the cell [405]. These translocation 
events likely govern 1a,25(OH)2D3 induced increases in intracellular calcium flux 
within skeletal muscle cell lines [406-408] and within chick skeletal muscle [409] 
(Figure 1.4).  Following longer periods of exposure, the VDR appears to return to the 
nucleus, possibly to carry out its genomic actions [398].  
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Figure 1.4. Genomic and non-genomic actions of vitamin D related signalling within skeletal 
muscle. 1a,25(OH)2D3 enters the cell prior to ligand binding to the VDR. Upon translocation to the 
nucleus, the VDR binds with RXRa forming a heterodimer protein complex that recruits co-regulatory 
binding partners and influences genomic transcription. 1a,25(OH)2D3 ligand binding also initiates 
transient signalling events mediated by the VDR that stimulate intracellular calcium uptake. Adapted 
from [410].  
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1.6.6 The Vitamin D Receptor in Mitochondria 
Over the last decade, evidence has begun to emerge suggesting a novel role for the 
VDR within the regulation of mitochondrial energy metabolism [411]. The localisation 
of the VDR within the mitochondria has been confirmed within a number of cell types 
including platelets, megakaryocytes, and keratinocytes [412, 413]. Whilst the 
detection of the VDR within the mitochondria has opened up a new line of 
questioning in terms of its precise role, the current evidence is conflicting and 
primarily based upon in vitro observations.  
 
Firstly, the treatment of human skeletal muscle myoblasts with 1a,25(OH)2D3 resulted 
in an increase in multiple parameters of mitochondrial function including basal, 
maximal and ATP dependent respiration as measured by extracellular flux analysis 
[414]. Similar observations were made following the treatment human skeletal 
muscle myoblasts with conditioned medium from the Lewis lung cancer carcinoma 
cell line 1 (LLC1). Whilst the conditioned medium reduced the spare capacity of the 
human derived myoblasts, the co-treatment with 1a,25(OH)2D3 was able to rescue 
observed impairments [415]. Increases in mitochondrial function following 
1a25(OH)2D3 treatment were reported to be mediated by increases in the 
mitochondrial volume fraction and OPA1, a key mediator of mitochondrial fusion 
[414]. In concert, decreases were observed in mediators of mitochondrial fission 
including Fis1 and Drp1, as well as a decrease in the amount of phosphorylated 
pyruvate dehydrogenase, which could increase the amount of acetyl-CoA entering 
the TCA cycle [414]. Interestingly, the positive effects of 1a,25(OH)2D3 were 
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abolished following the silencing of the VDR via siRNA suggesting a direct role for 
the VDR in mediating these effects within the mitochondria [414].  
 
Conversely, silencing of the VDR within the human keratinocyte cell line HaCaT and 
human breast cancer cell line MCF7, resulted in an increase in mitochondrial 
membrane potential and increased transcription of proteins involved in the 
mitochondrial electron transport chain [416, 417]. Whilst the authors suggested VDR 
silencing resulted in an increase in mitochondrial respiration, respiration was not 
directly measured and was indirectly assessed via measurements of membrane 
potential and ROS production [416, 417]. Additionally, similar analysis of human 
primary fibroblasts was reported, however data from the previously mentioned 
mitochondrial analysis was not reported, raising the question of whether similar 
effects of VDR silencing were observed [417]. Despite the questionable aspects of 
the aforementioned data, a study that did directly assess cellular bioenergetics in 
response to 1a,25(OH)2D3 reported a suppression of respiration in human brown 
adipocytes [418]. Both maximal and mitochondrial proton leak were suppressed in 
response to treatment with 1a,25(OH)2D3, whilst the overexpression of the VDR 
resulted in a decrease in mRNA expression of uncoupling protein 1 (UCP1), PGC-1a, 
as well as the expression and transactivation of peroxisome proliferator activated 
receptor gamma (PPARg) [418].  
 
In order to try to explain the discrepancies observed, it is interesting to note the 
localisation of the VDR within the cell types studied. Localisation of the VDR was 
observed within the mitochondria of the HaCaT cell line [412, 413] however, the VDR 
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was not detected within the mitochondria of human skeletal muscle myoblasts [414]. 
Therefore, the potential role of the VDR in modulating mitochondrial metabolism may 
rely on its subcellular localisation. The positive effects observed within skeletal 
muscle myoblasts may be as a result of the nuclear actions of the VDR or possibly 
due to its non-genomic actions in regulating Ca2+ flux.  
 
Currently, in vivo data regarding the precise role of the VDR within the mitochondria 
is lacking although, some evidence exists regarding the relationship between vitamin 
D and energy metabolism. Fatigue is a symptom commonly associated with vitamin 
D deficiency and markers of fatigue are negatively correlated with serum 25(OH)D 
levels [419], whilst supplementation also improves markers of fatigue in severely 
deficient individuals [420]. Interestingly, a beneficial effect of vitamin D 
supplementation in a group of severely deficient individuals was reported following 
the assessment of mitochondrial function via 31-phosphate nuclear magnetic 
resonance spectroscopy (31-P MRS) [420]. Whilst some parameters were 
unchanged, the time needed to recover PCr stores after exercise as well as the 
disappearance rate of ADP were significantly reduced following vitamin D 
supplementation [420]. Whilst these data are promising and potentially indicate an 
improvement in mitochondrial ATP production via oxidative phosphorylation following 
supplementation, a number issues exist within the study [420]. For example, the 
study design lacked proper randomisation and blinding and therefore adequate 
control. In addition, the control group did not have adequate serum 25(OH)D levels 
(18 ng.ml-1) themselves making comparisons difficult.  
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1.7 Summary 
Skeletal muscle is a highly plastic tissue with the ability to respond to both positive 
and negative stimuli. Within skeletal muscle there exists a morphologically tubular 
network of mitochondria that primarily functions to produce ATP at the expense of 
substrates and molecular O2 [76, 79]. In response to both exercise and nutritional 
interventions, this network undergoes remarkable remodelling processes including 
events of biogenesis, fusion, fission and mitophagy [66, 69-73]. Whilst a number of 
nutritional interventions are known to positively affect these processes [172], 
nutritional deficiencies can have opposing effects. A common deficiency is that of 
vitamin D [14, 277], with severe deficiencies resulting in skeletal muscle myopathies 
[421]. Interestingly, recent evidence has linked vitamin D to increased mitochondrial 
function with human skeletal muscle myoblasts [414, 415] and the supplementation 
of vitamin D in severely deficient patients improved markers of ATP production as 
well as reducing symptoms of fatigue [420]. In addition, diet-induced vitamin D 
deficiency in mice results in impaired physical function, highlighting a prominent role 
for vitamin D in maintaining skeletal muscle function [308]. Whilst these data are 
interesting, little is known about the precise role of the VDR in the maintenance of 
skeletal muscle mitochondrial function. Furthermore, whilst severe vitamin D 
deficiencies are known to impair physical performance, it is unknown how such 
deficiencies affect the process of exercise adaptation within skeletal muscle. 
Therefore, this thesis will explore the role of vitamin D and the VDR within skeletal 
muscle. The aims of this thesis are briefly outlined below and will be discussed in 
more detail in each respective chapter.   
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1.8 Thesis Aims 
The aims of this thesis are as follows; 
 
1. Develop a reliable method for the detection of the VDR within skeletal 
muscle samples (Chapter 3). 
 
2. Determine the role of the VDR within the maintenance of skeletal muscle 
mitochondrial function and protein content (Chapter 4). 
 
3. Examine the role of diet-induced vitamin D deficiency on anthropometric 
measures of body composition and mitochondrial function in C57BL/6J 
mice (Chapter 5). 
 
4. Determine whether diet-induced vitamin D deficiency impairs the positive 
impact of exercise on body composition and mitochondrial function in 
C57BL/6J mice (Chapter 6).  
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2.1 Ethical Approval 
2.1.1 Wistar Rats 
Ethical approval for rat studies was granted by the Royal Veterinary Colleges Ethics 
and Welfare committee. Experiments were carried out under UK Home Office license 
70/7437 and 70/25526 in order to comply with the Animals Scientific Procedures Act 
(1986). Male Wistar rats at 8-weeks of age were housed communally in a 
temperature controlled environment (22 ± 0.5°C) with a 12 h light-dark cycle. 
 
2.1.2 C57BL/6JAusb 
Ethical approval for mouse studies was granted by the Garvan Institute and St. 
Vincent’s Hospital Animal Experimentation Ethics Committee (approval number 
18/19). Ethical approval fulfils all the requirements of the NHMRC and the NSW State 
Government, Australia. All animal handling was carried out by trained personnel and 
all procedures were carried out according to the Australian code of practice for the 
care and use of animals for scientific purposes 8th edition [1]. Male C57BL/6JAusb 
mice at 3- and 10-weeks of age were housed communally in a temperature controlled 
environment (22 ± 0.5°C) with a 12 h light-dark cycle.  
 
2.2 Tissue Culture 
2.2.1 Tissue Culture Maintenance 
Tissue culture experiments were conducted on low passage number cells (<20). 
Tissue culture was carried out under sterile conditions in a class II safety cabinet. 
Cells were incubated in a HERAcell 150i CO2 Incubator (Thermo Scientific Inc, 
Chesire, UK) maintained at 37°C with 5% CO2. A VACUSAFE aspiration system 
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(Integra Biosciences Ltd, Berkshire, UK) was used to discard all waste media and 
liquids. Necessary solutions were made using ultra-pure water (Type 1) from a Milli-Q 
water purification system (Merck, Darmstadt, Germany). General cell populations 
were maintained on 15 cm2 plates (Corning Inc., Massachusetts, US).  
 
2.2.2 Tissue Culture Reagents 
All reagents were purchased from Gibco (Life Technologies, California, US) unless 
otherwise stated. Dulbecco’s modified eagles medium (DMEM) with added 
GlutaMAXTM and high glucose (4.5 g.L-1) was used as base for both growth and 
differentiation medium. Growth medium contained DMEM with the addition of 10% 
fetal bovine serum (FBS) purchased from GE Healthcare Life Sciences (GE 
Healthcare Bio-sciences, Pittsburgh, US), 1% penicillin-streptomycin (PS) and 2 
µg.ml-1 puromycin dihydrochloride (puromycin) purchased from Sigma-Aldrich 
(Sigma-Aldrich, Gillingham, UK). Differentiation medium contained DMEM with the 
addition of 2% horse serum (HS) purchased from Sigma-Aldrich and 1% PS. 
Phosphate buffered saline (PBS) was used to wash cell monolayers. Tryspin-EDTA 
(0.05%) with the addition of phenol red was used to dissociate cell monolayers. 
Frozen cells were stored in freeze medium containing FBS with 10% dimethyl 
sulfoxide (DMSO) purchased from Sigma-Aldrich (Sigma-Aldrich, Gillingham, UK).  
 
2.2.3 Generation of Vitamin D Receptor Knock-Down C2C12 Cell Line 
The lentiviral plasmid used (pLKO.1 backbone) was designed in-house and was 
based on (Clone ID: RMM3981-201757375) and targeted the (3’ UTR) mouse 
sequence 5′- TTA AAT GTG ATT GAT CTC AGG-3′ of the mouse Vdr gene; the 
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scramble short hairpin ribonucleic acid (shRNA) was used as a negative control as 
previously reported [2] with a hairpin sequence: CCT AAG GTT AAG TCG CCC TCG 
CTC TAG CGA GGG CGA CTT AAC CTT AGG (Addgene plasmid 1864, Cambridge, 
MA, USA). Oligos were obtained from ITDDNA USA and suspended, annealed and 
cloned into pLKO.1 at EcoRI and AgeI restriction sites as per the pLKO.1 protocol 
from Addgene. Resultant plasmids were transformed in DH5α cells for amplification 
and isolated. The actual DNA sequence was confirmed at the Pennsylvania State 
University College of Medicine DNA sequence core facility. Packaging plasmids 
psPAX2 and envelope protein plasmid pMD2.G were a gift from Trono Lab (Addgene 
plasmids 12260 and 12259 respectively). HEK293FT cells (Invitrogen, Carlsbad, CA, 
USA) were grown in DMEM; 80–85% confluent plates were rinsed once with Opti-
MEM (Invitrogen, Carlsbad, CA, USA) and then incubated with Opti-MEM for 4 h 
before transfections. psPAX2 and pMD2.G along with either scramble or pLKO.1 
clones targeting mouse Vdr (three clones) were added after mixing with 
Lipofectamine 2000 as per the manufacturer’s instructions (Invitrogen, Carlsbad, CA, 
USA). Opti-MEM was changed after overnight incubation with DMEM containing 10% 
FBS without antibiotics to allow cells to take up the plasmids and recover. Culture 
media were collected at 36 and 72 h post-transfection for viral particles. Viral 
particles present in the supernatant were harvested after a 15-minutes spin at 1,500 
g to remove cellular debris. The supernatant was further filtered using a 0.45-μm 
syringe filter. Supernatant-containing virus was either stored at −80°C for long-term 
storage or at 4°C for immediate use. C2C12 cells at 60% confluence were infected 
twice overnight with 3 ml of viral supernatant containing 8 μg.ml-1 polybrene in 
serum-free–antibiotic-free DMEM. Fresh DMEM media containing 10% FBS, 
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antibiotics and 2 μg.ml-1 puromycin (Sigma-Aldrich, St. Louis, MO, USA) were added 
the next day. Cells that survived under puromycin selection were either harvested (as 
stable cells), stored under liquid nitrogen (N2) or used as either myoblasts or 
myotubes depending on the experiment. Successful VDR knock-down (VDR-KD) 
was confirmed via the determination of VDR protein content via immunoblot.  
 
2.2.4 C2C12 Growth and Differentiation 
VDR-KD and respective scramble control C2C12s were plated at 1.0 x 105 cells/well 
in 2 ml of growth medium in 6-well plates (Nunc, Roskilde, Denmark). Upon reaching 
90% confluence, cells were either harvested for myoblast experiments or switched to 
differentiation medium. Before switching to differentiation medium, cells were washed 
once with PBS. Differentiation medium was changed every other day and myotube 
formation was monitored over a period of 7-days.  
 
2.3 Sample Lysis and Homogenization 
2.3.1 Cell and Tissue Lysis 
Upon collection, both myoblast and myotube cell monolayers were washed twice with 
ice-cold PBS. Each well was actively scraped and collected in 100 µl of sucrose lysis 
buffer. Tissue samples were powdered on dry ice using a CellcrusherTM tissue 
pulverizer (Cellcrusher Ltd, Cork, Ireland) and homogenized in a 10-fold mass of ice-
cold sucrose lysis buffer. The constituents of the sucrose lysis buffer are described 
below (section 2.3.2) 
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2.3.2 Sucrose Lysis Buffer 
Cell and tissue lysis was completed using sucrose lysis buffer (50 mM Tris pH 7.5; 
270 mM sucrose; 1 mM EDTA; 1 mM EGTA; 1% Triton X-100; 50 mM sodium 
fluoride; 5 mM sodium pyrophosphate decahydrate; 25 mM beta-glytcerolphosphate). 
Relevant inhibitors were added fresh on the day of use and included 1 cOmpleteTM 
protease inhibitor cocktail EDTA free tablet (cat. 1183617001) and Phosphatase 
Inhibitor Cocktail 3 (cat. P0044) both purchased from Sigma-Aldrich (Sigma-Aldrich, 
Gillingham, UK).  
 
2.3.3 Urea Lysis Buffer 
With the aim of detecting the VDR in whole skeletal muscle extracts (Chapter 3), 
tissue samples were also lysed in a hyperosmolar lysis buffer (6.7M urea; 10% 
glycerol; 10mM Tris-HCl, 1% sodium dodecyl sulfate; 1mM dithiothreitol; 1mM 
phenylmethylsulfonyl-fluoride). One Protease Inhibitor Cocktail tablet was added 
fresh upon the day of use. 
 
2.3.4 Cell and Tissue Homogenization 
Cell and tissue lysates were homogenized via shaking in a FastPrep 24 5G (MP 
Biochemicals, Santa Ana, California, USA) at 6.0 m·s-1 for 80 s. Samples were then 
centrifuged for 10 min at 8,000 g and at 4°C to remove any insoluble material. The 
resulting supernatant was removed and stored at -80°C for further analysis.  
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2.3.5 Determination of Protein Content 
Cell and tissue samples were diluted in a 1:5 and 1:20 ratio respectively and protein 
concentrations were determined using the DC protein assay as per manufacturer’s 
instructions (Bio-Rad, Hercules, California, USA). 
 
2.4 Immunoblotting 
2.4.1 Sample Preparation 
Total protein lysates of a known concentration were mixed 3:1 with 4x Laemmli 
sample loading buffer to generate polyacrylamide gel loading samples of a known 
concentration. Prior to gel loading samples were boiled at 95°C for 5 minutes 
(samples were un-boiled when using MitoProfile OXPHOS antibody). Prepared 
samples were stored at -80°C until analysis.  
 
2.4.2 Gel Preparation and Electrophoresis 
Gels (8-15%) were prepared by mixing relative amounts of 30% acrylamide/bis-
acrylamide (Bio-Rad, Hercules, California, USA), Tris-SDS (pH 8.8) and ultra-pure 
water. Subsequently, both 10% ammonium persulfate (APS) and TEMED were 
added in order to initiate polymerization. Gels were allowed to polymerize for ~30 
minutes prior to the addition of 5% stacking gel prepared as above. Gels were 
prepared using 10- or 15-well combs dependent upon the number of samples loaded. 
An equal volume of protein (10-75 µg) alongside a molecular weight marker 
(Precision Plus ProteinTM Dual Colour Standards, Bio-Rad, Hercules, California, 
USA) was separated by SDS-PAGE at a constant current of 23 mA per gel for ~60 
minutes.  
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2.4.3 Transfer and Blocking 
Proteins were then transferred on to BioTrace NT nitrocellulose membranes (Pall Life 
Sciences, Pensacola, Florida, USA) using a wet transfer system at 100 V for 1 h. 
Membranes were then stained in Ponceau S (Sigma-Aldrich, Gillingham, UK) and 
imaged to check for even loading and transfer. Membranes were then blocked for 1 h 
in 3% dry-milk in tris-buffered saline with tween (TBS-T). Membranes were then 
incubated overnight in primary antibodies at 4°C. Following primary antibody 
incubation, membranes were washed three times in TBS-T and subsequently 
incubated in the appropriate horseradish peroxidase-conjugated secondary antibody 
at room temperature for 1 h. Membranes were again washed three times in TBS-T 
prior to imaging.  
 
2.4.4 Antibodies 
All primary antibodies were used at a concentration of 1:1000 in TBS-T unless 
otherwise stated. Antibodies for the VDR were used at a concentration of 1:500 in 
TBS-T when aiming to detect the VDR in whole skeletal muscle lysates (Chapter 3). 
Antibodies for dynamin-1-like protein (DRP1; 8570) and vitamin D3 receptor (VDR; 
12550) were from Cell Signaling Technology; MitoProfile OXPHOS antibody cocktail 
(110413), vitamin D receptor (VDR; 109234) and mitofilin (110329) were from 
Abcam; dynamin-like 120 kDa protein (OPA1; CPA3687) was from BD Biosciences; 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1a; 
AB3242) was from Merck-Millipore; citrate synthase (CS; SAB2701077) and 
mitochondrial fission protein 1 (FIS1; HPA017430) were from Sigma-Aldrich; vitamin 
D receptor (D-6) (VDR; 13133) was from Santa Cruz Biotechnology. Secondary 
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antibodies were used at a concentration of 1:10,000 in TBS-T. Anti-mouse (7076) 
and anti-rabbit (7074) were from Cell Signaling Technology.  
 
2.4.5 Image Capture and Analysis 
Antibody detection was performed via enhanced chemiluminescence horseradish 
peroxidase substrate detection kit (Millipore, Watford, UK). Subsequent imaging and 
band quantification were performed using a G:Box Chemi-XR5 system (Syngene, 
Cambrige, UK).  
 
2.5 Extracellular Flux Analysis 
2.5.1 Cell Seeding and Maintenance 
Both scramble control and VDR-KD cells were seeded in XFe24-well cell culture 
microplates (Seahorse Bioscience, North Billerica, USA) at 3.0 x 105 cells/well in 100 
µl of growth medium and allowed to rest at room temperature for 1 h in order to 
promote an even cell distribution [3]. For myoblast experiments, cells were incubated 
at 37°C and 5% CO2 for 3 h in order to allow sufficient time for adherence to cell 
culture microplate and subsequently assayed. For myotube experiments, cells were 
incubated for a period of 24 h resulting in a confluence of 90%. Cells were then 
washed once with PBS and medium changed to differentiation medium. 
Differentiation was changed every other day for a period of 7 days.  
 
2.5.2 Mitochondrial Stress Test 
Prior to the assay, cells were washed once and placed in 500 µl of Seahorse XF 
Base Medium (glucose 10 mM, sodium pyruvate 1 mM, glutamine 1 mM, pH 7.4) pre-
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warmed to 37°C. The plate was then transferred to a non-CO2 incubator for 1 h. 
Following calibration, cell respiratory control [4] and associated extracellular 
acidification were assessed following the sequential addition of oligomycin (1 µM), 
carbonyl cyanide p-trifluoromethoxyphenylhydrazone (CCCP) (1 µM) and antimycin A 
with rotenone (1 µM). Upon completion of the assay, cells were lysed in sucrose lysis 
buffer and subjected to one freeze thaw cycle. Upon thawing, cell lysate was 
centrifuged for 10 minutes at 8,000 g and the supernatant was removed for protein 
determination. Protein concentration was determined using the DC protein assay 
(Bio-Rad, Hercules, California, USA) as previously described (section 2.3.5). Oxygen 
Consumption Rate (OCR) is reported relative to protein content (pmol/min/µg). 
Calculation for respiratory parameters derived from the mitochondrial stress test can 
be found below (Table 2.1).  
 
 
Table 2.1. Calculations for respiratory parameters derived from mitochondrial stress test.  
 
Respiratory Parameter Calculation 
Basal Respiration Last Rate Measurement Before Oligomycin Injection - Non-Mitochondrial Respiration Rate 
Coupled Respiration 
Last Rate Measurement Before Oligomycin Injection – 
Minimum Rate Measurement After Oligomycin 
Injection 
Maximal Respiration Maximum Rate Measurement After CCCP Injection – Non-Mitochondrial Respiration 
Spare Respiratory Capacity Maximal Respiration – Basal Respiration 
H+ (Proton) Leak Minimum Rate Measurement After Oligomycin Injection – Non-Mitochondrial Respiration 
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2.5.3 Estimation of ATP Production 
Estimation of intracellular rates of glycolytic and oxidative ATP production were 
performed as previously described [5]. Briefly, scramble control and VDR-KD cells 
were seeded in XFe24-well cell culture microplates (Seahorse Bioscience, North 
Billerica, USA) at 3.0 x 105 cells/well in 100 µl of growth medium (high glucose 
DMEM, 10% FBS, 1% PS, puromycin 2 µg.ml-1). Prior to the assay, cells were 
washed once and then incubated in 500 μl of Krebs-Ringer phosphate HEPES 
(KRPH) medium (2 mM HEPES, 136 mM NaCl, 2 mM NaH2PO4, 3.7 mM KCl, 1 
mM MgCl2, 1.5 mMCaCl2, 0.1% (w/v) fatty-acid-free bovine serum albumin (BSA), pH 
7.4 at 37 °C). Cell respiratory control [4] and extracellular acidification were assayed 
following the addition of glucose (10 mM), oligomycin (1 µM), CCCP (1 µM) and 
antimycin A/rotenone (1 µM). Upon completion of the assay cells were collected in 
sucrose lysis buffer (50 mM Tris pH 7.5; 270 mM sucrose; 1 mM EDTA; 1 mM EGTA; 
1% Triton X-100; 50 mM sodium fluoride; 5 mM sodium pyrophosphate decahydrate; 
25 mM beta-glytcerolphosphate; 1 cOmpleteTM protease inhibitor cocktail EDTA free 
tablet) and centrifuged for 10 minutes at 8,000 g and the supernatant was removed 
for protein determination. Protein concentration was determined using the DC protein 
assay (Bio-Rad, Hercules, California, USA). Following correction for the buffering 
power of the medium, rates of ATP production are reported relative to protein content 
(pmol/min/µg). Rates of ATP production are converted to the same unit accounting 
for the different amounts of ATP produced via glycolysis (2 ATP/Glucose) and 
oxidative phosphorylation (31.45 ATP/Glucose) [5].  
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2.6 Mitochondrial Membrane Potential 
Both scramble control and VDR-KD cells were plated at 1.0 x 105 cells/well in 100 µl 
of growth medium and incubated for 24 h. A black 96-well plate with a clear bottom 
(Corning, Costar, NY, US) was used in order to minimise well-to-well interference. 
Cells were subsequently incubated for 30 minutes with 100 nM of 
tetramethylrhodamine, ethyl ester (TRME). A set of cells were also incubated with 20 
µM carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) in order to 
completely depolarise the mitochondrial membrane and act as a negative control. 
Following incubation, cells were washed with phosphate buffered saline (PBS) with 
0.2% BSA and then read at 549 nm using a CLARIOstar microplate reader (BMG 
Labtech, Victoria, Australia) in 100 µl of PBS and 0.2% BSA.  
 
2.7 Rodent Studies 
2.7.1 Transient Electroporation in Male Wistar Rats 
Eight-week-old male Wistar rats were housed a described above (section 2.1.1) and 
fed a standard chow diet (18% fat, 33% protein, 48% carbohydrate) for one week. 
VDR-KD (n=7) was achieved in right hind leg tibialis anterior muscle through in vivo 
electrotransfer of four unique rat VDR pGFP-C-shLenti plasmid constructs driven by 
a U6 promoter [6]. These constructs spanned multiple regions of rat VDR mRNA 
(NM_017058.1) to ensure effective coverage and knockdown. Left leg tibialis 
anterior muscles received scramble cassette sequence controls (OriGene, Rockville, 
USA). Plasmid DNA amplification was undertaken within JM109 Escherichia coli cells 
under puromycin selection (0.5 µg/ml) overnight. Plasmid DNA was purified using an 
endotoxin free plasmid Maxi Kit (Qiagen, Manchester, UK) as per the manufacturers 
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instructions. VDR over-expression (VDR-OE) (n=7) was achieved in right leg tibialis 
anterior muscle through in vivo electrotransfer of pCAGGS-mVDR vector constructs. 
The mouse cDNA sequence utilised was 92% homologous to rat VDR mRNA. To 
obtain pCAGGS-mVDR, myc-DDK-mVDR was subcloned in the pCAGGS vector. 
Left leg tibialis anterior muscles received empty pCAGGS vector controls. Plasmid 
DNA amplification was undertaken within JM109 Escherichia coli cells under 
puromycin selection (0.5 µg/ml) overnight. Plasmid DNA was purified using an 
endotoxin free plasmid Maxi Kit (Qiagen, Manchester, UK) as per the manufacturers 
instructions. 
 
2.7.2 Mouse Diets 
C57BL/6J mice were received at 10-weeks of age. Following 1-week of acclimation in 
which mice were fed standard chow, mice were place on either a vitamin D-control 
diet or a vitamin D-deplete diet [7]. The vitamin D deplete contains no vitamin D but 
increased calcium (2%), magnesium (0.2%), and phosphorous (1.2%) in order to 
maintain normal mineral homeostasis (SF085-003, Speciality Feeds, Glen Forest, 
NSW). The vitamin D control diet contains vitamin D (cholecalciferol 2.2 IU/g), 
calcium (1%), magnesium (0.2%), and phosphorous (0.7%) (SF085-034, Speciality 
Feeds, Glen Forest, NSW). Mice were maintained on the respective diets for a period 
of either 1-, 2- or 3-months. Mice subjected to voluntary wheel running maintained 
their respective vitamin D replete or deplete diets across the 20-day running period.  
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Nutrient Standard Chow VitD Replete VitD Deplete 
Protein 23% 19.4% 19.4% 
Fat 6% 7% 7% 
Fibre 5% 4.7% 4.7% 
Digestible Energy 13 MJ/kg 15.8 MJ/kg 15 MJ/kg 
Vitamin D 200 IU/kg 2,200 IU/kg 0 IU/kg 
Calcium 1.1% 1% 2% 
Magnesium 1.8% 0.2% 0.2% 
Phosphorous 0.77% 0.7% 1.2% 
Table 2.2. Nutrient composition of mouse diets.  
 
2.7.3 Voluntary Wheel Running 
Mice were housed individually and given access to an upright, free-spinning running 
wheel (diameter 10.16 cm, Columbus Instruments, Columbus, OH, US) for 20 days. 
Wheel revolutions were recorded every hour via a digital recorder (Columbus 
Instruments, Columbus, OH, US) and the distance ran per day was calculated and 
reported in kilometres per twenty-four hours (km/24 h).  
 
2.7.4 EchoMRI Assessment of Body Composition 
Prior to each assessment of body composition, mice were briefly weighed. Body 
composition was assessed upon arrival (10-weeks of age) and then following 1-, 2- 
and 3-months of dietary intervention and post 20-days of voluntary wheel running 
using quantitative EchoMRI (EchoMRI LLC, Houston, USA). Both absolute and 
percentage of body weight fat and lean mass’ are reported.  
 
2.8 Sample Collection and Processing 
2.8.1 Tissue Collection 
Following anesthetization under isoflurane (induction 4%, maintenance 1%, flow rate 
1 L/min), tissues were excised from fasted (2 h) mice in order to minimise effects of 
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prior food intake. Mice subjected to voluntary wheel running had no access to a 
running wheel for 24 h prior to tissue collection. Tissues collected include; 
gastrocnemius, quadriceps, triceps, liver, kidney, white adipose tissue and tibia. 
Following tissue collection, a blood sample was taken via cardiac puncture. End 
stage termination was completed via cervical dislocation. All tissues were rinsed in 
sterile saline, blotted dry, weighed, and frozen in liquid N2. A small portion (~20 mg) 
of the gastrocnemius was removed before freezing and used for high-resolution 
respirometry. All tissues were stored at -80°C for subsequent analysis.  
 
2.8.2 Blood Processing 
Blood samples were allowed to coagulate at room temperature for 10 minutes before 
being placed on ice. Samples were then centrifuged at 14,000 g for 10 minutes. The 
resulting supernatant was removed and stored at -80°C prior to further analysis.  
 
2.9 Serum Calcium 
Serum calcium was measured using a Calcium Detection Assay kit (Abcam, 
Cambridge, UK, cat. ab102505). Serum samples were diluted 1:10 and 
manufacturers instructions were followed. The microplate was read at 575 nm using 
a CLARIOstar microplate reader (BMG Labtech, Victoria, Australia). Calcium 
concentrations are reported in mM.  
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2.10 High-Resolution Respirometry 
2.10.1 Tissue Preparation 
Small portions of gastrocnemius muscle (~20 mg) were removed and placed in ice-
cold BIOPS buffer (2.77 mM CaK2EGTA, 7.23 mM K2EGTA, 5.77 mM Na2ATP, 6.56 
mM MgCl2-6H2O, 20 mM Taurine, 15 mM Na2Phosphocreatine, 20 mM Imidazole, 
0.5 mM Dithiothreitol, 50 mM MES Hydrate, pH 7.1, 290 mOsm). Muscle fibres were 
trimmed of connective tissue and fat and separated into small bundles of 
approximately 1.0-2.5 mg wet weight. These bundles were subsequently teased 
apart using needle tipped forceps under magnification. Following separation, fibres 
bundles were placed in BIOPS buffer (2 ml) containing saponin (50 µg/µl) and gently 
rocked for 30 min at 4°C. Saponin, a cholesterol-specific detergent is used in order to 
permeabilize the sarcolemmal membranes while keeping the mitochondrial 
membranes intact. Following permeabilization, fibre bundles were placed in 
mitochondrial respiration medium (MiR05) (0.5 mM EGTA, 3 mM MgCl2-6H2O, 60 
mM Lactobionic Acid, 20 mM Taurine, 10 mM KH2PO4, 20 mM HEPES, 110 mM D-
Sucrose, 1 g/l BSA, pH 7.1) and gently rocked for 10 min at 4°C.  
 
2.10.2 High-Resolution Respirometry 
High-resolution respirometry was conducted in MiR05 (2 ml) with the addition of 
blebbistatin (25 µM) using the OROBOROS Oxygraph-2K (Oroboros Instruments, 
Corp., Innsbruck, AT) with stirring at 750 rpm at 37°C. Oxygen within the chamber 
was maintained between 150-220 µM for each experiment. Prior to the addition of the 
fibre bundles to the chamber, samples were blotted dry and weighed. Bundles 
totalling 2.5-5.0 mg were added to the chamber. Firstly, pyruvate (10 mM) and 
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malate (2 mM) were added as complex I substrates. Subsequently, ADP was titrated 
in step-wise increments (100-6000 µM) followed by the addition of glutamate (10 
mM) and succinate (10 mM) as complex I and II substrates respectively. Cyt c (10 
µM) was added in order to check outer mitochondrial membrane integrity [8]. The 
partial loss of cyt c during fibre preparation may limit respiration. Fibre preparations 
that exhibited an increase of >10% were removed from final analysis. CCCP was 
titrated in a step-wise manner (0.5 to 2.5 µM) until the maximal capacity of the 
electron transport chain was reached. Finally, antimycin A (2.5 µM) was injected in 
order to inhibit mitochondrial respiration.  
 
2.10.3 Determination of Michaelis-Menten Enzyme Kinetics 
The apparent Km for ADP was determined through the Michaelis-Menten enzyme 
kinetics – fitting model (Y = Vmax*X/(Km + X)), where X = (free ADP; ADPf), using 
Prism version 7 (GraphPad Software, Inc., La Jolla, CA).  
 
2.10.4 Flux Control Ratios 
Flux control ratios (FCR) provide a method of internal normalization were by 
respiration is normalized to maximal and minimal respiration by setting CCCP 
stimulated respiration as one and antimycin A respiration as zero.  
 
2.11 Statistical Analysis 
Statistics were performed using the Statistical Package for the Social Sciences 
(SPSS) version 24.0 and Prism version 7 (GraphPad Software, Inc., La Jolla, CA). 
Data are presented as means with standard deviation (SD). Statistical significance 
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was accepted as P < 0.05. Additional statistical tests are discussed in each 
respective chapter.  
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CHAPTER 3  
 
METHODOLOGICAL CONSIDERATIONS FOR DETECTING THE VITAMIN D 
RECEPTOR IN C2C12 MYOBLASTS AND MOUSE SKELETAL MUSCLE 
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3.1 Introduction  
Once in circulation, vitamin D undergoes a series of hydroxylation steps. The first, 
occurs within the liver and coverts vitamin D to 25(OH)D via 25-hydroxylation [1]. The 
second, occurs within the kidney and converts 25(OH)D to the biologically active 
1a,25(OH)2D3 via 1a-hydroxylation [2, 3]. In order to carry out the biological actions 
of vitamin D, 1a,25(OH)2D3 binds to the VDR, which subsequently binds to the RXR 
forming a heterodimer protein complex [4, 5]. This protein complex then binds to 
VDREs within the promotor regions of vitamin D regulated genes [6, 7]. Whilst the 
VDR is said to be ubiquitously expressed [8], its detection within skeletal muscle has 
remained problematic due to extremely low expression levels, the use of non-specific 
antibodies and the multicellular nature of skeletal muscle [9-11].  
 
Current in vitro evidence suggests that the positive detection of the VDR protein 
within skeletal muscle cell lines is consistent and less problematic than its respective 
detection in adult skeletal muscle [9, 12]. One of the first reports of positive VDR 
expression within skeletal muscle described the presence of a high affinity 
1a,25(OH)2D3 binding protein in human derived myoblasts and myotubes [13]. 
Further to this, the positive detection of the VDR within skeletal muscle cells derived 
from chicks [14-16], mice [9, 17-19] and humans [12, 13, 20, 21] has been reported 
on multiple occasions. Within C2C12 myoblasts, the VDR was detected at the 
transcript and protein level, both of which increased in response to the treatment with 
25(OH)D and 1a,25(OH)2D3 [19] and decreased during myogenesis [9]. Similarly, the 
detection of the VDR in C2C12 skeletal muscle cells has also been reported utilising 
immunohistochemistry with time-dependent localisation to the cell membrane or 
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nucleus in response to 1a,25(OH)2D3 [18, 22]. Multiple studies have also confirmed 
the expression of the VDR within human primary myoblasts [12, 20, 21]. Clearly, the 
detection of the VDR within skeletal muscle in vitro is reliable with consistent reports 
of a successful detection utilising a multitude of techniques.  
 
The detection of the VDR in whole skeletal muscle lysates however, remains a 
contentious issue with multiple studies reporting conflicting results [9, 11, 12, 23, 24]. 
For example, VDR at the protein level was reportedly undetectable in rat and mouse 
skeletal muscle via both immunoblot and immunohisotchemical approaches [11]. In 
addition, whilst VDR transcripts were detected at an extremely low level, in 
comparison to the duodenum a classical site of VDR action, skeletal muscle 
transcripts were detected at a substantially lower rate (4000x lower) [9, 11]. Given 
this low expression profile, the use of a HLB (6.7M urea; 10% glycerol; 10mM Tris-
HCl, 1% sodium dodecyl sulfate; 1mM dithiothreitol; 1mM phenylmethylsulfonyl-
fluoride) has been reported to improve the detection of the VDR [9]. The VDR is 
known to tightly bind to DNA and it is hypothesised that the use of HLB may be 
effective in reducing VDR/DNA association [25, 26]. Whilst this method has proved 
successful in mouse skeletal muscle [9], other studies have reported that the VDR 
was undetectable in human skeletal muscle extracts when employing this method 
[12]. In addition, the VDR remained undetectable even when a purified nuclear 
fraction was probed [21]. Despite the successful detection of the VDR in mouse 
skeletal muscle, its expression was reduced across development and decreased 
significantly when tissue from 3-month old mice was compared to tissue from mice at 
3-weeks of age [9]. Within human skeletal muscle samples, the positive expression 
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of the VDR has been reported utilising immunohistochemical [27, 28] and 
immunoblot approaches [21]. Despite this, the antibody utilised to detect the VDR via 
immunohistochemistry, Affinity BioReagents 9A7, has previously been called into 
question due to non-specific binding [29]. Similarly, whilst the successful detection of 
the VDR was reported utilising the VDR NR1I1 antibody (Perseus Proteomics), it was 
validated in comparison to the Santa Cruz D6 antibody and was not tested in VDR-
KO tissue [28].  
 
Despite the consistent detection of the VDR in vitro, its detection within whole 
skeletal muscle remains problematic. Within skeletal muscle cell lines, the VDR is 
known to play a role in proliferation, differentiation and cell cycle progression [19]. In 
addition, both whole body and skeletal muscle specific VDR-KO mice display 
impairments in skeletal muscle structure and function, suggesting a direct role for the 
VDR within said tissue [17, 23, 30-32]. Therefore, a protocol that results in the 
reliable and consistent detection of the VDR within skeletal muscle lysates would be 
significant addition to this thesis and the field as a whole. Expanding upon previously 
described methods [9], we sought to detect the VDR in skeletal muscle lysates from 
both young (3-weeks) and adult (10-weeks) mice. Comparisons were made across 
differing skeletal muscle samples, lysis buffers and antibodies with the aim of 
positively detecting the VDR.  
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3.2 Methods 
3.2.1 Tissue Culture 
VDR-KD and respective scramble control C2C12s were plated at 1.0 x 105 cells/well 
in 2 ml of growth medium in 6-well plates (Nunc, Roskilde, Denmark). Upon reaching 
90% confluence, cells were either harvested for myoblast experiment or switched to 
differentiation medium. Before switching to differentiation medium, cells were washed 
once with PBS. Differentiation medium was changed every other day and myotube 
formation was monitored over a period of 7 days.  
 
3.2.2 Mouse Characteristics and Tissue Collection 
Both 3- (n=3) and 10-week old (n=3) C57BL/6J mice were housed as previously 
described (Section 2.1.2). Within the first week of arrival, mice were anesthetized 
under isoflurane and tissues were excised following a 2 h fast. Tissues collected 
included; gastrocnemius, quadriceps, triceps, kidney and liver. Following tissue 
collection, a blood sample was taken via cardiac puncture. End stage termination 
was completed via cervical dislocation. Samples were handled and stored as 
previously described (Section 2.8).  
 
3.2.3 Cell and Tissue Lysis 
Upon collection, both myoblast and myotube cell monolayers were washed twice with 
ice-cold PBS. Each well was actively scraped and collected in 100 µl of sucrose lysis 
buffer. Tissue samples were powdered on dry ice using a CellcrusherTM tissue 
pulverizer (Cellcrusher Ltd, Cork, Ireland) and homogenized in a 10-fold mass of ice-
cold sucrose or urea lysis buffer. Cell and tissue lysates were homogenised via 
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shaking in a FastPrep 24 5G (MP Biochemicals, Santa Ana, California, USA) as 
previously described (Section 2.3.1). The constituents of the sucrose and urea lysis 
buffers are described below (Section 3.2.5).  
 
3.2.4 Lysis Buffers 
Cell and tissue lysis was completed using sucrose lysis buffer (50 mM Tris pH 7.5; 
270 mM sucrose; 1 mM EDTA; 1 mM EGTA; 1% Triton X-100; 50 mM sodium 
fluoride; 5 mM sodium pyrophosphate decahydrate; 25 mM beta-glytcerolphosphate). 
Relevant inhibitors were added fresh on the day of use and included 1 cOmpleteTM 
protease inhibitor cocktail EDTA free tablet and Phosphatase Inhibitor Cocktail 3 both 
purchased from Sigma-Aldrich. With the aim of detecting the VDR in whole skeletal 
muscle extracts, tissue samples were also lysed in a urea lysis buffer (6.7M urea; 
10% glycerol; 10mM Tris-HCl, 1% sodium dodecyl sulfate; 1mM dithiothreitol; 1mM 
phenylmethylsulfonyl-fluoride). One Protease Inhibitor Cocktail tablet was added 
fresh upon the day of use.  
 
3.2.5 Immunoblotting 
Total protein lysates of a known concentration were mixed 3:1 with 4x Laemmli 
sample loading buffer to generate polyacrylamide gel loading samples of a known 
concentration. Prior to gel loading, samples were boiled for 5 minutes unless 
otherwise stated. An equal volume of protein (10-75 µg) was separated by SDS-
PAGE on 10% gels at a constant current of 23 mA per gel. Proteins were then 
transferred on to BioTrace NT nitrocellulose membranes (Pall Life Sciences, 
Pensacola, Florida, USA) using a wet transfer system at 100 V for 1 h. Membranes 
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were then stained in Ponceau S (Sigma-Aldrich, Gillingham, UK) and imaged to 
check for even loading and transfer. Membranes were then blocked for 1 h in 3% dry-
milk in TBS-T prior to incubation overnight in primary antibodies at 4°C. Following 
primary antibody incubation, membranes were washed three times in TBS-T and 
subsequently incubated in the appropriate horseradish peroxidase-conjugated 
secondary antibody at room temperature for 1 h. Antibody detection was performed 
via an enhanced chemiluminescence horseradish peroxidase substrate detection kit 
(Millipore, Watford, UK). Subsequent imaging and band quantification were 
performed using the G:Box Chemi-XR5 system (Syngene, Cambrige, UK). 
 
3.2.6 Antibodies 
Three different antibodies for the VDR were utilised and the characteristics of each 
are displayed below (Table 3.1). All primary antibodies were used at a concentration 
of 1:500 in TBS-T. Secondary antibodies were used at a concentration of 1:10,000 in 
TBS-T. Anti-mouse (7076) and anti-rabbit (7074) were from Cell Signaling 
Technology.  
 
Antibody Manufacturer Host Isotype Epitopes 
D6 SC-12133 Santa Cruz Biotechnology Mouse Monoclonal Human VDR 344-424 
D2K6W Cell Signaling Technology Rabbit Monoclonal Human VDR N-terminal 
AB109234 Abcam Rabbit Monoclonal Human VDR 
Table 3.1. Antibody characteristics utilised for the detection of the vitamin D receptor. The 
exact sequence for the Abcam antibody is proprietary.  
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3.2.7 Statistical Analysis 
Statistical analysis was performed using the SPSS version 24.0. Control myoblasts 
and myotubes were compared to VDR-KD myoblasts and myotubes respectively via 
independent t-tests. Data presented as mean ± SD. Statistical significance set as P < 
0.05.  
 
3.3 Results 
3.3.1 Detection of the VDR in C2C12 Myoblasts 
Antibodies from Abcam, Cell Signaling Technology and Santa Cruz all successfully 
detected the VDR protein in C2C12 myoblasts. Positive detection of the VDR was 
confirmed through immunoblotting of C2C12 myoblasts in which VDR protein was 
abolished via shRNA interference (See chapter 4 for detailed characterisation of this 
cell line). Minimal signal was detected in VDR-KD myoblasts and no non-specific 
binding was detected for each antibody (Fig. 3.1A-B) suggesting that all three 
antibodies are specific to the VDR in C2C12 cells. 
 
Figure 3.1. Detection of the VDR in control and VDR-KD C2C12 myoblasts. A) Detection of the 
VDR within control and VDR-KD C2C12 skeletal muscle myoblasts utilising antibodies from Abcam, 
Cell Signaling Technology (CST) and Santa Cruz (SC). B) Representative images of VDR protein 
expression. Data mean ± SD (n=6). **P < 0.005.   
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3.3.2 Detection of the VDR in C2C12 Myotubes 
VDR protein content was detected in C2C12 myotubes when antibodies from Abcam, 
Cell Signaling Technology and Santa Cruz were utilised. Positive detection of the 
VDR was confirmed via the use of the VDR-KD C2C12 cell line (See chapter 4 for 
detailed characterisation of this cell line). Minimal signal and no non-specific binding 
was detected for each antibody (Fig. 3.2A-B).  
 
 
Figure 3.2. Detection of the VDR in control and VDR-KD C2C12 myotubes. A) Successful 
detection of the VDR protein within control and VDR-KD C2C12 skeletal muscle myotubes utilising 
antibodies from Abcam, Cell Signaling Technology and Santa Cruz. B) Representative images of VDR 
protein expression. Data mean ± SD (n=6). **P < 0.005. 
 
3.3.3 Detection of the VDR in Mouse Kidney 
We next aimed to detect the VDR in 3- and 10-week old mouse kidney lysates using 
antibodies from Abcam, Cell Signaling Technology and Santa Cruz. The kidney is a 
known site of action for the VDR and kidney lysates are commonly recommended as 
a positive control for VDR detection. We successful detected the VDR using all three 
antibodies. All three antibodies were successful in detecting the VDR following tissue 
lysis with either the urea or sucrose lysis buffer (Fig. 3.3A).  
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Figure 3.3. Successful detection of the VDR in mouse kidney. A) Successful detection of the VDR 
in 3- and 10-week old mouse kidney samples lysed in sucrose lysis buffer. B) Successful detection of 
the VDR in 3 and 10-week old mouse kidney samples lysed in a urea lysis buffer. Ladders represent 
50 and 37 kDa.    
 
 
3.3.4 Detection of the VDR in Mouse Gastrocnemius 
The detection of the VDR in gastrocnemius lysates was unsuccessful whether 
samples were lysed in sucrose (Fig. 3.4A) or urea lysis buffer (Fig. 3.4B). Antibodies 
from Abcam, Cell Signaling Technology and Santa Cruz were unable to detect the 
VDR in 3- and 10-week old mouse gastrocnemius lysates despite loading ~75 µg of 
protein. A mouse kidney sample was used as a positive control (10 µg) suggesting 
that the immunoblotting procedure was successful.   
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Figure 3.4. Unsuccessful detection of the VDR in mouse gastrocnemius. A) Unsuccessful 
detection of the VDR protein in 3- and 10-week old mouse gastrocnemius when lysed in sucrose lysis 
buffer. B) Unsuccessful detection of the VDR protein in 3- and 10-week old gastrocnemius when lysed 
in a urea lysis buffer. Ladders represent 37 and 50 kDa.  
 
3.3.5 Detection of the VDR in Mouse Quadriceps 
We also aimed to detect the VDR in mouse quadriceps samples following lysis in 
sucrose and urea lysis buffers. Both lysis buffers combined with the use of antibodies 
from Abcam, Cell Signaling Technology and Santa Cruz were unsuccessful in VDR 
detection within mouse quadriceps samples despite loading ~75 µg of protein (Fig. 
3.5A-B). A mouse kidney sample was utilised in order to act as a positive control (10 
µg).  
Figure 3.5. Unsuccessful detection of the VDR in mouse quadriceps. A) Unsuccessful detection 
of the VDR in mouse quadriceps lysed in sucrose lysis buffer. B) Unsuccessful detection of the VDR 
protein in mouse quadriceps lysed in urea lysis buffer. Ladder represents 37 and 50 kDa.  
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3.4 Discussion 
The detection of the VDR within skeletal muscle samples is a contentious issue. 
Whilst some have reported positive VDR expression [9], others have reported a lack 
of VDR protein expression within skeletal muscle samples [11, 12]. In vitro, a 
prominent role for the VDR in skeletal muscle proliferation, differentiation and 
myogenesis has been reported [19]. In addition, both whole-body and skeletal 
muscle specific VDR-KO mouse models display an altered skeletal muscle 
phenotype [17, 23, 30-32]. Although the current evidence points towards a significant 
role for the VDR within skeletal muscle development and function, its detection within 
skeletal muscle is problematic. This primarily caused by low expression levels, the 
multicellular nature of skeletal muscle, differences in VDR expression across 
development and the use of non-specific antibodies [29].  
 
Similar to previous studies, we report a successful detection of the VDR protein 
within C2C12 myoblasts [18, 19, 22, 33]. In order to confirm specificity of our 
antibodies, we also utilised a VDR-KD C2C12 cell line in which the protein content of 
the VDR is reduced following lentivirus mediated shRNA interference. The Santa 
Cruz D6 antibody has previously been reported to be highly specific for the VDR [29] 
however, we also show that antibodies from both Abcam and Cell Signaling 
Technologies also result in a robust detection of the VDR with C2C12 myoblasts and 
myotubes.  
 
Whilst the detection of the VDR within skeletal muscle cell lines is reliable, its 
detection in whole skeletal muscle lysates is more contentious [11]. In order to detect 
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the VDR, the use of a HLB has previously been recommended [9]. This buffer 
contains high amounts of urea which aids in separating the VDR from its tight binding 
to DNA [25, 26]. Given that the kidney is a known site of positive expression for the 
VDR [29] we first sought to detect the VDR in mouse kidney samples. It should be 
noted that prior analysis and optimisation experiments were conducted comparing 
blocking reagents as well as multiple concentrations of primary (1:1000 & 1:500) and 
secondary (1:10,000 & 1:20,000) antibodies. The detection of the VDR was 
successful using antibodies from Abcam, Cell Signaling Technology and Santa Cruz 
irrespective of lysis buffer used. Finally, we sought to detect the VDR in whole 
skeletal muscle lysates from both young and adult mice. Within skeletal muscle, the 
VDR has been proposed to play a more prominent role within the early stages of 
muscle development [9]. Previously, the protein content of the VDR has been 
reported to decrease when comparing skeletal muscle samples from new-born, 3-
week and 3-month old C57BL/6J mice [9]. Therefore, we also aimed to detect the 
VDR with skeletal muscle samples from both 3 and 10-week old C57BL/6J mice. 
Similar to others [12], we were unable to detect the VDR with skeletal muscle 
samples derived from the gastrocnemius and quadriceps irrespective of age. The 
detection of the VDR was unsuccessful irrespective of antibody or lysis buffer 
utilised. Although others have detected the VDR within skeletal muscle samples 
using similar methods [9], were unable to detect the VDR despite loading ~75 µg of 
protein and using primary antibodies at a concentration of 1:500.  
 
Whilst some have reported a positive detection of the VDR within skeletal muscle [9], 
we and others [12] have been unable to replicate such findings. The results 
	 116 
described within this chapter only raise further questions in regards to the relevance 
of the VDR with skeletal muscle in vivo. If the VDR is not expressed within adult 
skeletal muscle then the positive effects of vitamin D and the skeletal muscle 
phenotypes arising in VDR-KO animals may result indirectly from alterations in 
mineral homeostasis. However, in support of a direct role for the VDR within skeletal 
muscle, skeletal muscle specific VDR-KO mice do display an alerted phenotype [30, 
31]. Clearly, further research is needed to understand the role of the VDR within 
skeletal muscle and the development of more reliable methods to detect the VDR 
would be a significant addition to the field. A more comprehensive comparison of 
sample lysis and immunoblot protocols alongside the use of multiple antibodies 
would further the development of a protocol for VDR detection within skeletal muscle. 
Purification and subcellular fraction approaches may aid in the detection of the VDR 
in whole skeletal muscle lysates however, purification of the nuclear fraction also 
resulted in the unsuccessful detection of the VDR [12]. In addition, the analysis of 
VDR mRNA expression in the same samples utilised within this chapter may offer 
further insight into the relative expression levels of the VDR. Given the extremely low 
expression levels of the VDR within skeletal muscle, current methods may not be 
sensitive enough to reliably detect the VDR within whole skeletal muscle lysates on a 
consistent basis.  
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CHAPTER 4 
 
THE ROLE OF THE VITAMIN D RECEPTOR IN REGULATING MITOCHONDRIAL 
FUNCTION IN C2C12 CELLS AND RAT SKELETAL MUSCLE 
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4.1 Introduction 
Vitamin D deficiency is characterised by serum 25(OH)D levels of <50 nmol.L-1 [1] 
Based on these numbers, it has been reported that approximately 40% of adults in 
both the USA [2] and Europe [3] can be classified as deficient, with 13% of 
Europeans deemed severely deficient [3]. The classical actions of vitamin D are well 
established, primarily functioning to maintain calcium and phosphate balance in order 
to prevent rickets [4], osteomalacia [5] and osteoporosis [6]. Vitamin D carries out its 
actions via its active metabolite 1a,25(OH)2D3 which binds to the ubiquitously 
expressed VDR [7]. Part of the nuclear receptor superfamily, the VDR together with 
its binding partner RXRa recruits both coactivators or repressors to exert its effects 
on genomic transcription [8, 9]. 
 
As well as its role in the maintenance of bone health, vitamin D has been shown to 
play a much wider role within the body, and more specifically, within skeletal muscle 
[10]. Multiple observational studies have reported positive associations between 
serum 25(OH)D levels and lower extremity muscle strength and function in older 
individuals  [11-13], whilst those with serum concentrations of <25 nmol.L-1 are at a 
two-fold greater risk of developing sarcopenia [14]. Additionally, a prominent feature 
of vitamin D deficiency is proximal muscle weakness [15, 16] and chronic 
deficiencies are often accompanied by severe skeletal muscle myopathies which can 
be rescued via vitamin D supplementation [17]. Furthermore, markers of skeletal 
muscle function, including grip strength, grip endurance and sprint speed, are 
impaired in mouse models of vitamin D deficiency [18, 19].  
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Given that vitamin D exerts its biological actions through binding to the VDR, multiple 
studies have sought to elucidate the role of the VDR specifically within skeletal 
muscle. Investigations utilising multiple mouse models with the global deletion of the 
VDR have identified skeletal muscle-specific actions [20-23]. From an early age, 
muscle fibre atrophy, reduced grip strength and impaired motor function are all 
present within VDR-KO mice [18, 24]. However, the global deletion of the VDR 
results in a dysregulation of both calcium and phosphate homeostasis [20, 21, 23].  
Given the importance of intracellular calcium and phosphate in skeletal muscle 
contraction [25, 26] and ATP production [27], a dysregulation in mineral homeostasis 
could mediate the observed impairments in skeletal muscle function indirectly within 
VDR-KO mice. Although, despite the administration of a rescue diet containing 
increased calcium and phosphate, the observed impairments in muscle function 
persist, suggesting a direct role for the VDR within skeletal muscle [20]. More 
recently, skeletal muscle specific VDR-KO mice have been developed [28, 29]. 
These mice exhibited a number of metabolic defects including increased serum 
insulin levels, insulin resistance, glucose intolerance, slight decreases in muscle fibre 
size [28] as well as reductions in voluntary wheel running capacity and lean mass 
[29].  
 
Evidence is now emerging to suggest that the deleterious effects of vitamin D 
deficiency within skeletal muscle may be mediated by impairments in mitochondrial 
energy metabolism [30, 31]. In support of this, the repletion of vitamin D status in 
severely deficient humans resulted in improvements in oxidative phosphorylation 
(assessed via P-31 MRS) as well as reductions in symptoms of fatigue [30]. 
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Additionally, the treatment of human primary skeletal muscle myoblasts and C2C12 
myotubes with vitamin D metabolites resulted in an increase in mitochondrial 
respiration [32-34]. Furthermore, vitamin D treatment of human primary myoblasts 
increased mitochondrial volume (as assessed via MitoTracker staining and confocal 
microscopy), as well as increasing the expression of >80 mRNAs encoding for 
mitochondrial proteins [32]. Whilst the VDR was not detectable within the 
mitochondria of human skeletal muscle primary myoblasts [32], it is expressed within 
the mitochondria of other cell types [35, 36] making the precise role of the VDR within 
the mitochondria unclear. Whilst these data highlight a potential role for vitamin D in 
modulating mitochondrial function, they do not directly examine the precise role of 
the VDR in mediating these changes. Although a reduction in the VDR was reported 
to abolish the 1a,25(OH)2D3 mediated increases in mitochondrial respiration it was 
not the primary focus of the study [32]. Additionally, the knock-down of the VDR was 
achieved by siRNA approaches which are transient and the effects of a reduction in 
the VDR across skeletal muscle development cannot be established.  
 
Taken together, these data suggest a role for vitamin D, 1a,25(OH)2D3 and the VDR 
in the maintenance of skeletal muscle mitochondrial function. However, the specific 
role of the VDR within mitochondrial regulation in skeletal muscle remains largely 
underexplored. Therefore, the aims of this chapter were as follows; 1) Examine 
whether stable knock-down of the VDR within C2C12 cells affects mitochondrial 
respiration across myogenesis 2) determine how loss of VDR affects mitochondrial 
protein content across myogenesis 3) determine whether manipulating VDR 
expression in rat skeletal muscle alters mitochondrial protein content.   
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4.2 Materials and Methods 
4.2.1 Tissue Culture 
All tissue culture experiments were carried out under sterile conditions in a class II 
safety cabinet. Cell cultures were maintained in a HERAcell 150i CO2 Incubator 
(Thermo Scientific Inc., Chesire, UK) maintained at 37°C with 5% CO2. Growth 
medium consisted of DMEM with added GlutaMAXTM and glucose (4.5 g.L-1) as well 
as the addition of 10% FBS, 1% PS and 2 µg.ml-1 puromycin. Differentiation medium 
consisted of DMEM with added GlutaMAXTM and glucose (4.5 g.L-1) as well as the 
addition 2% HS and 1% PS.  
 
4.2.2 shRNA Mediated Knock-Down of the Vitamin D Receptor 
The lentiviral plasmid used (pLKO.1 backbone) was designed in-house and was 
based on (Clone ID: RMM3981-201757375) and targeted the (3’ UTR) mouse 
sequence 5′- TTA AAT GTG ATT GAT CTC AGG-3′ of the mouse Vdr gene; the 
scramble shRNA was used as a negative control as previously reported [37] with a 
hairpin sequence: CCT AAG GTT AAG TCG CCC TCG CTC TAG CGA GGG CGA 
CTT AAC CTT AGG (Addgene plasmid 1864, Cambridge, MA, USA). Oligos were 
obtained from ITDDNA USA (Integrated DNA Technologies, Inc. Iowa, USA) and 
suspended, annealed and cloned into pLKO.1 at EcoRI and AgeI restriction sites as 
per the pLKO.1 protocol from Addgene. The resultant plasmids were transformed in 
DH5α cells for amplification and isolated. The actual DNA sequence was confirmed 
at the Pennsylvania State University College of Medicine DNA sequence core facility. 
Packaging plasmids psPAX2 and envelope protein plasmid pMD2.G were a gift from 
Trono Lab Addgene plasmids 12260 and 12259 respectively. HEK293FT cells 
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(Invitrogen, Carlsbad, CA, USA) were grown in DMEM; 80–85% confluent plates 
were rinsed once with Opti-MEM (Invitrogen, Carlsbad, CA, USA) and then incubated 
with Opti-MEM for 4 h before transfections. psPAX2 and pMD2.G along with either 
scramble or pLKO.1 clones targeting mouse Vdr (three clones) were added after 
mixing with Lipofectamine 2000 as per the manufacturer’s instructions (Invitrogen, 
Carlsbad, CA, USA). Opti-MEM was changed after overnight incubation with DMEM 
containing 10% FBS without antibiotics to allow cells to take up the plasmids and 
recover. Culture media were collected at 36 and 72 h post-transfection for viral 
particles. Viral particles present in the supernatant were harvested after a 15-min 
spin at 1,500 g to remove cellular debris. The supernatant was further filtered using a 
0.45-μm syringe filter. Supernatant-containing virus was either stored at −80°C for 
long-term storage or at 4°C for immediate use. C2C12 cells at 60% confluence were 
infected twice overnight with 3 ml of viral supernatant containing 8 μg.ml-1 polybrene 
in serum-free–antibiotic-free DMEM. Fresh DMEM media containing 10% FBS, 
antibiotics and 2 μg.ml-1 puromycin (Sigma, St. Louis, MO, USA) were added the 
next day. Cells that survived under puromycin selection were either harvested (as 
stable cells) and stored in liquid N2 or used as either myoblasts or myotubes 
depending on the experiment.  
 
4.2.3 Extracellular Flux Analysis 
Both scramble control and VDR-KD cells were seeded in XFe24-well cell culture 
microplates (Seahorse Bioscience, North Billerica, USA) at 3.0 x 105 cells/well in 100 
µl of growth medium and allowed to rest at room temperature for 1 h in order to 
promote an even cell distribution [38].  For myoblast experiments, cells were 
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incubated at 37°C and 5% CO2 for 3 h in order to allow sufficient time for adherence 
to cell culture microplate and subsequently assayed. For myotube experiments, cells 
were incubated for a period of 24 h, resulting in a confluence of 90%. Cells were then 
washed once with PBS and medium changed to differentiation medium. 
Differentiation media was changed every other day for a period of 7 days. Prior to the 
assay, cells were washed once and placed in 500 µl of Seahorse XF Base Medium 
(glucose 10 mM, sodium pyruvate 1 mM, glutamine 1 mM, pH 7.4) pre-warmed to 
37°C. The plate was then transferred to a non-CO2 incubator for 1 h. Following 
calibration, cell respiratory control [39] and associated extracellular acidification were 
assessed following the sequential addition of oligomycin (1 µM), CCCP (1 µM) and 
antimycin A with rotenone (1 µM). Upon completion of the assay, cells were collected 
in sucrose lysis buffer and subjected to one freeze thaw cycle. Upon thawing, cell 
lysate was centrifuged for 10 minutes at 8,000 g and the supernatant was removed 
for protein determination. Protein concentration was determined using the DC protein 
assay (Bio-Rad, Hercules, CA). OCR is reported relative to protein content 
(pmol/min/µg). 
 
4.2.4 Estimation of ATP Production 
Estimation of intracellular rates of glycolytic and oxidative ATP production were 
performed as previously described [40]. Briefly, scramble control and VDR-KD cells 
were seeded in XFe24-well cell culture microplates (Seahorse Bioscience, North 
Billerica, USA) at 3.0 x 105 cells/well in 100 µl of growth medium (high glucose 
DMEM, 10% FBS, 1% penicillin/streptomycin, puromycin 2µg.ml-1). Prior to the assay 
cells were washed once and then incubated in 500 μl of KRPH medium (2 
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mM HEPES, 136 mM NaCl, 2 mM NaH2PO4, 3.7 mM KCl, 1 mM MgCl2, 1.5 mMCaCl2, 
0.1% (w/v) fatty-acid-free BSA, pH 7.4 at 37 °C). Cell respiratory control [39] and 
extracellular acidification were assayed following the addition of glucose (10 mM), 
oligomycin (1 µM), CCCP (1 µM) and antimycin A with rotenone (1 µM). Upon 
completion of the assay cells were collected in sucrose lysis buffer (50 mM Tris pH 
7.5; 270 mM sucrose; 1 mM EDTA; 1 mM EGTA; 1% Triton X-100; 50 mM sodium 
fluoride; 5 mM sodium pyrophosphate decahydrate; 25 mM beta-glytcerolphosphate; 
1 cOmpleteTM protease inhibitor cocktail EDTA free tablet) and centrifuged for 10 
minutes at 8,000 g and the supernatant was removed for protein determination. 
Protein concentration was determined using the DC protein assay (Bio-Rad, 
Hercules, CA). Rates of ATP production are reported relative to protein content 
(pmol/min/µg). 
 
4.2.5 Measurement of Mitochondrial Membrane Potential 
Both scramble control and VDR-KD cells were plated at 1.0 x 105 cells/well in 100 µl 
of growth medium and incubated for 24 h. A black 96-well plate with a clear bottom 
(Corning, Costar, NY, USA) was used in order to minimise well-to-well interference. 
Cells were subsequently incubated for 30 minutes with 100 nM of TRME. A set of 
cells were also incubated with 20 µM FCCP in order to completely depolarise the 
mitochondrial membrane and act as a negative control. Following incubation cells 
were washed with PBS with 0.2% BSA and then read at 549 nm using a CLARIOstar 
microplate reader (BMG Labtech, Victoria, Australia) in 100 µl of PBS and 0.2% BSA.  
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4.2.6 Transient Electroporation in Male Wistar Rats 
Eight-week-old male Wistar rats were housed as described above (section 2.1.1) and 
fed a standard chow diet (18% fat, 33% protein, 48% carbohydrate) for one week. 
VDR-KD (n=7) was achieved in right hind leg tibialis anterior muscle through in vivo 
electrotransfer of four unique rat VDR pGFP-C-shLenti plasmid constructs driven by 
a U6 promoter [41]. These constructs spanned multiple regions of rat VDR mRNA 
(NM_017058.1) to ensure effective coverage and knockdown. Left leg tibialis 
anterior muscles received scramble cassette sequence controls (OriGene, Rockville, 
USA). Plasmid DNA amplification was undertaken within JM109 Escherichia coli cells 
under puromycin selection (0.5 µg/ml) overnight. Plasmid DNA was purified using an 
endotoxin free plasmid Maxi Kit (Qiagen, Manchester, UK) as per the manufacturers 
instructions. VDR-OE (n=7) was achieved in right leg tibialis anterior muscle through 
in vivo electrotransfer of pCAGGS-mVDR vector constructs. The mouse cDNA 
sequence utilised was 92% homologous to rat VDR mRNA. To obtain pCAGGS-
mVDR, myc-DDK-mVDR was subcloned in the pCAGGS vector. Left leg tibialis 
anterior muscles received empty pCAGGS vector controls. Plasmid DNA 
amplification was undertaken within JM109 Escherichia coli cells under puromycin 
selection (0.5 µg/ml) overnight. Plasmid DNA was purified using an endotoxin free 
plasmid Maxi Kit (Qiagen, Manchester, UK) as per the manufacturers instructions. 
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4.2.7 Immunoblotting 
Total protein lysates of a known concentration were mixed 3:1 with 4x Laemmli 
sample loading buffer to generate polyacrylamide gel loading samples. Prior to gel 
loading, samples were boiled for 5 minutes. An equal volume of protein (10-30 µg) 
was separated by SDS-PAGE on 8-15% gels at a constant current of 23 mA per gel. 
Proteins were then transferred on to BioTrace NT nitrocellulose membranes (Pall Life 
Sciences, Pensacola, Florida, USA) using a wet transfer system at 100 V for 1 h. 
Membranes were then stained in Ponceau S (Sigma-Aldrich, Gillingham, UK) and 
imaged to check for even loading and transfer. Membranes were blocked for 1 h in 
3% dry-milk in TBS-T prior to overnight incubation in primary antibodies at 4°C. The 
following day, membranes were washed three times in TBS-T and subsequently 
incubated in the appropriate horseradish peroxidase-conjugated secondary antibody 
at room temperature for 1 h. Antibody detection was performed with an enhanced 
chemiluminescence horseradish peroxidase substrate detection kit (Millipore, 
Watford, UK). Subsequent imaging and band quantification were performed using the 
G:Box Chemi-XR5 system (Syngene, Cambrige, UK). 
 
4.2.8 Antibodies 
All primary antibodies were used at a concentration of 1:1000 in TBS-T unless 
otherwise stated. Antibodies for dynamin-1-like protein (DRP1;8570) and vitamin D3 
receptor (VDR; 12550) were from Cell Signaling Technology; MitoProfile OXPHOS 
antibody cocktail (110413), vitamin D receptor (VDR; 109234) and mitofilin (110329) 
were from Abcam; dynamin-like 120 kDa protein (OPA1; CPA3687) was from BD 
Biosciences; peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
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(PGC-1a; AB3242) was from Merck-Millipore; citrate synthase (CS; SAB2701077) 
and mitochondrial fission protein 1 (FIS1; HPA017430) were from Sigma Aldrich; 
vitamin D receptor (D-6) (VDR; 13133) was from Santa Cruz Biotechnology. 
Secondary antibodies were used at a concentration of 1:10,000 in TBS-T. Anti-
mouse (7076) and anti-rabbit (7074) were from Cell Signaling Technology.  
 
4.2.9 Statistical Analysis 
Statistical analysis was performed using the SPSS version 24.0. Differences between 
scramble control and VDR-KD C2C12s were determined by independent t-tests and 
two-way analysis of variance (ANOVA) where appropriate, with Bonferroni correction 
for multiple comparisons. Differences between control and VDR-KD or VDR-OE legs 
were determined by independent t-tests. All data is presented as mean ± SD. 
Statistical significance was set at P < 0.05.  
 
4.3 Results 
4.3.1 Knock-Down of the Vitamin D Receptor 
Following shRNA interference, VDR protein content was reduced by ~96 and ~94 % 
within C2C12 myoblasts (Fig. 4.1, A and B) and myotubes (Fig. 4.1, C and D) 
respectively. VDR protein content was significantly reduced in myoblasts when 
detected with antibodies from Abcam (P < 0.001), CST (P < 0.001) and Santa-Cruz 
(P < 0.001). Similar reductions were observed in myotubes with antibodies from 
Abcam (P < 0.001), CST (P < 0.001) and Santa-Cruz (P < 0.001).  
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Figure 4.1. Successful knock-down of the VDR in the C2C12 skeletal muscle cell line. A) Knock-
down of the VDR in C2C12 skeletal muscle myoblasts (n = 6/group). B) Representative images of 
VDR protein abundance in control and VDR-KD C2C12 myoblasts. C) Knock-down of the VDR in 
C2C12 skeletal muscle myotubes (n = 6/group). D) Representative images of VDR protein abundance 
in control and VDR-KD C2C12 myotubes. Data mean ± SD. **P < 0.005. Repeat of Figures 3.1 and 
3.2.  
 
4.3.2 Extracellular Flux Analysis 
VDR-KD within C2C12 myoblasts reduced basal respiration by 30% (Control 9.86 ± 
3.41 vs. VDR-KD 6.93 ± 1.03 pmol/min/µg, P = 0.034), in addition to reducing 
coupled respiration by 30% (Control 8.38 ± 2.69 vs. VDR-KD 5.87 ± 0.56 
pmol/min/µg., P = 0.023). Further, VDR-KD reduced maximal respiration by 36% 
(Control 30.76 ± 10.42 vs. VDR-KD 19.65 ± 1.24 pmol/min/µg, P = 0.013) and 
reduced spare capacity by 39% (Control 20.90 ± 7.01 vs VDR-KD 12.72 ± 1.17 
pmol/min/µg, P = 0.008) when compared to control (Fig. 4.2, A and C). Similarly, 
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VDR-KD within C2C12 myotubes reduced basal respiration by 34% (Control 17.06 ± 
2.76 vs. VDR-KD 11.22 ± 1.24 pmol/min/µg, P < 0.001), as well as reducing coupled 
respiration by 33% (Control 11.40 ± 2.10 vs. VDR-KD 7.69 ± 0.96 pmol/min/µg, P < 
0.001). Furthermore, VDR-KD in C2C12 myotubes also reduced maximal respiration 
by 48% (Control 58.89 ± 9.83 vs. VDR-KD 30.86 ± 6.04 pmol/min/µg, P < 0.001) and 
spare capacity by 53% (Control 41.83 ± 7.45 vs. VDR-KD 19.65 ± 5.06 pmol/min/µg, 
P < 0.001) when compared to control (Fig. 4.2, B and D). Whilst proton leak 
remained unchanged in myoblasts (Control 1.49 ± 0.74 vs. VDR-KD 1.06 ± 0.62 
pmol/min/µg, P > 0.05) (Fig. 4.2C), VDR-KD resulted in a decrease in proton leak by 
67% in myotubes (Control 2.78 ± 0.56 vs. VDR-KD 0.91 ± 0.35 pmol/min/µg, P < 
0.001) (Fig. 4.2D).  
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Figure 4.2. Knock-down of the VDR in C2C12 myoblasts and myotubes reduces mitochondrial 
respiration as measured by extracellular flux. A-B) Mitochondrial stress test traces from both 
control and VDR-KD myoblasts and myotubes (n = 9-10/group). C-D) Respiratory parameters derived 
from the mitochondrial stress test from both control and VDR-KD myoblasts and myotubes (n =9-
10/group). Data mean ± SD. *P < 0.05, **P < 0.005.  
 
 
4.3.3 Estimation of ATP Production 
VDR-KD reduced total ATP production by 18% in C2C12 myoblasts (Control 55.15 ± 
8.13 vs. 45.03 ± 3.01 pmolATP/min/µg, P = 0.002) when compared to controls (Fig. 
4.3A). In addition, estimated ATP production derived from oxidative phosphorylation 
(ATPox) was reduced by 20% in VDR-KD myoblasts (Control 46.13 ± 8.41 vs. VDR-
KD 36.87 ± 3.53 pmolATP/min/µg, P = 0.007). ATP production derived from 
glycolysis (ATPglyc) on the other hand remained unchanged (Control 9.04 ± 4.29 vs. 
8.13 ± 2.76 pmolATP/min/µg, P > 0.05) (Fig. 4.3A).  
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Figure 4.3. Reduction in ATP production via oxidative phosphorylation as opposed to 
glycolysis following VDR-KD in C2C12 myoblasts. A) Total ATP production and ATP production 
derived from oxidative and glycolytic means in control and VDR-KD myoblasts (n = 10/group). Data 
mean ± SD. *P < 0.05.  
 
4.3.5 Membrane Potential 
No main effect for group (P > 0.05) was observed for mitochondrial membrane 
potential although there was a main effect for treatment (P < 0.001) and group X 
treatment interaction (P = 0.001) indicating treatment with FCCP successfully 
depolarised the mitochondrial membrane. Post-hoc comparisons revealed a 
significant reduction in mitochondrial membrane in basal conditions (P = 0.001) when 
VDR-KD cells were compared with controls (Fig. 4.4A).  
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Figure 4.4. Mitochondrial membrane potential is reduced in VDR-KD C2C12 myoblasts. A) 
Mitochondrial membrane potential assessed via TMRE in both basal control and VDR-KD myoblasts 
as well as with the pre-treatment with FCCP (n = 5/group). Data mean ± SD. *P < 0.05, bmain effect 
for treatment, cmain interaction effect.  
 
4.3.5 Mitochondrial Related Protein Content 
No differences were observed in mitochondrial protein content including CI 
(NDUFB8), CII (SDHB), CIV (MTCO1) and CV (ATP5A), citrate synthase and 
cytochrome c following the knock-down of the VDR in both C2C12 myoblasts and 
myotubes (Fig 4.5. A-D., P > 0.05). 
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Figure 4.5. No change in markers of mitochondrial protein content following VDR-KD in both 
C2C12 myoblasts and myotubes. A) Protein abundance of mitochondrial electron transport chain 
subunits, CS and cyt c in control and VDR-KD C2C12 myoblasts (n = 6/group). B) Representative 
images of markers of mitochondrial protein content in control and VDR-KD C2C12 myoblasts. C) 
Protein abundance of mitochondrial electron transport chain subunits, CS and cyt c in control and 
VDR-KD C2C12 myotubes (n = 6/group). D) Representative images of markers of mitochondrial 
protein content in control and VDR-KD C2C12 myotubes. Data mean ± SD and represented as a fold 
change from control. 
 
 
4.3.6 Mitochondrial Fusion and Fission Related Protein Content 
Mitochondrial fusion related proteins MFN2 and mitofilin were unchanged following 
VDR-KD in both myoblasts and myotubes (Fig 4.6. A-D., P > 0.05). However, the 
mitochondrial fusion related protein, OPA1, was greater compared to CON by ~15% 
in both VDR-KD myoblasts (Fig. 4.6A-B., P = 0.021) and myotubes (Fig. 4.6C-D., P = 
0.046). Mitochondrial fission related proteins Fis 1 and DRP1 remained unchanged in 
both VDR-KD myoblasts and myotubes (Fig. 4.6A-D., P > 0.05).  
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Figure 4.6. Knock-down of the VDR in C2C12 myoblasts and myotubes results in an increase in 
OPA1 protein abundance but no change in markers of mitochondrial fission. A) Protein 
abundance of markers of mitochondrial fusion and fission in control and VDR-KD C2C12 myoblasts (n 
= 6/group). B) Representative images of markers of mitochondrial fusion and fission in control and 
VDR-KD C2C12 myoblasts. C) Protein abundance of markers of mitochondrial fusion and fission in 
control and VDR-KD C2C12 myotubes (n = 6/group). D) Representative images of markers of 
mitochondrial fusion and fission in control and VDR-KD C2C12 myotubes. Data mean ± SD and 
reported as a fold change from control. *P < 0.05.  
 
4.3.7 Mitochondrial Related Protein Content in VDR-KD Rat Skeletal Muscle. 
VDR-KD in rat skeletal muscle via electroporation resulted in no changed in markers 
of mitochondrial protein content (Fig 4.7. A-B, P > 0.05). Trends were observed for 
decreases in the content of mitochondrial CI (NDUFB8) (P = 0.055) and CIV 
(MTCO1) (P = 0.056) following VDR-KD (Fig. 4.7A-B). No changes were observed in 
markers of mitochondrial fusion and fission when VDR-KD was compared to control 
leg (Fig. 4.7C-D, P > 0.05).  
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Figure 4.7. No change in markers of mitochondrial protein content, fusion or fission following 
the knock-down of the VDR in rat skeletal muscle. A and C) Protein abundance of markers of 
mitochondrial protein content, fusion and fission in the tibialis anterior following VDR-KD via electro-
transfer (n = 7/group). B and D) Representative images of markers of mitochondrial protein content, 
fusion and fission. Data mean ± SD and reported as a fold change from control leg. 
 
4.3.8 Mitochondrial Related Protein Content in VDR-OE Rat Skeletal Muscle 
Overexpression of the VDR resulted in no change in markers of mitochondrial protein 
content or markers of mitochondrial fusion and fission (Fig. 4.8A-D, P > 0.05).  
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Figure 4.8. No change in markers of mitochondrial protein content, fusion and fission following 
over-expression of the VDR in rat skeletal muscle.  A and C) Protein abundance of markers of 
mitochondrial protein content, fusion and fission in the tibialis anterior following VDR-OE via electro-
transfer (n = 7/group). B and D) Representative images of markers of mitochondrial protein content, 
fusion and fission. Data mean ± SD and reported as a fold change from control leg.  
 
4.4 Discussion 
The role of vitamin D within skeletal muscle has received considerable interest in 
recent years and current evidence suggests that vitamin D related metabolites are 
able to increase mitochondrial function within skeletal muscle [30, 32-34, 42]. 
Building upon previous studies, we demonstrate that a loss-of-function of the VDR in 
C2C12 cells results in significant reductions in mitochondrial function in both 
myoblasts and myotubes (Fig. 4.2A-D). Impairments were specifically observed in 
respiration derived from oxidative phosphorylation (Fig. 4.3A) although, this was not 
as a result of decreases in mitochondrial protein content (Fig. 4.5A-D). Furthermore, 
both the knock-down and over-expression of the VDR in rat skeletal muscle resulted 
in no change in markers of mitochondrial protein content or fission (Fig. 4.7 & 8A-B).  
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Previously, difficulties in the detection of the VDR within skeletal muscle have been 
reported [43, 44]. Therefore, we utilised multiple antibodies including the reportedly 
highly specific D6 antibody in order to detect the VDR across skeletal muscle 
myogenesis [43, 45]. Following shRNA interference targeting the mouse VDR gene 
and puromycin selection, we observed a significant reduction in VDR protein content 
within both C2C12 skeletal muscle myoblasts and myotubes. Indicative of a 
successful and stable loss-of-function of the VDR. Further analysis revealed a 
significant reduction in mitochondrial respiration in both C2C12 myoblasts and 
myotubes following VDR-KD. Previously, it has been reported that the treatment of 
both human primary skeletal muscle myoblasts and C2C12 skeletal muscle cells with 
vitamin D metabolites resulted in an increase in mitochondrial respiration [32-34]. 
Whilst the observed increases in respiration were abolished following the siRNA 
mediated knock-down of the VDR in human skeletal muscle myoblasts [32], transient 
siRNA approaches are unable to determine the role of the VDR in mediating these 
changes across development. Therefore, our results build upon previous findings and 
indicate that mitochondrial impairments persist across development following VDR-
KD in skeletal muscle. Furthermore, we utilised a recently developed assay in which 
mitochondrial respiration coupled to the production of ATP can be separated into 
ATP production derived from either oxidative phosphorylation or glycolysis [40]. We 
observed significant reductions in ATP production derived from oxidative 
phosphorylation, suggesting impairments are intrinsic to the mitochondria following 
VDR loss-of-function. Although the supplementation of vitamin D3 in severely 
deficient individuals improves oxidative phosphorylation [30], it is yet to be 
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established if the loss of the VDR within skeletal muscle alters skeletal muscle 
mitochondrial function in vivo.  
 
In order to determine whether the observed impairments in mitochondrial respiration 
were related to reductions in mitochondrial volume, we assessed multiple markers of 
mitochondrial protein content [46]. Interestingly, we observed no change in 
mitochondrial protein content in both myoblasts and myotubes. Therefore, the 
reductions in mitochondrial function following VDR loss-of-function are not mediated 
by a decrease in mitochondrial content per se. Corresponding findings have been 
reported previously in both human skeletal muscle myoblasts following the treatment 
with 1a,25(OH)2D3 and within the quadriceps of mice with a myocyte specific deletion 
of the VDR, both resulting in no change in the protein content of members of the 
electron transport chain [29, 32]. Similarly, we observed no changes in mitochondrial 
protein content in rat skeletal following both VDR-KD and VDR-OE. Although, we did 
observe trends for a reduction in both complex I (P = 0.055) and IV (P = 0.056) 
following VDR-KD. Interestingly, morphological alterations such as decreased muscle 
fibre size within the skeletal muscle of VDR-KO mice are not limited to muscles of 
specific fibre types [18, 24]. Therefore, it could be reasoned that the observed trends 
may have been more apparent if the VDR-KD was administered to a skeletal muscle 
of a more oxidative phenotype.  
 
Although we observed no differences in mitochondrial protein content, an increase in 
the abundance of OPA1 was observed following VDR-KD in both myoblasts and 
myotubes. In contradiction to our results, OPA1 is also increased in response to 
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1a,25(OH)2D3 treatment in human skeletal muscle myoblasts [32] suggesting the 
increase in OPA1 following VDR-KD may be compensatory. OPA1 is known to 
possess a number of roles including modulating the fusion of the inner mitochondrial 
membrane and cristae remodelling [47, 48], in addition to protecting from apoptosis 
by reducing mitochondrial fragmentation [49]. OPA1 exists in both long and short 
isoforms, with the long isoforms undergoing proteolytic processing under conditions 
of cellular stress such as reduced mitochondrial membrane potential or increased 
ROS production [50, 51]. Given that we also report a loss of mitochondrial membrane 
potential following VDR loss-of-function, we may be observing an increase in OPA1 
proteolytic processing. A mechanism which has previously been described to reduce 
mitochondrial fusion and promote to sequestering of fragmented mitochondria for 
degradation [50]. In support of this, the loss of the VDR in cancer cell lines has been 
reported to increase the production of ROS which could also contribute to the 
processing of OPA1 [52]. In addition, the treatment of human skeletal muscle 
myoblasts with 1a,25(OH)2D3 resulted in a decrease in mitochondrial fragmentation 
[32]. Therefore, it is possible that the large functional decrements observed following 
VDR-KD may be as a result of a fragmented mitochondrial network and the increase 
in OPA1 is a compensatory mechanism. Further analysis examining the organisation 
of the mitochondrial network via the use of mitochondrial labelling techniques would 
help to shed light upon this [53]. Despite in vitro observations, we report no change in 
OPA1 protein abundance in rat skeletal muscle following both VDR-KD and VDR-OE.  
 
Whilst we and others have shown distinct changes in skeletal muscle mitochondrial 
function in response to VDR loss-of-function and treatment with vitamin D related 
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metabolites [32-34], the exact manner by which the VDR mediates this is unclear. 
Multiple studies have utilised microarray analyses to identify VDR target genes from 
multiple tissues [54-58]. However, the number of overlapping genes were low, 
indicating VDR target genes respond to 1a,25(OH)2D3 in a tissue-specific manner 
[59, 60]. Previously, a number of mRNAs encoding for mitochondrial proteins have 
been shown to be upregulated in human primary skeletal muscle myoblasts following 
the treatment with 1a,25(OH)2D3 [32] however, it is unclear whether these genes 
contain specific VDREs. Further studies combining microarray analysis, chromatin 
immunoprecipitation (ChIP) and rapid immunoprecipitation mass spectrometry of 
endogenous proteins (RIME) are much needed within skeletal muscle in order to 
identify VDR target genes and coregulatory binding partners  [61, 62]. A potential 
candidate for further exploration, PPARd has been shown to be responsive to the 
treatment of 1a,25(OH)2D3 and contain a functional VDRE, albeit within cancer cell 
lines [63]. Similar to the VDR, PPARd forms a heterodimer protein complex with 
RXRs [64] and is a known regulator of fatty acid oxidation and mitochondrial content 
within skeletal muscle [65]. The potential exploration of the VDRs interaction with 
PPARd within skeletal muscle may provide explanation towards the functional 
decrement observed following VDR-KD.  
 
In addition to its genomic actions, the VDR is also involved in non-genomic transient 
signalling events [66, 67]. The treatment of skeletal muscle cell lines with 
1a,25(OH)2D3 results in an increase in intracellular Ca2+ flux likely mediated by the 
VDR [68-70]. Intracellular and mitochondrial Ca2+ handling involving uptake, 
buffering and extrusion of Ca2+ is tightly coupled to the energetic state of the 
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organelle [71, 72]. Given the observed decrements in mitochondrial function, 
oxidative phosphorylation and membrane potential in response to VDR loss-of-
function, the exploration of Ca2+ handling dynamics should be an avenue for further 
exploration.  
 
In summary, for the first time, we build upon previous links between vitamin D and 
mitochondrial function [32-34, 42] by reporting a novel role for the VDR in the 
regulation of mitochondrial function in the C2C12 mouse skeletal muscle cell line. 
Reductions in mitochondrial function were as a result of reduced ATP production via 
oxidative phosphorylation whilst markers of mitochondrial protein content, fusion and 
fission were unchanged. Finally, markers of mitochondrial protein content, fusion and 
fission remain unchanged following the knock-down and over-expression of the VDR 
within rat skeletal muscle although, the role of the VDR within skeletal muscle in vivo 
requires further examination.  
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CHAPTER 5 
 
THE EFFECT OF DIET-INDUCED VITAMIN D DEFICIENCY ON BODY 
COMPOSITION AND SKELETAL MUSCLE MITOCHONDRIAL FUNCTION IN 
C57BL/6J MICE 
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5.1 Introduction 
Vitamin D deficiency, characterised by serum 25(OH)D levels of <50 nmol.L-1, 
remains a widespread issue across the world [1, 2]. Although the classical actions of 
vitamin D are well established [3-5], a number of non-classical actions have recently 
been identified including; the prevention of some cancers [6], the maintenance of 
immune function [7] and the maintenance of skeletal muscle function [8].  
 
Multiple studies have also sought to assess the effects of vitamin D deficiency upon 
skeletal muscle function within human populations [9-12]. Of note, observational 
studies have reported a positive association between serum 25(OH)D levels and 
muscle strength and lower extremity function in older individuals [9-11], with vitamin 
D supplementation able to increase skeletal muscle strength in this population [13, 
14]. Despite these associations, studies of this design are unable to infer causality. In 
addition, isolating the effects of vitamin D status within older populations is often 
difficult given individuals may suffer from a number of pre-existing conditions that 
may interfere with vitamin D status [15]. These difficulties highlight the importance of 
model systems that allow for the manipulation and isolation of vitamin D status in 
order to study the precise role of vitamin D within skeletal muscle.  
 
In order to study the impact of vitamin D deficiency on skeletal muscle function, a 
number of animal models have been utilised. A dysregulation of vitamin D status can 
be achieved via dietary means [16-19], a reduction in sunlight exposure [16] or by the 
administration of ethane 1-hydroxy-1, 1-diphosphonate which blocks the production 
of 1a,25(OH)2D3 [19]. Diet-induced vitamin D deficiency has been shown to result in 
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symptoms of skeletal muscle myopathy including impaired contraction kinetics, 
skeletal muscle weakness and decreases in muscle force in both chicks and rats [16, 
17, 20]. In order to isolate the effect of vitamin D and offset the observed 
hypocalcemia and hypophosphatemia that are associated with the induction of 
vitamin D deficiency [20], diets with increased calcium and phosphate have also 
been utilised [18]. However, despite the administration of this rescue diet, mice still 
display reduced grip strength and an increase in Myostatin gene expression [18], a 
known negative regulator of muscle mass [21]. Similarly, mice fed this diet chronically 
(8-12 months) show similar impairments in physical performance including; reduced 
grip endurance, sprint speed and stride length [22].  
 
The observed impairments in physical performance with vitamin D deficiency may be 
linked to impairments within skeletal muscle mitochondrial function [12, 23]. In vitro, 
vitamin D related metabolites are able to increase mitochondrial function in both 
immortalised and primary skeletal muscle cell lines [24-27]. In addition, the 
supplementation of vitamin D within a cohort of severely deficient individuals resulted 
in an increase in oxidative phosphorylation, as measured non-invasively by P-31 
MRS [12]. Whilst skeletal muscle mitochondrial content seems to remain unchanged 
following diet-induced vitamin D deficiency in mice [22], the functional characteristics 
of the mitochondria remain largely underexplored. Despite previous observations, 
current evidence is limited, specifically in relation to the in vivo effects of vitamin D 
deficiency upon skeletal muscle mitochondrial function. Therefore, the aims of this 
chapter are as follows; 1) Determine the effects of vitamin D deficiency upon body 
composition in C57BL/6J mice. 2) Determine the effects of vitamin D deficiency upon 
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skeletal muscle mitochondrial respiration in permeabilised skeletal muscle fibres from 
C57BL/6J mice.  
 
5.2 Methods 
5.2.1 Ethical Approval  
Ethical approval for mouse studies was granted by the Garvan Institute and St. 
Vincent’s Hospital Animal Experimentation Ethics Committee (approval number 
18/19). Ethical approval fulfils all the requirements of the NHMRC and the NSW State 
Government, Australia. All animal handling was carried out by trained personnel and 
all procedures were carried out according to the Australian code of practice for the 
care and use of animals for scientific purposes 8th edition [28]. C57BL/6J mice were 
received at 10-weeks of age and housed communally in a temperature controlled 
environment (22 ± 0.5°C) with a 12 h light-dark cycle.  
 
5.2.2 Composition of Diet 
Following 1-week acclimation in which mice were fed a standard chow diet, mice 
were placed on either a vitamin D-control diet or a vitamin D-deplete diet (Table 2.2) 
[18]. The vitamin D deplete contains no vitamin D but increased calcium (2%), 
magnesium (0.2%), and phosphorous (1.2%) in order to maintain normal mineral 
homeostasis (SF085-003, Speciality Feeds, Glen Forest, NSW). The vitamin D 
control diet contains vitamin D (cholecalciferol 2,200 IU/kg), calcium (1%), 
magnesium (0.2%), and phosphorous (0.7%) (SF085-034, Speciality Feeds, Glen 
Forest, NSW). Mice were maintained on the respective diets for a period of either 1- 
(n=10/group), 2- (n=10/group), or 3-months (n=6/group).   
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5.2.3 Assessment of Body Composition 
Prior to each assessment of body composition, mice were briefly weighed. Body 
weight was also obtained on a weekly basis throughout dietary intervention. Body 
composition was assessed upon arrival (10-weeks of age) and then following 1-, 2- 
and 3-months of dietary intervention using the EchoMRi (EchoMRI LLC, Houston, 
USA).  
 
5.2.4 Tissue Collection 
Tissue collections were completed following 1-, 2- and 3-months of dietary 
intervention. All samples were excised from fasted (2 h) mice following isoflurane 
(5%) anesthetization. Tissues collected include; gastrocnemius, quadriceps, triceps, 
liver, kidney, white adipose tissue and the tibia. Following collection, a blood sample 
was taken via cardiac puncture and animal terminated via cervical dislocation. All 
tissues were rinsed in sterile saline, blotted dry, weighed, and frozen in liquid 
nitrogen. A small portion (~20 mg) of the gastrocnemius was removed before 
freezing and used for high-resolution respirometry. All tissues were stored at -80°C 
for subsequent analysis.  
 
5.2.5 Tissue Processing 
Small portions of gastrocnemius muscle (~20 mg) were removed and placed in ice-
cold BIOPS buffer (2.77 mM CaK2EGTA, 7.23 mM K2EGTA, 5.77 mM Na2ATP, 6.56 
mM MgCl2-6H2O, 20 mM Taurine, 15 mM Na2Phosphocreatine, 20 mM Imidazole, 
0.5 mM Dithiothreitol, 50 mM MES Hydrate, pH 7.1, 290 mOsm). Blood samples 
were allowed to coagulate at room temperature for 10 minutes before being placed 
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on ice. Blood samples were then centrifuged at 14,000 g for 10 minutes. The 
resulting supernatant was removed and stored at -80°C for further analysis.  
 
5.2.6 Analysis of Serum Calcium 
Serum calcium was measured using a Calcium Detection Assay kit (Abcam, 
Cambridge, UK, cat. ab102505). Serum samples were diluted 1:10 and 
manufacturers instructions were followed. The assay plate was read at 575 nm using 
a CLARIOstar microplate reader (BMG Labtech, Victoria, Australia). Serum calcium 
concentrations are reported in mM.  
 
5.2.7 High-Resolution Respirometry 
High-resolution respirometry was conducted in MiR05 (2 ml) with the addition of 
blebbistatin (25 µM) using the OROBORS Oxygraph-2K (Oroboros Instruments, 
Corp., Innsbruck, AT) with stirring at 750 rpm at 37°C. Oxygen within the chamber 
was maintained between 150-220 µM for each experiment. Prior to the addition of the 
fibre bundles to the chamber, bundles were blotted dry and weighed. Bundles 
totalling 2.5-5.0 mg were added to the chamber. Firstly, pyruvate (10 mM) and 
malate (2 mM) were added as complex I substrates. Subsequently, ADP was titrated 
in step-wise increments (100-6000 µM) followed by the addition of glutamate (10 
mM) and succinate (10 mM) as complex I and II substrates. Cyt c (10 µM) was added 
in order to check outer mitochondrial membrane integrity. The partial loss of cyt c 
during fibre preparation may limit respiration. No fibre preparation exhibited an 
increase of >10%. CCCP was titrated in a step-wise manner (0.5 to 2.5 µM) until the 
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maximal capacity of the electron transport chain was reached. Finally, antimycin A 
(2.5 µM) was injected in order to inhibit mitochondrial respiration.  
 
The apparent Km for ADP was determined through the Michaelis-Menten enzyme 
kinetics – fitting model (Y = Vmax*X/(Km + X)), where X = (free ADP; ADPf), using 
Prism (GraphPad Software, Inc., La Jolla, CA). Flux control ratios (FCR) was 
calculated by setting CCCP stimulated respiration as 1 and antimycin A respiration 
as 0.  
 
5.2.8 Statistical Analysis 
Statistical analysis was performed using Prism version 7 (GraphPad Software 
Incorporated, La Jolla, CA, USA). Differences between 1-, 2- and 3-month vitamin D 
replete and deplete mice were determined by two-way ANOVA with Bonferroni 
correction for multiple comparisons. Differences between vitamin D deplete and 
replete mice in mitochondrial respiration in response to ADP titration were 
determined by multiple t-test. For baseline comparisons of body weight and 
composition, vitamin D replete and deplete mice were pooled and compared via 
independent t-test. All values are presented as mean ± SD. Statistical significance 
was set at P < 0.05.  
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5.3 Results 
 
Table 5.1. No differences in baseline measurements of body composition in mice prior to 
dietary intervention. Data mean ± SD (n=22/group).  
 
 
5.3.1 Body Weight 
Mice were matched for body weight (P > 0.05) at baseline when separated into 
individual groups (Table 5.1). Overall, body weight increased in both dietary groups 
when assessed over the 3-month dietary period, main effect for time (P < 0.001), with 
a significant increase as of week 2 when compared to baseline (P < 0.001) (Fig. 
5.1A). Similarly, body weight increased when mice were compared at 1-, 2- and 3-
months of dietary intervention, main effect for time (P < 0.001) (Fig. 5.1B). Body 
weight was increased at the 3-month time point when compared to mice at 1- and 2-
months respectively (P < 0.001) (Fig. 5.1B). No differences in body weight were 
observed when comparing vitamin D replete and deplete mice (P > 0.05) (Fig. 5.1A-
B).  
 
 Dietary Group  
 VitD Replete VitD Deplete P 
Body Weight (g) 27.2 ± 1.3 27.2 ± 1.5 0.88 
    
Lean Mass (g) 24.0 ± 1.3 23.5 ± 1.3 0.31 
    
Lean Mass (% of BW) 88 ± 2 89 ± 2 0.10 
    
Fat Mass (g) 2.0 ± 0.6 1.8 ± 0.5 0.19 
      
Fat Mass (% of BW) 7 ± 2 7 ± 2 0.23 
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Figure 5.1. Body weight increases during 3-month dietary intervention irrespective of vitamin D 
status. A) Weekly assessment of body weight over 3-month dietary period. B) Body weight at 1-, 2- 
and 3-month dietary time point. Data mean ± SD (n=6-10/group). bMain effect for time; P < 0.05. 
dSignificantly different from baseline; P < 0.05.  
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5.3.2 Lean Mass 
Mice were matched for lean mass (P > 0.05) at baseline when separated into 
individual groups (Table 5.1). Absolute lean mass increased across the 3-month 
dietary period, main effect for time (P < 0.001), with a significant increase as of week 
4 (P = 0.004) (Fig. 5.2A). Despite this, due to the increased body weight, lean mass 
as a percentage of body weight decreased, main effect for time (P < 0.001), with a 
significant decrease as of week 4 (P < 0.001) (Fig. 5.2B). No differences were 
observed in absolute lean mass when compared at the 1-, 2- and 3-month time 
points (P > 0.05) (Fig. 5.2C). When expressed as a percentage of body weight, lean 
mass decreased, main effect for time (P < 0.001) and group x time interaction (P = 
0.035), when compared across the 1, 2 and 3-month time points (Fig. 5.2D). Further 
analysis revealed a significant decrease in lean mass as a percentage of body when 
the 3-month (71 ± 7%) vitamin D deplete mice was compared with the 1-month (85 ± 
3%), whereas vitamin D replete remained unchanged (P > 0.05) (Fig. 5.2D). At the 1-
month time point, lean mass as a percentage of body weight was increased in the 
vitamin D deplete group (85 ± 3%) when compared to vitamin D replete (79 ± 5%) (P 
= 0.039) (Fig. 5.2D).  
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Figure 5.2. Lean mass as a percentage of body weight decreases in vitamin D deplete mice 
with no differences in comparison to replete mice. A) Repeated measurement of absolute lean 
mass (grams) across 3-month dietary intervention. B) Repeated measurement of lean mass as a 
percentage of body weight across 3-month dietary period. C) Absolute lean mass (grams) following 1-, 
2- and 3-months of dietary intervention. D) Lean mass as a percentage of body weight following 1-, 2- 
and 3-months of dietary intervention. Data mean ± SD (n=6-8/group). bMain effect for time; P < 0.05, 
cgroup x time interaction effect; P < 0.05, dSignificantly different from baseline; P < 0.05, eSignificantly 
different from 1-month time point of same dietary group; P < 0.05, *P < 0.05.  
 
 
5.3.3 Fat Mass 
At baseline, mice were matched for fat mass when split into individual groups (P > 
0.05) (Table 5.1). Overall, absolute fat mass increased across the 3-month dietary 
period, main effect for time (P < 0.001), with a significant increase as of week 4 (P < 
0.001) (Fig. 5.3A). Similarly, when expressed as a percentage of body weight, fat 
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mass increased in both groups, main effect for time (P < 0.001), with a significant 
increase as of week 4 (P < 0.001) (Fig. 5.3B). When compared across the 1-, 2- and 
3-month time points, absolute fat mass increased, main effect for time (P < 0.001) 
(Fig. 5.3C). Similarly, as a percentage of body weight, fat mass increased across the 
1, 2 and 3-month time points, main effect for time (P < 0.001) (Fig. 5.3D). An 
increased in fat mass as a percentage of body was observed in the vitamin D replete 
(16 ± 5%) when compared with vitamin D deplete (10 ± 2%) at the 1-month time point 
(P = 0.044) (Fig. 5.3D).  
Figure 5.3. Fat mass increases across dietary period irrespective of vitamin D status. A) 
Repeated measurement of absolute fat mass (grams) across 3-month dietary period. B) Repeated 
measurement of fat mass as a percentage of body weight across 3-month dietary period. C) 
Assessment of absolute fat mass (grams) at 1-, 2- and 3-months of dietary intervention. D) Fat mass 
as a percentage of body weight at 1-, 2- and 3-months of dietary intervention. Data mean ± SD (n=6-
8/group). bMain effect for time; P < 0.05, cgroup x time interaction effect; P < 0.05, dSignificantly 
different to 1-month time point of same group; P < 0.05, *P < 0.05.  
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5.3.4 Skeletal Muscle Mass 
No changes were observed in gastrocnemius mass in response to either dietary 
intervention (P = 0.408) or time point (P = 0.103) (Table 5.2). Overall, the mass of the 
quadriceps increased over time (P = 0.004) however, this was not changed by dietary 
intervention (P = 0.951) (Table 5.2). Collectively, triceps mass was increased when 
vitamin D replete mice were compared with deplete (P = 0.041) although, post-hoc 
analysis revealed no difference between groups at individual time points (P > 0.05) 
(Table 5.2).  
 
 
 
Table 5.2. Increased tricep and no differences in quadriceps or gastrocnemius mass when 
vitamin D replete mice are compared with deplete mice. Data mean ± SD (n=6-8/group). 
Significant set at P < 0.05.  
 
5.3.5 Serum Calcium 
Serum calcium remained unchanged irrespective of dietary group or time point (P > 
0.05) (Fig. 5.4).  
 
 
 Dietary Period (Months)  
 1 2 3 P 
Gastrocnemius    VitD Time 
(mg)      
  Replete 143 ± 14 166 ± 25 161 ± 14   
  Deplete 152 ± 16 149 ± 12 156 ± 15 0.408 0.103 
      
Quadriceps      
(mg)      
  Replete 160 ± 14 189 ± 12 182 ± 20   
  Deplete 169 ± 18 178 ± 22 184 ± 19 0.951 0.004 
      
Tricep      
(mg)      
  Replete 111 ± 20 113 ± 14 109 ± 10   
  Deplete 106 ± 9 96 ± 19 101 ± 13 0.041 0.695 
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Figure 5.4. No change in serum calcium following manipulation of vitamin D status. Data mean 
± SD (n=6-10/group).  
 
5.3.6 Skeletal Muscle Mitochondrial Function 
No changes were observed in complex I related leak in response to either differing 
vitamin D diets (P > 0.05) or time points (P > 0.05) (Fig. 5.5A). Complex I respiration 
increased across the 1, 2 and 3-month time points, main effect for time (P = 0.048) 
and group x time interaction (P = 0.035) (Fig. 5.5B). Further analysis revealed a 
significant increase in 2-month (319.97 ± 75.81 pmol.sec-1.mg-1.dry weight) and 3-
month (338.08 ± 170.46 pmol.sec-1.mg-1.dry weight) vitamin D replete groups when 
compared to the 1-month (172.41 ± 51.60 pmol.sec-1.mg-1.dry weight), whereas the 
vitamin D deplete groups remained unchanged (P > 0.05) (Fig. 5.5B). Group x time 
interaction effects were observed for both complex I and II phosphorylating (P = 
0.035) and maximal respiration (P = 0.017) (Fig. 5.5C-D). Complex I and II 
phosphorylating respiration increased in 2 (416.17 ± 94.96 pmol.sec-1.mg-1.dry 
weight) and 3-month (451.37 ± 196.40 pmol.sec-1.mg-1.dry weight) vitamin D replete 
groups when compared with the 1-month (274.86 ± 47.57 pmol.sec-1.mg-1.dry weight) 
whilst vitamin D deplete remained unchanged (P > 0.05) (Fig. 5.5C). Similar 
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increases were apparent in maximal respiration when the 2 (502.22 ± 109.35 
pmol.sec-1.mg-1.dry weight) and 3-month (560.58 ± 205.09 pmol.sec-1.mg-1.dry 
weight) vitamin D replete groups where compared with the 1-month (323.19 ± 48.68 
pmol.sec-1.mg-1.dry weight) and again, vitamin D deplete remained unchanged (P > 
0.05) (Fig. 5.5D). At the 3-month time point, phosphorylating respiration supported 
via complex I and II was significantly decreased in the vitamin D deplete mice 
(291.76 ± 48.66 pmol.sec-1.mg-1.dry weight) when compared to vitamin D replete 
(451.37 ± 196.40 pmol.sec-1.mg-1.dry weight) (P = 0.035) (Fig. 5.5C). Similarly, 
respiration supported via the maximal capacity of the electron transport chain was 
reduced in the vitamin D deplete group (352.90 ± 46.56 pmol.sec-1.mg-1.dry weight) 
when compared with vitamin D replete (560.58 ± 205.09 pmol.sec-1.mg-1.dry weight) 
at the 3-month time point (P = 0.015) (Fig. 5.5D).  
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Figure 5.5. Skeletal muscle mitochondrial respiration is reduced following 3-months of diet-
induced vitamin D deficiency in mice. A) Complex I related leak at following 1-, 2- and 3-months of 
dietary intervention. B) Complex I phosphorylation respiration following 1-, 2- and 3-months of dietary 
intervention. C) Complex I and II phosphorylating respiration following 1-, 2- and 3-months of dietary 
intervention. D) Maximal capacity of the electron transport chain following 1-, 2- and 3-months of 
dietary intervention. Data mean ± SD (n=6-8/group). bMain effect for time; P < 0.05, cgroup x time 
interaction effect; P < 0.05, dSignificantly different from baseline; P < 0.05, eSignificantly different from 
1-month time point of same dietary group; P < 0.05, *P < 0.05.  
 
5.3.7 ADP Sensitivity 
No differences were observed in the apparent Km for ADP in response to either 
dietary intervention (P > 0.05) or time point (P > 0.05) (Fig. 5.6D).  
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Figure 5.6. No change in mitochondrial respiration across ADP titration following manipulation 
of vitamin D status in mice. A) ADP stimulated respiration following 1-month of dietary intervention. 
B) ADP stimulated respiration following 2-month of dietary intervention. C) ADP stimulated respiration 
following 3-month of dietary intervention. D) Apparent Km for ADP in vitamin D replete and deplete 
mice at 1-, 2- and 3-month of dietary intervention. Data mean ± SD (n=6-8/group).  
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5.3.8 Flux Control Ratios 
When normalised to maximal respiration, the flux control ratios revealed no 
differences in mitochondrial respiration supported via complex I alone (P > 0.05) or 
complex I and II (P > 0.05) (Fig. 5.7A-B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. Flux control ratios remain unchanged following diet-induced vitamin D deficiency in 
mice. A) Complex I related flux control ration following 1-, 2- and 3-months of dietary intervention. B) 
Complex I and II related flux control ratio following 1-, 2- and 3-months of dietary intervention. Data 
mean ± SD (n=6-8/group).  
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5.4 Discussion 
We sought to determine the effects of vitamin D deficiency upon skeletal muscle 
mitochondrial function in the C57BL/6J mouse line. Utilising the current gold standard 
method to assess mitochondrial function in permeabilised skeletal muscle fibres [29, 
30], we report that 3-months of diet-induced vitamin D deficiency reduces 
mitochondrial respiration supported via complex I and II and the maximal capacity of 
the electron transport chain (Fig. 5.5C-D). However, following internal normalisation, 
these reductions were no longer apparent, suggesting that changes in mitochondrial 
respiration following dietary intervention are a result of reduced mitochondrial 
quantity (Fig. 5.7A-B). In addition, 1-month of diet-induced vitamin D deficiency 
resulted in an increase in lean mass (Fig. 5.2D) and a decrease in fat mass (Fig. 
5.3D) as a percentage of body weight, although these effects were transient as they 
did not manifest over 2-month and 3-months of dietary intervention. Furthermore, 
diet-induced vitamin D deficiency resulted in a decrease in lean mass as a 
percentage of body weight across the 3-month time period (Fig. 5.3D). Despite this, 
no changes in body weight, lean mass or fat mass were apparent when comparing 
vitamin D replete to the deplete group following 3-months of dietary intervention.  
 
The ability of vitamin D related metabolites to increase skeletal muscle mitochondrial 
function across both immortalised and primary cell lines has been well established 
[24-27]. Despite this, there is little evidence for the effects of vitamin D status upon 
skeletal muscle mitochondrial function in vivo. To date, just one study has sought to 
determine the effects of vitamin D upon skeletal muscle mitochondrial function in 
vivo. Skeletal muscle mitochondrial function was assessed non-invasively (P-31 
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MRS) in a cohort of severely deficient patients following the supplementation of 
vitamin D [12]. Whilst a decrease in PCr recovery time was reported, indicative of 
increased oxidative phosphorylation, the study lacked a number of experimental 
controls including proper randomisation and blinding [12], making the interpretation of 
said results difficult. Therefore, in order to assess the effects of vitamin D status upon 
skeletal muscle mitochondrial function, we utilised a mouse model of diet-induced 
vitamin D deficiency. This mouse model has been previously utilised and allows for 
the manipulation of vitamin D status without a dysregulation in mineral homeostasis 
[18]. Following 3-months of diet-induced vitamin D deficiency, we report that 
respiration supported via complex I and II and the maximal capacity of the electron 
transport chain are reduced when compared to respective controls at the same time 
point. In addition, vitamin D replete mice exhibited increases in multiple parameters 
of mitochondrial respiration (CIL, CI+IIP and ETC) across the 3-month dietary 
intervention period, whilst respiration in vitamin D deplete mice remained stable.  
Previously, both mitochondrial number and the activity of components of the electron 
transport chain have been reported to increase from 3 to 12 months of age within 
mouse skeletal muscle [31, 32]. Therefore, diet-induced vitamin D deficiency may 
well impair the age-related increases in skeletal muscle mitochondrial content. In 
support of this, we examined mitochondrial respiration as a flux control ratio, which 
offers a method of internal normalisation and the assessment of whether changes in 
respiration are as a result of mitochondrial quality or quantity [33-35]. Interestingly, 
the previously observed increases in mitochondrial respiration are abolished 
following internal normalisation, suggesting alterations in mitochondrial respiration 
following diet-induced vitamin D deficiency are a product of reduced mitochondrial 
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quantity. In contrast, no changes in mitochondrial protein content, mtDNA/nDNA ratio 
or citrate synthase activity have been reported following 12-months of diet-induced 
vitamin D deficiency in C57BL/6J mice [22]. It should be noted that diet-induced 
vitamin D deficiency was commenced from 6-months of age, whereas we examined 
a dietary period between 3- and 6-months of age. Therefore, it is possible that the 
effects of vitamin D deficiency upon skeletal muscle mitochondrial content and 
function are more potent during development. In addition, it could also be reasoned 
that our results may have been more prominent had vitamin D deficiency been 
induced in an older animal model given that in human populations vitamin D is most 
potent in such cohorts [14]. Unfortunately, time constraints limited the exploration of 
vitamin D deficiency in a setting of older age and sarcopenia. The further assessment 
of mitochondrial function across a longer period of diet-induced vitamin D deficiency 
would potentially address previous discrepancies. We also assessed the sensitivity of 
oxidative metabolism to ADP (apparent Km) via the titration of ADP from biological to 
saturating concentrations [36]. Whilst absolute respiration was slightly increased, 
albeit non-significantly in the 3-month vitamin D replete mice, we observed no 
differences in the apparent Km for ADP at any time point suggesting ADP sensitivity 
is unaffected by diet-induced vitamin D deficiency.  
 
In addition, we sought to determine the effects of diet-induced vitamin D deficiency 
upon body composition within C57BL/6J mice. Following 3-months of diet-induced 
vitamin D deficiency we observed no differences between the vitamin D replete and 
deplete groups in body weight, lean mass or fat mass. We did however observe a 
reduction lean mass as a percentage of body weight from 1- to 3-months in vitamin D 
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deplete mice whereas replete mice remained the unchanged over the same time 
period. This may in part be driven by the fact we also observed an increase in lean 
mass as a percentage of body weight following 1-month of diet-induced deficiency. 
Previously, no differences in body weight and lean mass were observed following 12-
months of diet-induced deficiency in male C57BL/6J mice [22]. On the other hand, 
12-months of diet-induced vitamin D deficiency in female C57BL/6J mice results in 
reductions in body weight, lean mass and fat mass [37]. Given those with serum 
concentrations of 25(OH)D <25 nmol.L-1 are at a greater risk of developing 
sarcopenia [38], vitamin D status is an important consideration for the preservation of 
muscle mass. Furthermore, whilst we and others observe minimal differences in lean 
mass following diet-induced vitamin D deficiency in male mice [22, 39], decrements 
have been observed in females [37]. Observations from human populations indicate 
that the effects of vitamin D deficiency on physical performance may be more potent 
in women although, this was likely mediated by increased physical activity in males 
[40]. Further characterisation of the sex-specific differences in skeletal muscle 
function and physical performance in the context of vitamin D deficiency may well be 
warranted.  
 
In conclusion, we report that mitochondrial function (CI+IIP and ETC) is reduced in 
C57BL/6J mice following 3-months of diet-induced vitamin D deficiency. These 
effects are no longer apparent when data is internally normalised suggesting 
changes are a consequence of mitochondrial quantity as opposed to quality. Similar 
to others, we observed minimal difference in body composition following 3-months of 
diet-induced vitamin D deficiency in male C57BL/6J mice [22, 39]. Our data highlight 
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a possible impairment in the development of skeletal muscle mitochondrial function in 
young C57BL/6J mice. Further analysis of mitochondrial morphology across this time 
period may offer more insight into how this impairment manifests.  
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CHAPTER 6 
 
THE EFFECT OF DIET-INDUCED VITAMIN D DEFICIENCY ON BODY 
COMPOSITION AND SKELETAL MUSCLE MITOCHODNRIAL FUNCTION 
FOLLOWING 20-DAYS OF VOLUNTARY WHEEL RUNNING IN C57BL/6J MICE 
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6.1 Introduction 
Vitamin D deficiency can be characterised by serum 25(OH)D concentrations of <50 
nmol.L-1. Currently, it has been estimated that ~40% of individuals within Europe and 
the USA can be classified as deficient [1, 2]. Further to this, ~13% may be classified 
as severely deficient with serum 25(OH)D concentrations of <12 nmol.L-1 [2]. Whilst 
severe deficiencies are known to dysregulate mineral homeostasis and impair bone 
health [3-5], severe deficiencies are also associated with skeletal muscle weakness, 
increased muscle pain and fatigue [6-8].  
 
In order to study the effects of vitamin D deficiency upon skeletal muscle function a 
number of models are available. The induction of vitamin D deficiency has previously 
been achieved within animal models by dietary means [9-12], a reduction in sunlight 
exposure [9] or by the administration of ethane 1-hydroxy-1, 1-diphosphonate [12]. 
Vitamin D deficiency achieved via dietary means is the most common and in such 
scenarios, vitamin D is completely removed from the diet [9-12]. Alongside the 
reduction in vitamin D, the dietary content of calcium and phosphorous is increased. 
The increased mineral content prevents the previously observed hypocalcemia and 
hypophosphatemia that are associated with the induction of vitamin D deficiency [11]. 
Further characterisations of vitamin D deficiency have been performed, with multiple 
human studies having sought to assess skeletal muscle function within individuals 
deemed deficient [13-15]. Within animal models, the induction of deficiency results in 
a reduction in skeletal muscle force, strength and endurance [9-11, 16, 17]. In 
addition, observational studies in humans have reported positive associations 
between serum 25(OH)D levels and skeletal muscle strength  [13-15]. Whilst the 
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majority of studies focus on skeletal muscle mass and strength in association with 
vitamin D status, vitamin D status has also been linked to the regulation of 
mitochondrial function [18-21]. For example, severely deficient individuals 
supplemented with vitamin D for a period of 12-weeks showed improvements in 
markers of oxidative phosphorylation and reduced symptoms of fatigue [20].  
 
Increases in mitochondrial function are a common adaptation to endurance exercise 
training (Section 1.3.2) [22, 23]. Increases in protein content and activity of enzymes 
involved in the mitochondrial electron transport chain are observed in rodent skeletal 
muscle following endurance based training [24, 25]. Alongside increases in protein 
content, mass specific respiration is also known to be increased in response to 
training, allowing for a greater production of ATP [26-28]. Despite the above 
evidence, limited studies have assessed skeletal muscle mitochondrial adaptations to 
training alongside the manipulation of vitamin D status. Given vitamin D deficiency is 
widespread and even common amongst athletic populations [29, 30], it may well be 
an important consideration for maximising the adaptive response to training. 
Therefore, the aim of this chapter was to determine the effects of diet-induced 
vitamin D deficiency upon skeletal muscle adaptation to 20-days of voluntary wheel 
running in C57BL/6J mice.  
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6.2 Methods 
6.2.1 Ethical Approval  
Ethical approval for mouse studies was granted by the Garvan Institute and St. 
Vincent’s Hospital Animal Experimentation Ethics Committee (approval number 
18/19). Ethical approval fulfils all the requirements of the NHMRC and the NSW State 
Government, Australia. All animal handling was carried out by trained personnel and 
all procedures were carried out according to the Australian code of practice for the 
care and use of animals for scientific purposes 8th edition [31]. C57BL/6J mice were 
received at 10-weeks of age and housed communally in a temperature controlled 
environment (22 ± 0.5°C) with a 12 h light-dark cycle. 
 
6.2.2 Composition of Diet 
Following 1-week of acclimation in which mice were fed standard chow (Table 2.2), 
mice were placed on either a vitamin D replete or a vitamin D deplete diet [11]. The 
vitamin D deplete diet contained no vitamin D but increased calcium (2%), 
magnesium (0.2%), and phosphorous (1.2%) in order to maintain normal mineral 
homeostasis (SF085-003, Speciality Feeds, Glen Forest, NSW). The vitamin D 
control diet contained vitamin D (cholecalciferol 2.2 IU/g), calcium (1%), magnesium 
(0.2%), and phosphorous (0.7%) (SF085-034, Speciality Feeds, Glen Forest, NSW). 
Mice were maintained on the respective diets for a period of either 1- or 3-months.  
 
6.2.3 Voluntary Wheel Running 
Following a 1- (n=10/group) or 3-month (n=10/group) dietary intervention period, 
mice were housed individually and given access to a running wheel for 20-days. Mice 
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continued to consume their respective vitamin D replete, deplete or standard chow 
diets during the 20-day voluntary wheel running period. Wheel revolutions were 
recorded every hour via a digital recorder (Columbus Instruments, Columbus, OH, 
US) and the distance ran per day was calculated and reported in kilometres per 
twenty-four hours. Diet only controls were maintained across the same dietary period 
but without access to a running wheel. Previous observations within our lab indicate 
that 20 days of voluntary wheel running is a suitable timeframe to induce training 
adaptations in mitochondrial protein content and respiration.  
 
6.2.4 Assessment of Body Composition 
Body composition was assessed upon arrival (10-weeks of age) and then following 1-
, 2- and 3-months of dietary intervention as well as post 20-days voluntary wheel 
running using the EchoMRi (EchoMRI LLC, Houston, USA). Body weight was 
measured on a weekly basis throughout the dietary and voluntary wheel running 
period.  
 
6.2.5 Tissue Collection 
Tissue collections were completed following 1- and 3-months of dietary intervention 
alone and following 1- and 3-months of dietary intervention plus 20-days of voluntary 
wheel running. Following anesthetization under isoflurane tissues were excised from 
fasted (2 h) mice. Tissues collected include; gastrocnemius, quadriceps, triceps, 
liver, kidney, white adipose tissue and the tibia.  Following collection, a blood sample 
was taken via cardiac puncture and mice terminated via cervical dislocation. All 
tissues were rinsed in sterile saline, blotted dry, weighed, and frozen in liquid 
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nitrogen. A small portion (~20 mg) of the gastrocnemius was removed before 
freezing and used for high-resolution respirometry. All tissues were stored at -80°C 
for subsequent analysis.  
 
6.2.6 Tissue Processing 
Small portions of gastrocnemius muscle (~20 mg) were removed and placed in ice-
cold BIOPS buffer (2.77 mM CaK2EGTA, 7.23 mM K2EGTA, 5.77 mM Na2ATP, 6.56 
mM MgCl2-6H2O, 20 mM Taurine, 15 mM Na2Phosphocreatine, 20 mM Imidazole, 
0.5 mM Dithiothreitol, 50 mM MES Hydrate, pH 7.1, 290 mOsm). Blood samples 
were allowed to coagulate at room temperature for 10 minutes before being placed 
on ice. Samples were then centrifuged at 14,000 g for 10 minutes. The resulting 
supernatant was removed and utilised for further analysis.  
 
6.2.7 Analysis of Serum Calcium 
Serum calcium was measured using a Calcium Detection Assay kit (Abcam). Serum 
samples were diluted 1:10 and manufacturers instructions were followed. The assay 
plate was read at 575 nM using a CLARIOstar microplate reader (BMG Labtech, 
Victoria, Australia). Calcium concentrations are reported in mM.  
 
6.2.8 High-Resolution Respirometry 
High-resolution respirometry was conducted in MiR05 (2 ml) with the addition of 
blebbistatin (25 µM) using the OROBORS Oxygraph-2K (Oroboros Instruments, 
Corp., Innsbruck, AT) with stirring at 750 rpm at 37°C. Oxygen within the chamber 
was maintained between 150-220 µM for each experiment. Prior to the addition of the 
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fibre bundles to the chamber, bundles were blotted dry and weighed. Bundles 
totalling 2.5-5.0 mg were added to the chamber. Firstly, pyruvate (10 mM) and 
malate (2 mM) were added as complex I substrates. Subsequently, ADP was titrated 
in step-wise increments (100-6000 µM) followed by the addition of glutamate (10 
mM) and succinate (10 mM) as complex I and II substrates. Cyt c (10 µM) was added 
in order to check outer mitochondrial membrane integrity. The partial loss of cyt c 
during fibre preparation may limit respiration. Multiple fibre preparations from 3-
month mice exhibited increases in respiration (>10%) following the addition of cyt c 
and were therefore removed. CCCP was titrated in a step-wise manner (0.5 to 2.5 
µM) until the maximal capacity of the electron transport chain was reached. Finally, 
antimycin A (2.5 µM) was injected in order to inhibit mitochondrial respiration.  
 
The Km for ADP was determined through the Michaelis-Menten enzyme kinetics – 
fitting model (Y = Vmax*X/(Km + X)), where X = (free ADP; ADPf), using Prism 
(GraphPad Software, Inc., La Jolla, CA). FCRs were calculated by setting CCCP 
stimulated respiration as 1 and antimycin A respiration as 0.  
 
6.2.9 Statistical Analysis 
Statistical analysis was performed using Prism version 7 (GraphPad Software 
Incorporated, La Jolla, CA, USA). Differences in voluntary wheel running 
performance and body composition between 1 and 3-month vitamin D replete and 
deplete mice were determined by two-way ANOVA with Bonferroni correction for 
multiple comparisons. Differences between 1-month standard chow, vitamin D 
replete and deplete mice were determined by one-way ANOVA. Differences in 
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mitochondrial function between 1-month dietary intervention mice and 1-month 
dietary intervention plus 20-days of voluntary wheel running were determined via 
two-way ANOVA with Bonferroni correction for multiple comparisons. All values are 
presented as mean ± SD. Statistical significance was set a P < 0.05.  
 
6.3 Results 
6.3.1 Voluntary Wheel Running 
Overall, the average running distance was greater in the vitamin D replete mice when 
compared to vitamin D deplete (P = 0.041) (Fig. 6.1A). Similarly, the total distance 
covered during the 20-day voluntary wheel running period was greater in the vitamin 
D replete mice when compared with vitamin D deplete (P = 0.041) (Fig. 6.1B). No 
differences were observed when comparing individual groups (P > 0.05) (Fig. 6.1A-
D). We also compared the 1-month vitamin D replete and deplete mice to mice fed a 
standard chow diet across the same dietary and voluntary wheel running period (Fig. 
6.2A-B). We observed no differences between the individual groups in either daily or 
total running distance (P > 0.05) (Fig. 6.2A-C). 
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Figure 6.1. Increased running distance and volume in vitamin D replete mice when compared to 
vitamin D deplete. A) Daily average running distance in kilometres (km) during 20-days of voluntary 
wheel running (VWR) following 1- or 3-months of dietary intervention. B) Total distance run in 
kilometres (km) following 20-days of voluntary wheel running following 1- or 3-months of dietary 
intervention. C) Daily distance run (km) across 20-days of VWR following 1-month dietary intervention. 
D) Daily distance run (km) across 20-days of VWR following 3-months of dietary intervention. Data 
mean ± SD (n=5-8/group). AMain effect for vitamin D diet; P > 0.05.  
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Figure 6.2. No difference in running distance or volume when vitamin D diet mice are compared 
to standard chow diet mice. A) Average of daily running distance in kilometres (km) following 20-
days of voluntary wheel running in mice fed a standard chow, vitamin D replete and vitamin D deplete 
diets. B) Total running distance in kilometres (km) following 20-days of voluntary wheel running in 
mice fed a standard chow, vitamin D replete and vitamin D deplete diet. C) Daily running distance in 
kilometres in standard chow diet mice. Data mean ± SD (n = 3-8/group).  
 
 
 
6.3.2 Body Weight 
No differences were observed in body weight at baseline between each group (P > 
0.05) (Table 6.1). Mice were given voluntary access to a wheel for a period of 20-
days following either 1- or 3-months of dietary intervention. Following 20-days of 
voluntary wheel running, no differences in final body weight were observed when 
comparing vitamin D replete to deplete mice following 1- or 3-months of dietary 
intervention (P > 0.05) (Fig. 6.3A). Similarly, no changes were observed in the 
percentage change in body weight from pre to post voluntary wheel running (P > 
0.05) (Fig. 6.3B). A slight trend however was observed in the percentage change in 
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body weight when vitamin D replete mice were compared with vitamin D deplete (P = 
0.066) (Fig. 6.3B).   
 
Table 6.1. No differences in baseline body composition in mice prior to dietary and exercise 
intervention. Data mean ± SD (n = 5-8/group).  
 
 Dietary Period (Months)   
 1 3 P 
Body Weight   VitD Time 
(g)     
  Replete 27.7 ± 1.4 27.4 ± 0.4   
  Deplete 27.8 ± 0.7 28.2 ± 0.7 0.374 0.883 
     
Lean Mass     
(g)     
  Replete 24.2 ± 1.4 24.4 ± 0.8   
  Deplete 24.7 ± 1.7  25.3 ± 0.9 0.149 0.397 
     
Lean Mass     
(% of BW)     
  Replete 87.4 ± 1.8 88.8 ± 2.3   
  Deplete 88.8 ± 1.3 89.4 ± 2.0 0.168 0.148 
     
Fat Mass     
(g)     
  Replete 1.9 ± 0.5 1.7 ± 0.7   
  Deplete 1.8 ± 0.5 1.8 ± 0.4 0.917 0.409 
     
Fat Mass     
(% of BW)     
  Replete 7.1 ± 1.9 6.2 ± 2.8   
  Deplete 6.5 ± 1.6 6.3 ± 1.7 0.698 0.430 
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Figure 6.3. No differences in the final or percentage change in body weight following 20-days 
of voluntary wheel running in vitamin D replete and deplete mice. A) Final body weight following 
1- or 3-months dietary intervention and 20-days of voluntary wheel running (VWR). B) Change in body 
weight as a percentage across 20-days voluntary wheel running period. Data mean ± SD (n=5-
8/group). AMain effect of vitamin D diet; P < 0.05.  
 
6.3.3 Lean Mass 
No differences in baseline lean mass were observed at baseline in each of the 
groups (P > 0.05) (Table 6.1). Following 20-days of voluntary wheel running, 
absolute lean mass was similar between all groups (P > 0.05) (Fig. 6.4A). Similarly, 
absolute lean mass remained unchanged following 20-days of voluntary wheel 
running in all groups (P > 0.05) (Fig. 6.4B). In addition, no differences were observed 
in lean mass as a percentage of body weight (P > 0.05) (Fig. 6.4C). However, the 
change in lean mass as a percentage of body weight pre to post voluntary wheel 
running was greater in the vitamin D replete mice when compared to vitamin D 
deplete (P = 0.013) (Fig. 6.4D). No differences were observed when comparing the 
change in lean mass as a percentage of body weight when comparing individual 
groups (P > 0.05) (Fig. 6.4D).  
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Figure 6.4. Reduction in lean mass as a percentage of body weight across 20-days of voluntary 
wheel running in vitamin D deplete mice. A) Final lean mass following 1- or 3-months of dietary 
intervention and 20-days of voluntary wheel running. B) Percentage change in lean mass across 20-
days of voluntary wheel running period. C) Final lean mass as a percentage of body weight following 1 
or 3-months of dietary intervention and 20-days of voluntary wheel running. D) Percentage change in 
lean mass as a percentage of body weight across 20-days of voluntary wheel running. Data mean ± 
SD (n=5-8/group). AMain effect of vitamin D diet; P < 0.05.   
 
6.3.4 Fat Mass 
No differences were observed in fat mass baseline between individual groups (P > 
0.05). Following 20-days of voluntary wheel running, there were no differences in 
absolute fat mass (P > 0.05) (Fig. 6.5A). However, the change in absolute fat was 
greater in the vitamin D deplete mice when compared to vitamin D replete (P = 
0.003) (Fig. 6.5B). Furthermore, the 3-month vitamin D deplete mice gained fat mass 
(6 ± 30%) following 20-days of voluntary wheel running whilst the vitamin D replete 
mice was reduced (-43 ± 50%) (P = 0.032) (Fig. 6.5B). No differences between 
groups were observed in fat mass as a percentage of body weight (P > 0.05) (Fig. 
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6.5C). However, the change in fat mass as a percentage of body weight pre to post 
voluntary wheel running was greater in the vitamin D deplete mice when compared to 
vitamin D replete (P = 0.002) (Fig. 6.5D). Furthermore, the 3-month vitamin D replete 
mice reduced fat mass (-38 ± 41%) as a percentage of body weight pre to post 
voluntary wheel running whilst the vitamin D deplete mice remained unchanged (5 ± 
27%) (P = 0.030) (Fig. 6.5D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. Increase in absolute fat mass and as a percentage of body weight in vitamin D 
deplete mice when compared to vitamin D replete following 3-months of dietary intervention 
and 20-days of voluntary wheel running. A) Final fat mass following 1- or 3-months of dietary 
intervention and 20-days of voluntary wheel running. B) Percentage change in fat mass across 20-day 
voluntary wheel running period. C) Final fat mass as a percentage of body weight following 1 or 3 
months of dietary intervention and 20-days of voluntary wheel running. D) Percentage change in fat 
mass as a percentage of body weight across 20-days of voluntary wheel running. Data mean ± SD 
(n=5-8/group). AMain effect of vitamin D diet; P < 0.05.   
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6.3.5 Skeletal Muscle Mass 
An increase in gastrocnemius (P = 0.006) and triceps (P = 0.003) mass was 
observed with the 3-month mice displaying greater tissue weights than those of the 
1-month. In contrast, no differences were observed in quadriceps mass (P = 0.069). 
No differences were observed between vitamin D replete and deplete mice in 
gastrocnemius, quadriceps and triceps weights (P > 0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.2. Increase in gastrocnemius and triceps mass in 3-month mice when compared to 1-
month with no effect of diet-induced vitamin D deficiency. Data mean ± SD (n=5-8/group).  
 
6.3.6 Serum Calcium 
Serum calcium measurements were similar between vitamin D replete and deplete 
mice when measured following 1-month of dietary intervention and 20-days of 
voluntary wheel running (P > 0.05) (Fig. 6.6A).  
 
 
 
 
 Dietary Period (Months)   
 1 3 P 
Gastrocnemius   VitD Time 
(mg)     
  Replete 150 ± 9 159 ± 13   
  Deplete 149 ± 12 166 ± 17 0.597 0.014 
     
Quadriceps     
(mg)     
  Replete 184 ± 20 162 ± 18   
  Deplete 165 + 34 159 ± 13 0.217 0.128 
     
Triceps     
(mg)     
  Replete 103 ± 11 116 ± 13   
  Deplete 99 ± 17 118 ± 11 0.782 0.004 
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Figure 6.6. No change in serum calcium following diet-induced vitamin D deficiency and 20-
days of voluntary wheel running. Data mean ± SD (n = 8-10/group).  
 
6.3.7 Skeletal Muscle Mitochondrial Function 
In response to both dietary intervention and 20-days of voluntary wheel running, 
complex I related leak remained unchanged (P > 0.05) (Fig. 6.7A). Overall, complex I 
phosphorylating respiration increased in response to voluntary wheel running (P = 
0.005) and a main interaction effect was observed (P = 0.027) (Fig. 6.7B). A 
significant training response in complex I phosphorylating respiration was observed 
in vitamin D replete mice when comparing the diet only group (172.42 ± 51.60 
pmol.sec-1.mg-1.dry weight) to diet and voluntary wheel running (333.32 ± 86.15 
pmol.sec-1.mg-1.dry weight) (P = 0.004) (Fig. 6.7B). Similarly, complex I and II 
phosphorylating respiration increased in response to voluntary wheel running (P = 
0.007) and an interaction effect was observed (P = 0.039) (Fig. 6.7C). In response to 
voluntary wheel running, vitamin D replete mice displayed a significant training 
response in complex I and II phosphorylating respiration when comparing the diet 
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only group (274.86 ± 47.57 pmol.sec-1.mg-1.dry weight) to diet and voluntary wheel 
running (427.33 ± 89.48 pmol.sec-1.mg-1.dry weight) (P = 0.008) (Fig. 6.7C).  Overall, 
the maximal capacity of the electron transport chain increased in response to 
voluntary wheel running (P = 0.003) and a main interaction effect was observed (P = 
0.039) (Fig. 6.7D). In response to voluntary wheel running, vitamin D replete mice 
increased the maximal capacity of the electron transport chain when comparing the 
diet only group (323.19 ± 48.68 pmol.sec-1.mg-1.dry weight) to diet and voluntary 
wheel running (517.01 ± 91.28 pmol.sec-1.mg-1.dry weight) (P = 0.005) (Fig. 6.7D).  
Figure 6.7. Increases in mitochondrial function following 20-days of voluntary wheel running in 
vitamin D replete mice. A) Complex I related leak (CIL) in response to diet-induced vitamin D 
deficiency and 20-days of voluntary wheel running. B) Complex I phosphorylating respiration (CIP) in 
response to diet-induced vitamin D deficiency and 20-days of voluntary wheel running. C) Complex I 
and II phosphorylating respiration (CI+IIP) in response to diet-induced vitamin D deficiency and 20-
days of voluntary wheel running. D) Maximal capacity of the electron transport chain (ETC) in 
response to diet-induced vitamin D deficiency and 20-days of voluntary wheel running. Data mean ± 
SD (n=5-8/group). bMain effect for VWR; P < 0.05. cMain interaction effect; P < 0.05. *P < 0.05.  
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6.3.8 ADP Sensitivity 
The titration of ADP across multiple concentrations (100-6000 µM) revealed no 
differences between vitamin D replete and deplete mice in ADP stimulated 
respiration following 20-days of voluntary wheel running (P > 0.05) (Fig. 6.8A). 
Overall, ADP sensitivity as measured by the apparent Km for ADP, increased in 
response to voluntary wheel running (P = 0.004) (Fig. 6.8B). In response to 20-days 
of voluntary wheel running, ADP sensitivity decreased in vitamin D replete mice when 
comparing the diet only group (209.4 ± 37.2 µM) to diet and voluntary wheel running 
group (460.1 ± 71.9 µM) (P = 0.011) (Fig. 6.8B).     
 
 
Figure 6.8. Increased ADP sensitivity in response to 20-days of voluntary wheel running in 
vitamin D replete mice. A) ADP stimulated respiration following 20-days of voluntary wheel running in 
vitamin D replete and deplete mice. B) The apparent Km for ADP following 1-month of dietary 
intervention and 20-days of voluntary wheel running in vitamin D replete and deplete mice. Data mean 
± SD (n=5-8/group).  
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6.3.9 Flux Control Ratios 
When normalised to maximal respiration, there were no differences in respiration 
support via complex I (P < 0.05) or complex I and II (P > 0.05) combined in response 
to 20-days of voluntary wheel running (Fig. 6.9A-B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9. No differences in flux control ratios following 20-days of voluntary wheel running. 
A) Complex I related flux control ratio following 1-month dietary intervention and 20-days of voluntary 
wheel running. B) Complex I and II related flux control ratio following 1-month dietary intervention and 
20-days of voluntary wheel running. Data mean ± SD (n=5-8/group).  
 
 
1 Month 1 Month + VWR
0.0
0.2
0.4
0.6
0.8
1.0
Dietary Period
Fl
ux
 C
on
tr
ol
 R
at
io
(C
I p
)
1 Month 1 Month + VWR
0.7
0.8
0.9
1.0
Dietary Period
Fl
ux
 C
on
tr
ol
 R
at
io
(C
I+
II p
)
A.
B.
	 196 
6.4 Discussion 
We sought to determine the effects of diet-induced vitamin D deficiency upon the 
adaptive responses to 20-days of voluntary wheel running in C57BL/6J mice. Overall, 
diet-induced vitamin D deficiency resulted in a reduced daily and total volume in 
running performance in comparison to vitamin D replete mice (Fig. 6.1A-B). Whilst no 
changes in body weight were observed (Fig. 6.3A-B), diet-induced vitamin D 
deficiency resulted in a diminished accretion of lean mass (Fig. 6.4D) and loss of fat 
mass (Fig. 6.5C) as a percentage of body weight across the 20-days of voluntary 
wheel running. Alongside alterations in body composition, vitamin D replete mice 
displayed an increase in multiple parameters of mitochondrial function (CIP, CI+IIP, 
ETC and ADP sensitivity) following 20-days of voluntary wheel running (Fig. 6.7A-D; 
Fig. 6.8B).  
 
Previously, diet-induced vitamin D deficiency has been shown to reduce physical 
performance within the C57BL/6J mouse line [11, 17]. Reductions in grip strength, 
grip endurance, sprint speed and stride length have been observed across a range of 
dietary intervention periods (3-12 months) [11, 17]. Furthermore, mice with a 
myocyte-specific deletion of the VDR display a reduction in voluntary wheel running 
capacity when assessed over a 24 h period [32]. Despite this, no previous study has 
examined the effects of diet-induced vitamin D deficiency upon voluntary wheel 
running capacity in C57BL/6J mice. Voluntary wheel running offers an interesting 
model to study physical capacity and exercise adaptation within mice. In comparison 
to forced treadmill exercise, voluntary wheel running offers a more natural pattern of 
running behaviour in mice, the exercise intervention is performed under non-stressed 
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conditions and it can easily be applied in longer term intervention studies [33]. 
Although a large degree of variation exists, which is to be expected with voluntary 
wheel running, vitamin D replete (1-month; 3.7 ± 2.0 km, 3-month; 4.0 ± 2.8 km) mice 
did run on average more than that of their vitamin D deplete (1-month; 2.2 ± 0.8 km, 
3-month; 2.7 ± 1.1 km) counterparts. Similar to previous observations [11, 17], this 
supports the notion that vitamin D deficiency reduces physical performance in mice. 
Whilst strain to strain variations exist, mice have been to known to run between ~4 to 
20 km per day [33-35]. Given this, our mice were on the lower end of this spectrum. 
In addition to these low running distances a large number of mice (11/40) were 
removed from the above analysis due to running distances of <1 km per day. The 
removal of mice was not limited to a certain cohort of vitamin D replete or deplete 
mice suggesting low running distances were not as a result of vitamin D deficiency. 
In order to further explore this issue, we also gave mice fed a standard chow diet 
over the same period as the 1-month dietary intervention mice access to a running 
wheel. We observed similar running distances (4.5 ± 1.8 km) in standard chow mice 
as well as a large proportion running <1 km per day (3/6). Therefore, the lower 
running distances we observed previously were not as a result of the vitamin D 
replete and deplete diets. A number of factors may be contributing to these lower 
running distances including; genetic influences, sex differences and running wheel 
design [35-38]. All of which will be discussed in more detail below (Chapter 7).  
 
Despite the low running distances, vitamin D replete mice displayed some favourable 
adaptations in body composition, particularly within the 3-month mice. Whilst we and 
others have shown no differences in body weight or skeletal muscle tissue weight 
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following voluntary wheel running in C57BL/6J mice [39], we also report no difference 
in absolute fat and lean mass following diet-induced vitamin D deficiency and 20-
days of voluntary wheel running. However, as a percentage of body weight, vitamin D 
replete mice displayed positive responses in the accretion of lean mass and the loss 
of fat mass following 20-days of voluntary wheel running. Whilst others have also 
reported favourable adaptations in body composition to voluntary wheel running 
including reductions in fat mass [40], we now highlight that these changes are 
dependent upon vitamin D status. It is important to note that given the reduced 
running distances in the vitamin D deplete mice, the favourable adaptations in 
vitamin D replete mice may be a consequence of an increased training volume. It 
would be interesting to see if these effects are more pronounced in a voluntary wheel 
running model that encourages increased running distances than that observed 
within this study.  
 
Adaptations to the mitochondria are a prominent feature in the response of skeletal 
muscle to endurance training [22, 24, 25]. In addition, voluntary wheel running in 
mice is known to result in an increase in citrate synthase activity, mitochondrial 
protein content and markers of mitochondrial biogenesis (PGC-1a and TFAM) [40, 
41]. Whilst diet-induced vitamin D deficiency has been shown to impair physical 
performance in mice [11, 17], its effects upon the adaptive response to a period of 
endurance exercise have not been studied. Given this, we sought to assess 
mitochondrial function with permeabilised skeletal muscle fibres following 20-days of 
voluntary wheel running in vitamin D replete and deplete mice. In response to 
endurance exercise, both mitochondrial mass and oxygen consumption are known to 
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increase in rodent skeletal muscle [22, 40-42]. Similarly, we report an increase in 
multiple parameters of mitochondrial function (CIP, CI+IIP and ETC) following 20-days 
of voluntary wheel running in C57BL/6J mice. However, these increases were only 
apparent in vitamin D replete mice indicating an impaired training adaptation 
following 1-month of diet-induced vitamin D deficiency. Similarly, the apparent Km for 
ADP increased in vitamin D replete mice only following 20-days of voluntary wheel 
running, indicating a reduced sensitivity to ADP. Whilst this seems counter intuitive, a 
decrease in the sensitivity to ADP within skeletal muscle is a prominent feature of the 
adaptive response to endurance exercise [43-46]. Whilst absolute rates of respiration 
are increased, no differences were observed when respiration was reported as a 
ratio of maximal respiration (FCR). This likely indicates that alterations in respiration 
are mediated by changes in mitochondrial quantity as opposed to quality although, 
this would need confirming via the assessment of mitochondrial mass via TEM, CS 
activity or mitochondrial protein content [47]. In addition, we completed the same 
analysis following 3-months of diet-induced vitamin D deficiency however, technical 
issues with the analysis resulted in an unusable dataset. Alongside considerable 
increases (>10%) in respiration in response to the addition of cyt c, overall respiration 
values were much lower than normally observed throughout this thesis and in 
previous reports [48].  
 
In conclusion, we report that diet-induced vitamin D deficiency results in a reduced 
capacity for voluntary wheel running in C57BL/6J mice. Vitamin D replete mice 
displayed favourable responses in body composition pre to post voluntary wheel 
running, highlighted by an accretion of lean mass and decrease in fat mass as a 
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percentage of body weight. Although mitochondrial function increased in the vitamin 
D replete mice, there was no difference in mitochondrial function when comparing 
vitamin D replete mice to vitamin D deplete at the same time point. Mitochondrial 
respiration data from the 3-month cohort of mice may have revealed more prominent 
differences following diet-induced vitamin D deficiency. Given that vitamin D 
deficiency remains widespread [1, 2] in the general population and even within 
athletic populations [29], vitamin D status may be an important consideration for 
those looking to maximise the adaptive benefits of exercise. Further characterisation 
of the adaptive process in models of vitamin D deficiency over longer timeframes 
would provide further evidence towards to determining the role of vitamin D in 
exercise adaptation.  
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CHAPTER 7 
 
GENERAL DISCUSSION 
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7.1 Introduction 
Skeletal muscle is a highly adaptive (i.e. plasticity) tissue, capable of undergoing 
distinct periods of hypertrophy and atrophy in response to both positive and negative 
stimuli [1, 2]. Contributing to this plasticity, a dynamic network of mitochondria exists 
within skeletal muscle [3]. In response to physiological stressors such as contractile 
activity, this network undergoes events of biogenesis, fusion, fission and mitophagy 
[4-9]. Primarily functioning to produce ATP via oxidative phosphorylation [10], the 
maintenance of mitochondrial health is therefore crucial to meet the energy demands 
of skeletal muscle and other tissues throughout the body [11]. Indeed, mitochondrial 
dysfunction has been linked to numerous disease states including, the age related 
loss of muscle mass termed sarcopenia [12]. Whilst physical inactivity is a major risk 
factor for age related diseases, poor nutritional status and dietary deficiencies have 
also been linked to impaired physical function [13-16]. A common nutritional 
deficiency is that of vitamin D [17, 18]. Recent investigations have shown that vitamin 
D related metabolites are able to increase mitochondrial function in skeletal muscle in 
vitro [19-21] and within human populations of severe vitamin D deficiency [22]. 
Despite this, little is known with regard to the role of the VDR in mediating this 
adaptive response. Furthermore, the effects of vitamin D deficiency upon skeletal 
muscle mitochondrial function in vivo remain largely underexplored. Therefore, the 
aims of this thesis were as follows; 
 
1. Develop a reliable method for the detection of the VDR within skeletal 
muscle samples (Chapter 3). 
 
2. Determine the role of the VDR within the maintenance of skeletal muscle 
mitochondrial function and protein content (Chapter 4). 
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3. Examine the role of diet-induced vitamin D deficiency on anthropometric 
measures of body composition and mitochondrial function in C57BL/6J 
mice (Chapter 5). 
 
4. Determine whether diet-induced vitamin D deficiency impairs the positive 
impact of exercise on body composition and mitochondrial function in 
C57BL/6J mice (Chapter 6).  
 
In order to address these aims, this thesis utilised both in vitro and in vivo 
approaches. Firstly, methodological considerations were evaluated for the detection 
of the VDR within skeletal muscle. This was followed by a combination of in vitro and 
in vivo approaches to assess the skeletal muscle-specific role of the VDR in 
regulating mitochondrial function and protein content. Finally, two in vivo studies 
investigated the influence of diet-induced vitamin D deficiency upon skeletal muscle 
mitochondrial function. This chapter will further summarise and amalgamate the data 
obtained throughout this thesis.  
 
7.2 The Vitamin D Receptor in Skeletal Muscle 
Recent investigations have shown that vitamin D related metabolites are able to 
increase mitochondrial function in both immortalised and primary skeletal muscle cell 
lines [19-21]. To directly assess the role of the VDR on mitochondrial function, we 
utilised RNA interference approaches to generate a stable C2C12 clone in which 
VDR protein content was reduced by ~95%. Utilising this novel approach, we report 
that loss of VDR in C2C12s resulted in a significant decrement in mitochondrial 
function (Chapter 4). Despite this, no changes were observed in mitochondrial 
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protein content in both VDR-KD myoblasts or myotubes (Chapter 4). In continuation, 
we also studied the skeletal muscle-specific role of the VDR within rat skeletal 
muscle. Whilst the knock-down of the VDR resulted in a trend towards a decrease in 
both mitochondrial complex I and IV, overall, we observed no differences in 
mitochondrial protein content following both the knock-down and over-expression of 
the VDR (Chapter 4). Results that have recently been corroborated in a mouse 
model with the skeletal muscle-specific deletion of the VDR [23]. Despite this, this 
does not preclude a role for the VDR in mediating mitochondrial function in vivo. 
Given that we report a reduction in mitochondrial function following 3-months of diet-
induced vitamin D deficiency in C57BL/6J mice (Chapter 5), the examination of 
mitochondrial function in mouse models with the skeletal muscle-specific deletion of 
the VDR may also reveal functional decrements despite no change in mitochondrial 
protein content. Unfortunately, we were unable to perform such measurements due 
to limited access to tissue of VDR-KD and –OE rats.  
 
The precise role by which the VDR may mediate changes in skeletal muscle 
mitochondrial function remains unclear. Previously, microarray analysis has identified 
potential VDR target genes however, the overlap between tissues is minimal, 
highlighting that VDR target genes respond in a highly tissue specific manner [24, 
25]. Within skeletal muscle, >80 mRNAs encoding for mitochondrial proteins have 
been shown to be upregulated in response to treatment with 1a,25(OH)2D3 [19] 
however, it is unclear whether these genes contain specific VDREs. A potential target 
for further exploration, the chromosome 15 open reading frame 48 (C15orf48) is 
responsive to 1a,25(OH)2D3 within skeletal muscle [19]. Whilst this protein remains 
largely uncharacterised, particularly within skeletal muscle, one study reported an 
interaction with both complex I and IV, suggesting that it regulates either the activity 
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of said complexes or potential supercomplex formation [26]. Therefore, the potential 
characterisation of said protein within skeletal muscle may provide an opportunity to 
establish a mechanism by which the VDR mediates mitochondrial function.  
 
Due to its extremely low expression levels within skeletal muscle [27, 28], we were 
unable to detect the VDR in adult mouse skeletal lysates (Chapter 3). Whilst the 
detection of the VDR was not central to aim of each chapter (Chapter 5-6), the ability 
to reliably detect the VDR would have enabled further analysis throughout this thesis. 
Previously, the successful detection of the VDR within human skeletal muscle has 
been reported following a period of vitamin D supplementation [29, 30], suggesting 
the tissue-specific expression levels of the VDR are mediated by whole-body vitamin 
D status. In addition, whilst the expression of the VDR has been reported to increase 
in response to an acute bout of muscle damage [31], its expression in response to a 
period of chronic exercise has not been explored. Therefore, the ability to reliably 
detect the VDR within adult skeletal muscle would have enabled the further 
exploration of these questions and added further novelty to this thesis (Chapter 5-6). 
Given that we were unable to detect the VDR within skeletal muscle, this raises 
questions in regards to its potential relevance in vivo. Given the systemic changes 
that occur in models of vitamin D deficiency and VDR-KO mice, the phenotypes 
observed may be as a result of indirect effects as opposed to VDR signalling. Further 
characterisation of models with skeletal muscle VDR-KO will shed light upon the role 
of the VDR within skeletal muscle in vivo [23].  
 
7.3 Vitamin D Deficiency, Body Composition and Physical Function 
Previously, no changes in body composition were reported in male C57BL/6J mice 
following diet-induced vitamin D deficiency across a 12-month period [32]. On the 
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other hand, reductions in body weight, lean mass and fat mass were reported in 
female mice across the same time period [33]. In response to 3-months of diet-
induced vitamin D deficiency, we observed no differences in body weight, lean mass 
or fat mass between vitamin D replete and deplete C57BL/6J male mice. Vitamin D 
deplete mice did display a reduction in lean mass as a percentage of body weight 
from 1- to 3-months of diet-induced deficiency. This however, is likely due to the 
observed increase in lean mass as a percentage of body weight at the 1-month time 
point between vitamin D replete and deplete mice. In continuation of this, we also 
examined body composition in response to a period of voluntary wheel running 
(Chapter 6). Whilst physical function has been reported to be impaired in mouse 
models of diet-induced vitamin D deficiency [32, 34], these effects have only been 
explored in the basal state and not following a period of adaptation. In order to 
explore the effects of diet-induced vitamin D deficiency upon exercise adaptation, we 
utilised a model of voluntary wheel running in which mice were given access to a 
wheel for a period of 20-days following either 1 or 3-months of diet-induced vitamin D 
deficiency. In comparison to vitamin D replete mice, diet-induced vitamin D deficiency 
resulted in a reduced overall running performance (Chapter 6). Reductions in both 
sprint speed and stride length have previously been reported and likely contribute to 
reduced running performance observed in our study [32, 34]. In addition, mice with 
the skeletal muscle-specific deletion of the VDR display similar reductions in running 
performance over a 24 h period, suggesting direct effects for vitamin D related 
signalling in mediating physical function [23]. Whilst the running distances we 
observed were lower than that previously observed [35-37], similar running distances 
in mice fed a standard chow indicate that this is a strain issue as opposed to an 
effect of the vitamin D diets. The further analysis of running performance and 
subsequent adaptation in a mouse model of increased running volume may reveal 
	 211 
more prominent effects of diet-induced vitamin D deficiency. Whilst, no changes in 
body weight were observed between vitamin D replete and deplete mice, we did 
observe some favourable adaptations in body composition in vitamin D replete mice. 
Most notably, vitamin D replete mice displayed a positive accretion of lean mass and 
a decrease in fat mass as percentages of body weight in response to 20-days of 
voluntary wheel running. These beneficial effects are likely due to an increase in 
running volume observed within vitamin D replete mice.  
 
7.4 Vitamin D Deficiency and Skeletal Muscle Mitochondrial Function 
Whilst vitamin D related metabolites are reported to increase skeletal muscle 
mitochondrial function in vitro [19-21], in vivo investigations are currently lacking. To 
date, one study explored skeletal muscle mitochondrial function following vitamin D 
supplementation in a cohort of severely deficiency patients exhibiting symptoms of 
skeletal muscle myopathy [22]. Skeletal muscle mitochondrial function was assessed 
indirectly via 31-P MRS and vitamin D supplementation was reported to reduce PCr 
recovery time, a marker of improved oxidative phosphorylation [22]. Despite this 
observation, a number of limitations were evident in this study, such as improper 
randomisation and blinding [22]. Therefore, in order to further examine the role of 
vitamin D status in modulating mitochondrial function in vivo, we utilised a well-
established mouse model of diet-induced vitamin D deficiency [34] in combination 
with high-resolution respirometry, the current gold-standard method to assess 
mitochondrial function within skeletal muscle fibres [38]. Initially, we examined the 
role of diet-induced vitamin D deficiency alone upon skeletal muscle mitochondrial 
function. We reported that 3-months of diet-induced deficiency reduced the capacity 
of multiple parameters of skeletal muscle mitochondrial function to increase (CI+IIP 
and ETC) (Chapter 5). In continuation of this, we also assessed the effects of diet-
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induced vitamin D deficiency upon skeletal muscle mitochondrial function following a 
period of voluntary wheel running (Chapter 6). We reported that following 1-month of 
diet-induced vitamin D deficiency and 20-days of voluntary wheel running, only 
vitamin D replete mice displayed an increase in multiple parameters of mitochondrial 
function (CIP, CI+IIP and ETC) (Chapter 6). Therefore, we build upon previous 
research reporting impairments in physical function following diet-induced vitamin D 
deficiency [32, 34] by highlighting a role for vitamin D status in modulating skeletal 
muscle mitochondrial function not only in the basal state, but also following a period 
of adaptation.  
 
Furthermore, we also examined the effects of diet-induced vitamin D deficiency upon 
mitochondrial ADP sensitivity within skeletal muscle. Whilst diet-induced vitamin D 
deficiency alone did not alter mitochondrial ADP sensitivity (Chapter 5), only the 
vitamin D replete mice displayed an increase in the apparent Km for ADP following 1-
month of diet-induced deficiency and 20-days of voluntary wheel running (Chapter 6). 
Whilst an increase in the apparent Km highlights a decrease in sensitivity, this is a 
common characteristic of a trained skeletal muscle phenotype [39-42]. A decrease in 
sensitivity possibly indicates an increase in mitochondrial mass, however, time 
constraints limited the scope of analysis performed within these studies (Chapter 5-
6). In support of this notion, the reported effects upon skeletal muscle mitochondrial 
function following diet-induced vitamin D deficiency and voluntary wheel running 
where abolished when subjected to internal normalisation (Chapter 5-6). This 
suggests that the alterations observed within parameters of skeletal muscle 
mitochondrial function are as a consequence of mitochondrial quantity as opposed to 
quality. The further analysis of tissues collected throughout these studies will provide 
further insight into the above notion.  
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7.5 Limitations 
As with all research, a number of limitations exist within this thesis that should be 
considered when making interpretations in regards to the results obtained. Firstly, we 
were unsuccessful in our attempt to detect the VDR in adult skeletal muscle samples 
(Chapter 3). Whilst the detection of the VDR was not central to aims of each chapter, 
it did preclude the further analysis of the role of the VDR in response to diet-induced 
vitamin D deficiency and voluntary wheel running. Furthermore, our examination of 
the role of the VDR in modulating skeletal muscle mitochondrial function and protein 
content was only conducted in the basal state (Chapter 4). Further characterisation of 
such rodent models in response to physiological stressors such as exercise training 
and ageing may reveal further skeletal muscle-specific roles for the VDR. 
Unfortunately, the scope of our analysis of VDR-KD and –OE rat skeletal muscle was 
limited due to restrictions upon tissue availability as this tissue was utilised in 
previous research. The analysis of skeletal muscle mitochondrial function within 
these samples would have also provided further translational of in vitro findings 
(Chapter 4). Furthermore, the analysis of protein content via immunoblotting is semi-
quantitative in nature which may limit the sensitivity of such analyses. Given the VDR 
is proposed to be highly tissue specific [24, 25], untargeted based approaches 
utilising ‘omics’ platforms may have provided broader insight into the skeletal muscle-
specific role of the VDR.  
 
As discussed previously, a large proportion of mice were removed from analyses due 
to running distances of <1 km/day (Chapter 6). Even with these mice removed, 
running distances overall were on the lower end of those previously reported in mice 
[35-37]. These issues resulted in a reduced sample size and training volume. This 
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reduced running performance may be as a result of the mouse strain chosen for such 
studies. The C57BL/6J mouse is known to contain a mutation in the nicotinamide 
nucleotide transhydrogenase (Nnt) gene which encodes for an inner membrane 
mitochondrial protein [43]. Whilst running distances have not been directly compared 
to mice without the Nnt mutation, metabolic defects in glucose homeostasis and 
mitochondrial redox abnormalities have previously been reported [43, 44]. In addition, 
the design of the running wheel is an important consideration when evaluating 
running performance in mice. For example, an upright wheel, as used within our 
study (Chapter 6), results in reduced running distances when compared to an angled 
wheel [35]. Furthermore, given our analyses was conducted using only adult male 
mice, sex or age-related differences cannot be excluded. The further comparison of 
mouse strains for running performance may have alleviated such issues. We also 
assessed skeletal muscle mitochondrial function in response to 3-months of diet-
induced vitamin D deficiency and subsequently 20-days of voluntary wheel running. 
Unfortunately, this analysis was not included due to a number of issues. Firstly, 
multiple data points exhibited signs of poor fibre preparation including a cyt c 
response of >10%. In addition, the overall respiration rates were much lower than 
that previously observed for C57BL/6J skeletal muscle both within this thesis 
(Chapter 5-6) and by others [45]. Finally, time constraints meant that it was not 
feasible to repeat analyses with the above issues nor was it feasible to conduct 
further analysis of the multiple tissue samples that were collected during mouse in 
vivo studies (Chapter 5-6).   
 
7.6 Future Research 
Further studies in continuation of recent publications [23, 46] should examine the 
skeletal muscle-specific role of the VDR in response to physiological stressors such 
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as exercise training and ageing. In addition, given the role of the VDR is tissue 
specific [24, 25], the use of unbiased ‘omics’ approaches may aid in the 
characterisation of specific VDR target genes within skeletal muscle. The 
combination of in vitro models of VDR-KD with microarray analysis, ChIP and RIME 
would aid in the identification of skeletal muscle specific VDR targets genes and 
coregulatory binding partners [47, 48]. Furthermore, the translation of rodent studies 
of diet-induced vitamin D deficiency into human populations is particularly interesting. 
The utilisation of techniques such as high-resolution respirometry would shed light 
upon the effects of vitamin D deficiency upon skeletal muscle mitochondrial function. 
Such analysis could be combined with the assessment of ROS production, 
membrane potential or calcium concentrations via the use of O2k-fluorometry [49-51] 
providing broader insight into the regulation of mitochondrial function in response to 
vitamin D deficiency and supplementation. Furthermore, recent technical 
developments that allow for the measurement of multiple vitamin D metabolites 
provide the opportunity for the further characterisation of the vitamin D metabolome 
[52, 53]. Recent investigations have reported differential effects of vitamin D2 and D3 
supplementation upon this metabolome [54]. Similar studies in the context of skeletal 
muscle may provide broader insight into the positive effects of vitamin D 
supplementation upon skeletal muscle metabolism.  
 
7.7 Conclusions 
Throughout this thesis we have provided direct evidence that loss of VDR leads to 
significant decrements in mitochondrial function during myogenesis, whilst diet-
induced vitamin D deficiency reduces skeletal muscle mitochondrial respiration 
(CI+IIP and ETC), voluntary wheel running performance and an impaired adaptive 
response in mitochondrial function (CIP, CI+IIP and ETC) and body composition in 
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male C57BL/6J mice. Therefore, we highlight vitamin D status as an important 
consideration within the maintenance of skeletal muscle mitochondrial function both 
in the basal state and following a period of adaptation. Given that vitamin D 
deficiency remains prevalent across multiple populations including both the elderly 
and athletes [17, 55], maintaining sufficient vitamin D levels may aid in the 
maintenance of skeletal muscle function. Finally, this thesis contributes novel data 
towards the understanding of the role of the vitamin D and the VDR in modulating 
skeletal muscle mitochondrial function.  
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